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IV SUMMARY 
 
SUMMARY 
Programmed cell death (apoptosis) is an important process in development and tissue homeostasis of 
multicellular organisms. Apoptosis is triggered by various stimuli that lead to signal transduction and 
the activation of a complex proteolytic network consisting of cysteine aspartate-specific peptidases 
(caspases). Caspases cleave tetra peptide sequences with an absolute requirement of an aspartic acid in 
P1, while the remaining three amino acids contribute to the specificity of the caspases; yet, 
overwhelming evidence indicates that the eleven caspase family members have overlapping sequence 
specificities. This latter feature has long been ignored in the design of putative caspase specific peptide 
substrates and inhibitors which are commonly used to dissect the apoptotic pathway.  
In order to overcome the limited specificity of active-site directed compounds we have used designed 
ankyrin repeat proteins (DARPins) which are able to recognize their target proteins with high 
specificity. Based on a panel of DARPins that were selected against nine different caspases we aimed 
to develop novel strategies to specifically inhibit, activate and analyze caspases.  
 
To this end, we first established expression protocols and a comprehensive kinetic characterization 
procedure for caspase-1 to -9. These caspases were used as target proteins for the selection of 
DARPins with ribosome display. The selected DARPins were systematically characterized using high 
throughput techniques such as ELISA, protein arrays and surface plasmon resonance. In total, over 
200 DARPins selected against nine caspases were evaluated and ranked according to their kinetic 
properties and specificity. 
 
Through this approach we identified two DARPins that inhibit the catalytic activity of caspase-3 with 
high affinity (KD=9.6 or 3.4 nM) and specificity. Both DARPins were found to inhibit caspase-3 while 
not affecting the catalytic activity of the closely related caspase-7 (57% sequence identity). This 
example demonstrates that specificity can be achieved by using larger proteins instead of small active-
site directed molecules. Our structural and kinetic description of this protein inhibitor complex 
revealed a competitive inhibition mechanism involving a direct interaction with the peptide binding 
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interface. Interestingly, we found that this DARPin mediates inhibition via a similar mechanism used 
by the natural inhibitor XIAP and the peptide inhibitor DEVD. 
 
Furthermore we have found a DARPin which specifically interacts with caspase-8 leading to an 
significant increase of the activity. Based on a high resolution structure we were able to uncover the 
molecular basis of this finding. The interaction increases the activity of caspase-8 by locking loop1 in 
a substrate bound conformation leading to formation of a caspase-8 dimer. This study provides new 
evidence on the dynamic nature of caspase-8 active site loops and the link with dimer formation. 
Taken together, this thesis describes a set of comprehensive protocols for the expression and 
characterization of caspases as well as presents evidence for, the selection of DARPins specific for 
each of the caspase family member. We have identified caspase inhibitors, activators and high 
resolution structures allowing us to uncover the molecular basis of the functional DARPin/caspases 
interactions.  
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ZUSAMMENFASSUNG 
Programmierter Zelltod (Apoptose) ist ein wichtiger Prozess in der Entwicklung und Homöostase 
mehrzelliger Organismen. Verschiedene Reize können Apoptose auslösen, dies führt wiederrum zu der 
Aktivierung eines proteolytischen Netzwerkes, welches von den sogenannten Caspase gebildet wird. 
Caspasen schneiden ihre Substrate an definierten Tetra-Peptid Sequenzen hinter Asparaginsäure in 
Position P1. Die Erkennung der weiteren drei Aminosäuren tragen zur Spezifität der Caspases bei, 
wobei die elf humanen Caspasen stark überlappenden Sequenzspezifitäten aufweisen. Diese Tatsache 
wurde in der Entwicklung und Verwendung von Caspase Substraten oder Inhibitoren oft nur 
unzureichend berücksichtigt da sie nach wie vor als „caspase-spezifisch“ bezeichnet werden. Während 
meiner Doktorarbeit habe ich neue Strategien entwickelt um Caspasen spezifisch zu detektieren, zu 
inhibieren oder zu aktivieren. Als Technologie haben ich sogenannte „designed ankyrin repeat 
proteins“ (DARPins) verwendet und habe neun verschiedene humane Caspasen in meine Studie mit 
einbezogen. 
In einer ersten Studie haben wir ein umfassendes Protokoll für die Expression und der kinetischen 
Charakterisierung von Caspase-1 bis -9 entwickelt. Gegen diese Caspases haben wir DARPins unter 
der Verwendung von Ribosome Display selektioniert und anschliessend systematisch charakterisiert. 
Insgesamt wurden ca.200 DARPins aufgrund ihrer Bindungseigenschaften und Spezifität gegen jeden 
Caspase klassifiziert. 
In diesem Ansatz haben wir zwei DARPins identifiziert, welche Caspase 3 mit hoher Affinität bindet 
(KD=9.6 und 3.4 nM) und gleichzeitig inhibiert. Beide DARPins sind spezifisch für Caspase-3 und 
erkennen weder die homologe Caspase-7 (57 % Sequenzidentität) noch andere Caspasen. Desweiteren 
haben wir diesen Proteinkomplex mittels Röntgenstrukturanalyse aufgeklärt und können so den 
kompetitiven Inhibitionsmechanismus und die Grenzfläche der Interaktion beschreiben. 
Interessanterweise verwenden die DARPins einen ähhnlichen Inhibitionsmechanismus wie diese auch 
bei den natürlichen Inhibitoren DEVD.fmk und XIAP beobachtet wurde. 
Des Weiteren haben wir einen DARPin identifiziert, welcher Caspase-8 spezifisch bindet (KD=5.2 
nM) und gleichzeitig die Aktivität von Caspase-8 steigert. Aufgrund einer Kristallstruktur haben wir 
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den molekularen Mechanismus, welcher die Aktivität steigert, beschreiben können. Der DARPin 
bindet Loop1 in einer Konformation die einer Bindung des Substrates begünstig und die 
Dimerisierung des Enzyms unterstützt.   
Insgesamt betrachtet haben wir eine umfassende Strategie für die Expression und Charakterisierung 
humaner Caspasen erstellt, aufgrund welcher wir DARPins gegen neun Caspasen selektioniert haben. 
Diese DARPins haben wir systematisch unter der Verwendung von Hochdurchsatz-Screening 
Methoden wie Protein Microarrays und surface plasmon resonance (SPR) evaluiert. Aus dieser 
„Library“ konnten wir interessante DARPins identifizieren und Strategien zur Inhibition oder 
Aktivierung von Caspasen entwickeln. Röntgenstrukturanalysen dieser Caspase/DARPin Komplexen 
haben es uns ermöglicht die molekulare Grundlagen dieser funktionellen DARPins aufzuklären. 
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1. INTRODUCTION 
1.1 Apoptosis 
During the evolutionary development of multicellular organisms it became crucial to maintain 
the size and form of the body and organs. This process is important in development and 
growth but also in tissue homeostasis in order to counterbalance cell proliferation in bone 
marrow and the intestine with billions of cells dying every hour. This removal of unwanted 
cells is known as programmed cell death where cells activate an intracellular protein cascade 
to kill themselves in a controlled manner. In 1972 Currie and colleagues termed this suicide 
program Apoptosis (from the Greek term “dropping of leaves from a tree”) to describe 
morphological features that are observed when cells die [1]. These distinct morphological 
features include cell shrinkage, chromatin condensation, DNA fragmentation and plasma 
membrane blebbing (Figure 1.1) [2, 3]. Several years later, researchers began to understand 
the molecular principles of apoptosis after the discovery of distinct proteases that are involved 
in programmed cell death of the nematode worm Caenorhabditis elegans by Horovitz and 
colleagues [4]. This finding led to the discovery of the first human apoptotic peptidases, 
“interleukin-1-converting enzyme” ICE which was later renamed Caspase-1 [5, 6]. These 
fundamental discoveries represent the starting point of 20 years of intensive research in the 
field of apoptosis with over 200.000 scientific articles in the field. Although apoptosis is by 
far the most important and best described form of programmed cell death, other mechanisms 
and pathways have been described. Necrosis, necroptosis, caspase independent mitotic death 
and autophagy are the most common alternative forms; however in the context of this thesis, 
these processes will not be further described. 
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Figure 1-1: Apoptosis 
(A) Morphological changes of a cell after induction of apoptosis shows cell shrinkage and membrane blebbing [3]. 
B) Nuclear morphology of a virus induced apoptotic cell shows shrinkage of the nucleus (arrows) due to loss of 
volume regulation [7]. C) Paw during embryonic development (left). Green fluorescing cells undergo apoptosis to 
remove unwanted tissue leading to separation of fingers (right)[8]. D) Agarose gel electrophoresis of apoptotic 
DNA fragments after treatment of cells with arsenic. DNA is cut into fragments of 180bp, a typical feature of 
apoptotic cells [9]. 
 
1.1.1 Apoptosis in physiology and pathologies 
Although apoptosis occurs in a multitude of processes in physiology and pathogenesis the 
principle sequence of events remains the same. Cells receive an apoptotic stimulus which 
activates a complex proteolytic network leading to severe morphological changes and 
destruction of the cell. At the same time, the surface of an apoptotic cell becomes modified 
leading to a display of ligands that promote their engulfment by phagocytosis. Most of the 
proteins that are cleaved during apoptosis are believed to be essential for cell survival, 
however recent studies suggest that caspase mediated proteolysis also acts as a switch to 
dampen proinflammatory properties as it was shown for Interleukin-33 [10]. Thus Apoptosis 
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is not only responsible for cell death but plays a crucial role in cell removal, deactivation of 
proinflammatory proteins and survival of neighboring cells unlike necrosis which triggers an 
inflammatory response in the surrounding tissue. Apoptotic cells, even when large numbers of 
cells have died, are rapidly cleared and thus difficult to detect. For this reason researchers 
have for many years overlooked apoptosis and still underestimate its extent today [8].  
The life of multicellular organisms is unthinkable without apoptosis. It is most critical in 
processes such as defining and shaping of embryos, development of the immune system, 
hematopoiesis and counterbalance of proliferating cells. Mutations of individual proteins in 
the apoptotic cascade lead to severe phenotypes or even death. The activation of apoptosis 
must be highly regulated as this process is irreversible once activated. Consequently evolution 
has derived a highly balanced system of pro apoptotic molecules and intrinsic inhibitor to 
orchestrate the activation of apoptosis in a spatial and time dependent manner. The 
complexity of this regulation is still poorly understood and further understanding is absolutely 
necessary because deregulation of apoptosis leads to many human diseases. It is generally 
accepted that too little apoptosis can lead to cancer and autoimmunity while inappropriate 
activation of apoptosis causes tissue damage and functional decline in acute diseases (tissue 
injury, stroke, myocardial infarction) and chronic diseases such as diabetes and Alzheimer’s 
[11]. In order to target apoptosis a profound knowledge of intracellular and extracellular 
processes is required.  
1.1.2 Signal transduction leads to the activation of a complex proteolytic network 
Studies by Horvitz and colleagues in the nineties led to the discovery of the apoptotic 
pathway in the nematode Caenorhabditis elegans. The execution of apoptosis is controlled by 
a simple and elegant pathway which involves only four genes (Egl1, Ced-9, Ced-4 and Ced-3) 
[12, 13]. The general principle of signal transduction is conserved in the mammalian 
apoptotic mechanism and several functional homologues for each C. elegans apoptotic gene 
can be found in humans. It is thought that mammalian ced-like genes arose through gene 
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duplication and have evolved during evolution to meet the challenges complex multicellular 
organisms face [11].  
In both, C. elegans and mammalians, four sequential events control the onset of apoptosis and 
result in the activation of a proteolytic network of caspases which is entirely represented by 
CED-3 in nematodes. The activation of these peptidases is mediated by an upstream adaptor 
protein (CED-4) which oligomerizes in the absence of CED-9, an upstream regulator of 
apoptosis. This negative regulation of CED-4 and CED-9 is controlled by EGL-1 which is again 
transcriptionally activated by various cell death stimuli [14]. This pathway can be considered 
as a simplified view of the more complex human pathway which involves a multitude of 
proteins and crosstalk’s between different pathways (Figure 1.2). The numerous gene 
duplications during evolution allowed the development of functional specification so that 
different regulators can respond to different pro-apoptotic stimuli. These stimuli are either 
intracellular or extracellular and lead to the activation of the intrinsic and extrinsic pathway 
respectively. 
1.1.2.1 The intrinsic pathway is triggered by different signals from various intracellular 
events such as DNA damage, oncogene activation, cell stress, hypoxia, and cell cycle defects 
[15]. These events lead to the permeabilization of the outer mitochondrial membrane 
regulated by the proapoptotic members of the Bcl family [16]. The disruption of the outer 
mitochondrial membrane then releases several proteins into the cytoplasm to trigger the 
apoptotic machinery. Among those proteins are cytochrome c, SMAC (second mitochondria-
derived activator of caspases)/DIABLO (direct inhibitor of apoptosis binding protein with low 
pI) and AIF (apoptosis-inducing factor)[14, 17]. Cytochrome c and ATP-dependent 
oligomerization of Apaf-1 allows the recruitment of Caspase-9 into a large heptameric protein 
complex known as the apoptosome [18, 19]. Caspase-9 is recruited via the caspase 
recruitment domain (CARD) forming a homotypical CARD-CARD interaction. The resulting 
high local concentration of caspase-9 in the apoptosome favors dimerization and leads to the 
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formation of a catalytic active site. Active caspase-9 can now cleave other downstream 
caspases such as caspase-3, -6 and caspase-7 to execute apoptosis by cleaving specific 
substrates essential for cell survival.  
1.1.2.2 The extrinsic pathway is sensitive to extracellular stimuli and involves binding of a 
death ligand to a death receptor. Currently 6 different death receptors are known including 
Fas (CD95/APO-1), TNF-1, TRAMP, TRAIL and DR6 with Fas representing the most 
important receptor [20]. The ligand of Fas (FasL) is a type-II transmembrane homotrimeric 
protein which is expressed in different cells such as cytolytic T lymphocytes (CTL’s) and 
natural killer (NK) cells. Binding of the trimeric FasL to the Fas receptor (FasR) induces a 
potent apoptotic signal through the trimerization of the FasR and the subsequent recruitment 
of Fas-associated death domain (FADD) [21]. FADD forms a complex with FasR via a DD 
homotypic interactions [22] which frees the death effector domain (DED) of FADD to 
interact with the DED domain of the inactive caspase-8 monomer. This oligomeric death-
inducing signaling complex (DISC) activates the recruited caspase-8 by a proximity induced 
dimerization with subsequent linker cleavage to obtain active and dimeric caspase-8 [23, 24]. 
As in the intrinsic pathway, the initiator caspase cleaves caspases-3, -6 and -7 to execute 
apoptosis. 
The biological relevance of both pathways is highlighted by Weinberg and colleagues who 
claim that the required resistance of apoptosis is a hallmark of most if not all types of cancer 
cells [25]. 
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Figure 1-2: Apoptotic cascade 
Apoptotic pathway in mammalian cells aligned with the apoptotic pathway in the nematode C.elegans. Figure 
adapted from [11]. 
 
1.1.3 Activation of caspases leads to severe morphological changes  
The ultimate outcome of the intrinsic or extrinsic pathways is the activation of executioner 
caspases including caspase-3, -6 and -7. Executioner caspases are responsible to cleave a 
large set of proteins that are required for cell survival, proliferation and integrity of the cell. 
Apoptotic cells share many morphological features which are distinct from features observed 
in necrotic cell death. Eliminating or inhibiting caspases using pharmacological inhibitors can 
slow down or even prevent apoptosis [26]. Caspases cleave their target proteins at very 
specific sites and possess the absolute requirement of an aspartic acid, rather then degrading 
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proteins randomly. The preferred peptide sequence for executioner caspases is V/D-E-X-D 
followed by a small non charged residue. There has been extensive research over the last 
decade to analyze caspase substrate specificity, but to date no caspase structure has been 
solved in complex with a target protein. All target proteins that have been characterized 
structurally, reveal that the site of cleavage is in disordered mobile loop regions. The potential 
cleavage sites map to highly flexible and exposed linkers that are accessible to caspases. Thus 
all speculations about the secondary structure and nature of caspase cleavage sites remains 
speculative and most probably caspases cleave their natural substrates probably even without 
the need for exosite interactions [27]. 
The substrate specificity that has been defined by two independent research groups [28, 29] 
and subsequent proteomic analysis of whole apoptotic cell extracts based on the consensus 
recognition sequence suggest a multitude of caspase substrate in vivo. Two databases that are 
available online and offer a searchable list of verified and potential caspase substrates: 
- The CASBAH: 777 entries (April 2011), http://bioinf.gen.tcd.ie/casbah/ [30] 
- CutDB: 820 entries (April 2011), http://cutdb.burnham.org/ [31] 
The number of possible caspases substrates is somewhere in the several hundred, but only few 
of those assigned target proteins have been carefully studied. The large majority probably 
simply represent `innocent bystanders` or false assignments [27]. In addition, some of the 
`legitimate targets` have been analyzed in vitro at totally arbitrary concentrations that may 
have no physiological relevance [30]. A preferred substrate sequence has been defined for 
each caspase, but due to the high homology within the caspase family, a single caspase can 
cleave almost any of the proposed sequences if the concentration of the caspase is high 
enough. This indicates the problem of physiological relevance and specificity of caspase 
cleavage events to distinguish between `legitimate targets` and `innocent bystanders` that are 
unavoidable regarding the complexity of the human proteome. 
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Nonetheless a handful of caspase substrates have been analyzed rigorously and affect mainly 
four classes of proteins: structural proteins, regulators of transcription/translation, kinases and 
signaling intermediates and Caspases themselves. Cleavage of those proteins generally results 
in gain-of-function or loss-of-function which is illustrated in Figure 1.3 and by some of the 
following examples. 
Poly(ADP-ribose)polymerase (PARP) catalyzes ADP-ribose ligation to acceptor proteins in 
response to damaged DNA and thus plays a crucial role in DNA repair mechanisms. PARP is 
cleaved by caspase-3 and -7 resulting in a two fragments that have lost their function in DNA 
repair. 
The serine/threonine kinase rho-associated kinase I (ROCK I) is a rather well studied 
substrate of executioner caspases and is thought to play an important role in two distinct 
apoptotic morphologies: nuclear fragmentation and plasma membrane blebbing [32, 33]. 
ROCK I is expressed as a zymogen with an auto inhibitory C-terminal domain and caspase 
mediated cleavage of the C-terminal domain results in a constitutively active kinase, an 
example for gain-of-function. Active ROCK I can phosphorylate myosin light chain kinase 
which leads to beaking of the nuclear envelope and contraction of microfilaments. 
Interleukin-33 (IL-33) has been assigned to be cleaved by the inflammatory caspase-1 similar 
to IL-1 and IL-18 but only recently it was found that IL-33 is cleaved by executioner 
caspases in order to inactivate this inflammatory protein. Inactivation of IL-33 and other 
alarmins is a beautiful example of how caspase mediated proteolysis acts as a switch to 
dampen proinflammatory properties [10, 34]. 
The multiple cleavage events that occur during apoptosis lead to several distinct 
morphological changes that can be attributed to apoptosis only and has been first described 
almost 40 years ago [1]. The characteristic morphologic pattern show chromatin condensation 
and nucleosomal fragmentation followed by cell shrinkage, fragmentation of the nucleus and 
blebbing of the plasma membrane (Figure 1.1) [35]. The apoptotic cell forms apoptotic bodies 
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with maintained integrity and are ingested by neighboring cells. Most of these morphological 
changes can be completely blocked by inhibition of Caspase activity which indicates that they 
are specifically induced by Caspase directed limited proteolysis. 
 
Figure 1-3: Common damages of an apoptotic cell.  
A) Membrane blebbing is a characteristic phenotype of apoptotic cells and lead to the formation of apoptotic 
bodies. The phenomenon is based on the activation of the Kinase domain in ROCK-I by Caspase-3 cleavage. 
Cleavage of Caspase-3 releases the autoinhibitory domain leading to phosphorylation of several protein involved 
in cell contraction. CYS, Cysteine rich domain; PH, pleckstrin-homology domain. The picture and the schematic 
drawing are adapted from [32]. B) DNA fragmentation is a key feature of apoptotic cells. After the activation of 
endogenous endonucleases (Caspase-activated DNAse, CAD), the DNA is cleaved into fragments of 180 bp or 
multiples thereof. CAD is constitutively inhibited by Inhibitor of CAD (ICAD). Inactivation of ICAD through limited 
proteolysis of Caspases releases CAD which then cleaves DNA between the nucleosomes leading to the 
characteristic well defined DNA fragments. The schematic figures was copied from [36]. 
 
1.1.3 Targeting apoptosis 
A review by Nicholson DW published in 2000 summarized possible targets in the apoptotic 
pathway and stated that practical therapeutics that modulate apoptosis will “no doubt appear 
in the clinic or on the shelf in the next few years” [37]. Until today more than 140,000 articles 
have been published on molecules that mediate the apoptotic cascade also due to the 
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substantial interest to therapeutically modulate this pathway [38]. Despite this large effort no 
drug that targets the apoptotic pathway has been approved to date. In order to understand why 
exhaustive research efforts have not yet been met with success a closer look is warranted on 
the principles and possible targets leading to therapeutic benefits. 
As described in chapter 1.1.1, deregulation of Apoptosis is implied with several human 
diseases including cancer, autoimmunity, tissue damage in acute diseases, diabetes and 
Alzheimer to name a few. In addition apoptotic proteins such as caspase-3 have been 
connected to infection of human pathogens such as propagation of the human influenza virus 
and maturation of Salmonella enterica [39, 40]. Resisting cell death has been described as a 
hallmark of cancer and commonly involves signaling imbalances and attenuated apoptosis 
leading to hyper-proliferation and resistance to therapy [41]. In contrast, tissue damage often 
occurs in acute diseases such as stroke and myocardial infarction where it would be desirable 
to prevent apoptosis. From these two examples we can derive two directions of possible 
therapeutic strategies, selective activation or blocking of apoptosis (Figure 1.4). 
The apoptotic pathway involves various types of proteins including, cell surface receptors and 
their respective ligands (Fas and FasL), transcription factors (NF-κB), tumor suppressors 
(p53) regulatory proteins (BCL-2), adaptors or oligomerization platforms (FADD, APAF-1), 
inhibitors (IAPs), heme proteins (Cytochrome C), proteases (Caspases) and even ions such as 
Calcium. Every single molecule plays a decisive role on the cascade and reveals many 
opportunities for apoptosis modulation. Instead of discussing the potential of every single 
protein involved in apoptosis I would like to highlight four major strategies in modulating 
apoptosis. 
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Figure 1-4: Targeting apoptosis 
The main therapeutic strategies that have been pursued in the last decade are highlighted green or red for 
activation and inhibition of the apoptotic pathway respectively. 
 
1.1.3.1 Targeting the receptors  
The starting point for the extrinsic pathway (also known as death receptor pathway) is 
trimerization of receptors that are presented on the cell surface including FasR, TNF receptors 
or death receptor 4 and 5 (DR4/DR5 or TRAILR1/TRAILR2). These receptors are attractive 
targets to promote cancer because they are extracellular and can be targeted by their natural 
ligand or antibodies with no need of traversing the cellular membrane. Their activation would 
ultimately result in the activation of the apoptotic pathway independent of apoptotic resistance 
of cancer cells by p53 inactivation or Bcr-2 overexpression [42]. Multiple studies in recent 
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years showed that soluble TNF and agonistic anti-FAS antibodies have toxic side effects 
limiting their therapeutic use mainly because these drugs do not discriminate between healthy 
and malignant cells [43]. An alternative target are the TRAIL receptors, type II 
transmembrane proteins which are able to trigger the death receptor pathway. Agonistic 
antibodies against both TRAIL receptors and truncated TRAIL ligand have been made and 
are in phase I/II clinical trials for the treatment of cancer. These antibodies induce apoptosis 
in cancer cells but not in normal cells and are able to slow the growth of tumours without 
toxic side effects [42]. 
1.1.3.2 Regulating the regulators  
BCL-2 family proteins are the main regulators of apoptosis and represent a switch that 
controls the activation of the intrinsic apoptotic pathway. Some BCL-2 homologs are pro-
apoptotic including BH3-only proteins (BAX/BAK/BID/SMAC) whereas others are anti-
apoptotic (BCL-2/BCL-XL). BAK and BAX activate the release of cytochrome-c by 
mitochondria. BCL-2 in contrast inhibits BAK/BAX and thus controls their activity. BCL-2 is 
overexpressed in many types of cancer leading to a resistance of cell death and various 
treatments including radiotherapy and cytotoxic agents [42]. In order to overcome the 
deregulation of the apoptotic regulators one could inhibit overexpression of BCL-2 with the 
aim to activate apoptosis or inhibit BAK/BAX leading to inhibition of apoptosis. Different 
kinds of drugs are currently in clinical trials including Bcl-2 antisense oligonucleotides and 
small molecule BCL-2 family inhibitors for the treatment of leukemia and solid tumours. 
1.1.3.3 Targeting peptidases 
Caspases, the main executioners of apoptosis are present as zymogens within the cell and 
require activation through dimerization and/or linker cleavage. This secured apoptotic 
regulation sometimes fails which leads to diverse disorders. In addition it is extremely 
attractive to activate caspases specifically to combat diseases that involve cells which are 
resistant to apoptosis as described in this chapter. Caspases were one of the most obvious 
targets in modulating apoptosis and soon after their discovery and characterization, active-site 
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mimetic peptide ketones (e.g. z-VAD.fmk) were developed [44]. These inhibitors are very 
unselective and do not only target caspases but also other neutrophil-containing peptidases 
leading to undesired off-target effects.  
In preclinical studies, inhibition of caspases has shown remarkable effects e.g. treatment of 
ischaemia-reperfusion injury [37], which highlights the tremendous potential of caspase 
inhibitors. Despite this, active site directed approaches so far have not led to appropriate drugs 
because of poor drug like properties and pharmacological constraints [45]. 
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1.2 Caspases 
1.2.1 Caspases – The main mediators of apoptosis 
1.2.1.1 History 
The first caspase discovered was the human protease involved in activating the precursor of 
interleukin-1 and was called ICE (Interleukin-1-converting enzyme) [5]. Shortly after, 
scientists discovered a role in apoptosis for the C.elegans gene CED3 which is homologous to 
ICE [46]. This link prompted many research groups to search for ICE homologous that are 
involved in human cell death and led to the discovery of several different peptidases. The 
frenetic pace of discovery of new homologous has let to multiple names for these enzymes 
until a common nomenclature was found in 1996 – caspases [47]. The name caspase is based 
on the catalytic properties with “c” representing the catalytic active site residue cysteine and 
“asp” for the absolute specificity of aspartic acid in P1. The subsequent number of each 
caspase represents the order of discovery. The first caspase crystal structure was solved and 
published in 1994 and revealed that caspase-1 is a dimer consisting of two subunits - the 
“caspase fold” was born [48]. To date eleven different caspases have been discovered with 
different roles in inflammation, apoptosis and keratinocyte maturation. Nine out of these 
fourteen caspases have been described structurally. 
1.2.1.2 Classification  
Caspases are classified into the clan CD, family C14 according to the MEROPS peptidase 
database (http://merops.sanger.ac.uk/) or referring to IUBMB; caspases are cysteine 
endopeptidases with caspase-1 in the category: 3.4.22.36.  
The caspase family with its eleven members can be divided into different groups depending 
on sequence homology, function or substrate specificity. Caspase-1, -4 and -5 represent the 
inflammatory caspases whereas all other caspases are involved in apoptosis except for 
caspase-14 being involved in keratinocyte maturation. The apoptotic caspases are subdivided 
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into initiator- (caspase-2, -8, -9 and -10) and executioner caspases (caspase-3, -6 and -
7)(Figure 1.5).  
 
Figure 1-5: The Caspase family. 
The domain architecture of all human caspases and Ced3 are shown. Loop1, -2, -3 and -4 are indicated in the 
respective color and the catalytic residues His237(green) and Cys285 (red) are marked by a line on the large 
subunit. The phylogenetic tree shows the evolutionary conservation within the caspase family. Numbers between 
two caspases within the tree represent the sequence homology of the respective caspases. 
 
1.2.1.3 Architecture 
Caspases are expressed as inactive zymogens and have a highly conserved sequence and 
domain architecture. All caspases have a large (p20) and a small (p10) subunit connected with 
a short linker. This catalytic domain contains all domains and residues of the catalytic 
machinery. Two of the active site forming loops (L3 and L4) are situated in the small subunit 
whereas loop1 (L1) is in the large subunit. Loop2 (L2) including the catalytic cysteine 
(Cys285) residue is mainly located in the large subunit but reaches to some extend into the 
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small subunit. The linker connecting the small and large subunit within L2 is relatively short 
with around ten amino acid residues and is cleaved upon activation of the caspase. 
Executioner caspase have a short N-terminal sequence with a length of 23 to 28 amino acids 
which is also cleaved upon activation. It is believed that this unstructured domain is involved 
in subcellular targeting [49]. The N-terminal prodomain of initiator caspases contains 
homotypic interaction motifs such as the caspase-recruitment domain (CARD) or death 
effector domain (DED) [14](Figure 1.5). Both domains are distantly related and are 
implicated in homophilic interactions with other CARD or DED domains in order to be 
recruited to multimeric caspases activation platforms. Activation of the procaspase by 
dimerization and/or proteolytic cleavage separates both subunits and removes the prodomain. 
The active site and the catalytically active enzyme are then formed in a homodimer with each 
monomer consisting of a small and large subunit. The homodimerization is mediated through 
a large hydrophobic interface with an antiparallel -strand. The dimeric caspase has twelve 
continuous -stands building the hydrophobic core and is surrounded by several -helices 
leading to a globular fold. Loop1 to loop4 form the active sites which are located at two 
opposite ends.  
1.2.1.4 Sequence and homology 
Caspases are evolutionary highly conserved and have the same fold, quaternary arrangement 
and catalytic mechanism by which they cleave their substrates [50]. Based on multiple 
sequence alignments and similarity determinations it is observed that the catalytic core of all 
caspases is highly conserved especially around the catalytic residues His238 and Cys 285 
[51]. There are additional highly conserved features such as the peptide binding pockets, the 
oxyanion hole, the dimer interface and cleavage sites that are essential for activation (Figure 
1.6 and 1.8). Highest sequence similarity is found within the distinct groups where 
inflammatory caspase have an overall homology of 60%, initiator caspases 40% and 
executioner caspases 50%. The overall sequence identity is about 30% with the main 
differences between apoptotic and inflammatory caspases (less than 25%) due to a greater 
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evolutionary distance. The phylogenetic tree of the caspase family is a beautiful example of 
the relation between sequence homology and functional relationship (Figure 1.5). The 
inflammatory caspases segregate well from others caspases and other caspases that have 
partly redundant activity and the same sequence specificity group into distinct classes. A good 
example are caspase-3 and -7 which play a combined role in the execution of apoptosis and 
caspase-8 and -10 which play a similar role in receptor stimulated activation of apoptosis. 
Caspase-2 remains an enigmatic protein with an unclear functional role which is also 
illustrated by the position within the phylogenetic tree being close to inflammatory caspases 
with a suggested role in apoptosis [52]. 
1.2.1.5 Catalytic mechanism 
Mutational studies revealed that Cysteine285 and Histidine237 are the catalytic residues in the 
active site. The similarity of chemical groups involved in peptide catalysis suggests a similar 
mechanism as in serine and other families of cysteine proteases [53, 54]. The catalytic 
mechanism (Figure 1.6) is based on a SN1 mechanism with Cysteine285 and His237 
representing the nucleophile and active site base respectively. Binding of a peptide in the 
substrate pockets and the carbonyl oxygen into the oxyanion hole is followed by a 
nucleophilic attack of the Cys285 sulfur atom on the highly electrophilic carbonyl carbon (1). 
His 237 then protonates the a-amino group of the leaving peptide product and thus avoids the 
reformation of the peptide bond (2). The formed acyl-enzyme complex is then deacylated by 
the deprotonated His237 which abstracts a proton from a water molecule, which is then 
activated to attack the thioester bond. This represents the second tetrahedral intermediate (4) 
with a nucleophilic attack of the hydroxyl group on the carbonyl carbon. The N-terminal 
peptide product is then bound to the enzyme non-covalently and is released eventually leaving 
the free enzyme (5) [53]. 
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Figure 1-6: Catalytic mechanism of cysteine peptidases 
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1.2.2 Caspase regulation – From zymogen to the active peptidase 
1.2.2.1 Activation of executioner caspases 
Executioner caspases are expressed as dimeric procaspases containing the N-terminal domain 
and the linker connecting both subunits. Although they are in a stable dimeric form they do 
not possess any catalytic activity and need to be activated by apical caspases in order to form 
the active site. The activation occurs through processing of the N-terminal domain and the 
linker leading to structural rearrangements and formation of the active site. This mechanism 
has been deduced from crystal structures of active caspase-7 in complex with an inhibitor and 
caspase-7 zymogen [55, 56]. The active site in the active caspase is formed by L1 – L4 where 
L3 and L4 are rather flexible. L2 contains the active site cysteine and is additionally stabilized 
by L2’. The procaspase-7 zymogen structure in contrast shows that L2’ is locked in a closed 
conformation and occludes it from stabilizing the active site. Only cleavage of the inter-chain 
allows L2 and L2’ to place the cysteine and stabilize the active site. In addition L3 is very 
flexible and steric hindrance with the inter-chain linker prevents positioning of the active 
conformation of L3. These predictions were also confirmed for caspase-3 and -6 and are 
believed to be the general mechanism for executioner caspases [14]. 
1.2.2.2 Activation of initiator caspases - proximity induced activation 
Active site formation upon inter-chain cleavage most likely also accounts for the activation of 
initiator caspases; however the situation here is fundamentally different since they are present 
as monomeric inactive precursors. They have to dimerize in order to become active by 
autoproteolysis, leading to interchain and linker processing, active site formation and 
dimerization. Furthermore there is evidence that association with multimeric complexes such 
as the apoptosome are essential for full catalytic activity [57]. 
The induced proximity model for the activation of apical caspases was proposed by two 
independent groups [24, 58] and has later been corrected to the more accurate term proximity-
induced activation [59-61]. The model is based on two main observations. First, apical 
caspases are activated by adaptor-mediated clustering of inactive zymogens followed by 
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dimerization due to the high local concentration. In a second step it is believed that residual 
autocatalytic activity is sufficient for proteolysis of the inter-chain linker that is required to 
stabilize and activate dimeric caspases. As it accounts for executioner caspases, the cleaved 
linker allows the formation and stabilization of the active site leading to catalytic activity. The 
relative order of these events remains a hypothesis but recent structural and functional studies 
on monomeric caspase-8 zymogen by solution NMR have revealed novel insights [23]. It was 
proposed that dimerization is required to relocate the cleavage motifs to become accessible 
for the neighboring monomer and initiated pre-building of the active site which finally forms 
upon substrate binding [23, 62]. Thus dimerization, relocation, active site formation, cleavage 
and release of DISC seem to be a highly dynamic but well controlled process. Whether the 
exact same model is also valid for caspase-9 is unclear but the basic mechanism seems to be 
similar. It was for example shown, that inter-chain cleavage of caspase-9 is not necessary for 
inducing apoptosis [19]. In addition caspase-9 possesses only full activity when associated 
with the apoptosome suggesting that activation of procaspase-9 has little to do with inter-
chain cleavage but requires apoptosome-mediated enhancement of the catalytic activity [60].  
1.2.3 Activation platforms 
The apoptotic machinery is a two-step proteolytic cascade that results in the activation of 
executioner caspases. In order to activate this cascade, an upstream signal is required which 
senses an apoptotic (or inflammatory) stimulus and translates it into caspase activation. This 
process is implemented by multimeric protein complexes which oligomerize and recruit the 
according caspase via recruitment domains such as DED or CARD. Four different activation 
platforms have been defined to date which are related to either apoptosis or inflammation. 
The first to be discovered was the death-inducing signaling complex (DISC) in 1995 by Peter 
Krammer and colleagues who identified an oligomeric assembly of FasR (APO-1/CD95) 
which recruits other molecules to start an apoptotic cascade [63, 64]. Later on the apoptosome 
was defined to be the starting point of intrinsic apoptosis [65, 66] and Juerg Tschopp and 
32 INTRODUCTION 
 
 32 
colleagues discovered two additional multimeric complexes involved in apoptosis and 
inflammation, the inflammasome [67] and the Piddosome [68]. 
Structural information of an entire complex is so far only available for the apoptosome, where 
x-ray structures of the single components were positioned into a single particle Cryo-Electron 
Microscopy structure determined at 9.5 Å [19, 69]. The single components of the DISC have 
also been structurally described but their precise arrangement and the stoichiometry of the 
complex remains controversial to date. However, current knowledge of these two multimeric 
complexes presents a solid basis for the understanding of how apoptosis is triggered. 
1.2.3.1 The apoptosome – a soluble receptor 
The formation of the apoptosome is dependent of upstream events that are regulated by 
proteins of the bcl-2 family. They sense apoptotic events and control the release of 
cytochrome c from mitochondria which is then translated into the activation of the death 
cascade. The death cascade largely depends on the cofactor Apaf-1 which exists in a 
monomeric and auto inhibited state in the absence of an apoptotic signal. Apaf-1 has a rather 
complex domain structure comprised of CARD, a nucleotide-binding and oligomerization 
domain (NB-ARC/NOD) and two WD40 repeats. CARD is clearly involved in caspase 
recruitment and WD40 is responsible for cytochrome-c binding. NB-ARC with its three 
subdomains is involved in ATP binding and formation of the apoptosome. The first trigger of 
apoptosome formation is binding of cytochrome-c to the WD40 domain which unlocks the 
locked state of Apaf-1. This involves large structural rearrangements, (d)ATP hydrolysis and 
leads to a semi-open, auto-inhibited state. The complex of Apaf-1, cytochrome c and ADP is 
still monomeric, unable to bind caspase-9 and requires a second signal to proceed. This 
control device is believed to be (d)ADP – (d)ATP exchange so that apoptosome formation 
will only occur if enough unlocked Apaf-1 molecules co-localizes with (d)ADP – (d)ATP 
exchange [70]. After exchange of (d)ADP with (d)ATP, all described components form a 
heptameric wheel-like structure built on seven Apaf-1 molecules. The most recent structure 
reveals how the CARD domains assemble in a circular arrangement, which is the key 
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platform for the recruitment and activation of caspase-9 [69]. Recruitment at this platform via 
homotypic CARD – CARD interactions between Apaf-1 and monomeric procaspase-9 leads 
to high local concentration above the KD for dimerization resulting in activation of caspase-9 
by the proximity-induced model. 
 
Figure 1-7: Apoptotic activation plattforms 
(A) Crystal structure schows a tetrameric arrangement of the FAS/FADD complexbuilding the core of the DISC. 
Here the receptor signaling is supposedly only regulated by oligomerization and clustering events [71](B) 
Proposed asymmetric arrangement of the Fas/FADD complex is composed of 5 to 7 FAS DD and 5 FADD domains 
[72] (C) Structure of the apoptosome at a resolution of 27 Å. The wheel like structure (blue) is formed by Apaf-1 
and cytochrome-c with a 7-fold symmetry. Caspase-9 is recruited to the CARD domain Disk (violet) [69] 
(D)Domain arrangement within the apoptosome. 
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1.2.3.2 The DISC – a membrane receptor 
The DISC is a classic example of a ligand-dependent transmembrane signaling receptor and 
represents a standard solution that is used by cells to transduce signals from outside to the 
inside. Many other receptors such as TRAIL or TNF are believed to function in a similar way 
[70]. The formation of the DISC requires two trimeric or an engineered hexameric FasL 
complex [73]. This signal leads to oligomeric clustering of the FasR and their intracellular 
death domains (DD) which bind the homotypic DD of FADD, an adaptor protein which 
comprises a DD and a DED domain. The DED domain of FADD then recruits the N-terminal 
DED domain of caspase-8 leading to an increased local concentration and thus proximity 
induced activation of the apical procaspase. The general sequence of oligomerization and 
recruitment remains still highly controversial and to a large extent it is unknown how 
precisely this clustering is regulated and formed. In one model [74] a tetrameric arrangement 
of four FADD death domains bound to four Fas death domains is proposed. Fas undergoes 
structural rearrangements upon FasL binding and binds FADD in an open conformation 
which stabilizes the complex. This leads to a processive interlinked DISC formation and 
clustering upon sufficient stimulus. The proposed mechanism is solely based on clustering 
events and prevents accidental DISC formation. A second proposed mechanism [72] claims 
that the Fas-FADD complex forms an asymmetric oligomeric structure composed of 5 – 7 Fas 
DD and 5 FADD DD. Wang and colleagues further revealed that Fas lacks larger structural 
rearrangements upon FADD binding. 
Although these two studies conclude different models they both describe experimental 
observations of higher order clustering events (Figure 1.7). Whether the DISC actually has a 
precise stoichiometry is unclear and might not be necessary provided that caspase-8 is 
specifically activated by a well-controlled mechanism. The DISC also shows the often 
observed highly dynamic and transient nature of regulatory complexes which is also believed 
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to be the case for the inflammasome and the PIDDosome where no structural information is 
available at all. 
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1.2.4 Structure and biochemistry of caspases 
1.2.4.1 Caspase structure 
Active caspases are homodimers with each monomer containing a large (~20 kDa) and small 
(~10 kDa) subunit. To date several crystallographic structures have been solved and they all 
show the same basic globular fold, also termed ‘caspase fold’ (Figure 1.8). In this caspase 
fold, both subunits are packed into an ellipsoid of approximate dimensions 25 Å x 50 Å x 30 
Å. The catalytically active dimer is arranged by a twofold symmetry axis and each monomer 
derives from a single procaspase. The two active sites are found at opposite site ends of the 
dimer. Each monomer contains the entire apoptotic machinery and folds into  sandwiches 
forming a compact cylinder. The center is built with 6 stranded -strands surrounded by five 
helices [51]. Two monomers assemble into a dimer through hydrophobic interactions, 
forming an antiparallel -sheet at the interface. This generated a continuous 12-stranded -
sheet, a highly conserved and characteristic feature in all caspases. 
Initiator or inflammatory caspases contain N-terminal domains such as caspase recruitment 
domains (CARD) or death effector domains (DED) (Figure 1.5). These domains play a crucial 
role in caspase activation by recruiting the procaspase to large oligomerization platforms via 
homophilic interactions, as described in chapter 1.2.1.3. Although these domains have no or 
very low sequence similarity they share a common fold which is also found in other protein 
binding domains such as LRRs, DDs and NACHT domains. These globular domains are 
mainly composed of six antiparallel -helices, with helices 1 – 5 building an -helical 
Greek key motif [53]. Executioner caspases in contrast, have short unstructured N-terminal 
peptides.  
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Figure 1-8: Protein structure of Caspases.  
A) The structure of caspase-3 with continuous12 stranded -sheets (red) surrounded by -helices (blue) is shown 
(pdb entry code 2DKO). The antiparallel -sheet in brown forms the dimer interface. B) The active site of a 
caspase monomer is shown in a cartoon and transparent surface representation with a distinct color for each 
loop forming the active site. The catalytic residues His237 and Cys285 are shown in red. C) Secondary structure of 
a caspase monomer with a small and large subunit is represented in this sketch. The -helices and -sheets and 
the loop are colored according to the colors used in (A and B). The linker connecting the large and small subunit is 
illustrated in light orange but is not present in the crystal structure shown in (A). D) The substrate binding groove 
is conserved in all caspases as illustrated by the diagram. L1 and L4 are flanking the active site and L3 serves as 
the base with crucial residues in substrate recognition. L2 positions the catalytic Cys and is stabilized by L2’ after 
linker cleavage. E) Rearrangement of loops in executioner caspases is illustrated. L2 has drastic conformational 
changes after cleavage while L3 and L4 have only minor rearrangements. Part C, D and E have been adapted from 
[14, 53] 
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1.2.4.2 Active site architecture 
A common rule for enzymes is that the active site is often found at ‘topological switch 
points’, meaning that the active site residues are positioned close to the C-terminal of the 
central -sheet [75]. This general rule is also true for caspases where both catalytic residues, 
His237 and Cys285 are located at the C-terminal of -strand 3 and -strand 4 respectively. 
The majority of caspase structures that have been solved show the caspase in complex with a 
peptide inhibitor and thus show the active site in a substrate bound conformation. The two 
active sites are formed by four protruding loops (L1 to L4) in each monomer and are 
additionally stabilized by L2’ by the neighboring monomer. The backbone configuration of 
the active site is highly conserved and L1 and L4 form the two sides of the substrate-binding 
groove [76] (Figure 1.8D). L3 forms the base of the active site with critical residues for 
substrate recognition. L2 which is cleaved during caspase activation is critical for active site 
formation and positions the catalytic residue Cys285 by traversing the active site. Cleavage of 
the L2 loop also results into formation of a L2’ loop-fragment, L2’ is important for the 
stabilization of the neighboring monomer. However before a caspase has formed the active 
site cleft, cleavage of the linker is required for activation, as described in chapter 1.2.2. 
Structural studies on procaspase-7 and procaspase-8 have revealed the very dynamic nature of 
the active site forming loop before and after linker processing. [23, 55, 56]. Procaspase-7 and 
other executioner procaspases have a rather short but highly flexible linker which impairs the 
formation of a functional substrate binding and active site formation. The cleavage sites are 
exposed on the dimer surface and are accessible for proteolytic attack. Cleavage of the linker 
leads to rearrangements of the loops so that the S1, S2 and S4 subsites will be sculpted, the 
catalytic residue Cys285 will be positioned properly and the oxyanion holes are formed, 
rendering the binding sites and the active sites functional [55]. The structure of procaspase-8 
shows a partially flexible linker which is located on one side of the central -sheet. 
Dimerization supposedly triggers conformational changes of the linker and active-site loops, 
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thus allowing the active site pocket to form. The active site residue Cys285 which is buried by 
the linker is released and shifts by 6 Å into a substrate accessible position [23]. 
The active site architecture of caspases has evolved to fulfill several criteria including 
activation, substrate recognition and specific proteolytic activity. It represents a highly 
dynamic part of the protein and the formation of the active site cleft is tightly connected with 
the regulation and activation of the enzyme. 
1.2.4.3 Substrate recognition 
After the activation of the procaspase, the enzyme is capable of binding its substrates in order 
to cleave the polypeptide chain specifically after an Aspartate residue. However it should be 
noted, that substrate binding might also play an important role in procaspase activation by an 
induced-fit mechanism [62]. The general convention of substrate recognition by proteases is 
to name its residue to the N-terminal of the scissile bond P1 and the on to the C-terminal side 
P1’. Any residue next to these positions is named P2 – Px, depending on the position in respect 
to the first residue (Figure 1.9). The binding pocket that harbors the respective substrate 
residue is named ‘S’ denoted with the according number [77]. Caspases have an absolute 
requirement of an aspartic acid in P1, a very unique primary specificity for peptidases in 
general which can be only found in serine proteases. The S1-pocket is highly conserved 
among the whole family and is constructed of three charged residues, namely Arg179, 
Arg341 and Gln283 which form a highly positively charged pocket which is ideally shaped to 
harbor an aspartic acid and replacement of Asp by Glu reduces the catalytic efficiency by four 
orders of magnitude [53]. Next to the P1-residue the binding affinity and specificity is 
determined by P2 to P4 with the exception of caspase-2 which has an additional pocket to bind 
a fifth residue P5. The S2, S3 and S4 subsite mainly contribute to the specificity of the 
individual caspase but are often conserved among caspase subclasses, such as initiator or 
inflammatory caspases. In addition to the four main binding pockets it has later been 
discovered, that the first residue after the scissile bond P1’ is as important and has a significant 
role in substrate binding [78].  
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Figure 1-9: Caspase substrate specificity 
A) Schematic presentation of a peptidase active site binding to its substrate. The region responsible for substrate 
binding is called subsite and is divided into primed and non-primed site with respect to the cleavage site. 
Substrate residues and binding sites that are N-terminal of the cleavage site are called P1-PX and S1 – SX 
respectively. The C-terminal site is marked by an additional apostrophe. The structure of the active site 
determines the intrinsic subsite occupancy and specificity [77]. B) Human caspases, their optimal substrate 
sequence and kinetic properties are listed.  
 
1.2.4.4 Peptide specificity 
A combinatorial screen using positional scanning synthetic peptide-based libraries by 
Thornberry and colleagues in 1997 was the first systematic approach to determine specificity 
of caspase substrates [28]. Each of the positions (P1 to P4) of the substrate was scanned to 
reveal preferences and derive a general specificity scheme for caspase cleavage. Next to the 
absolute requirement of an aspartic acid in P1, caspases have preferences in the other positions 
including the P1’ position. A simplified substrate sequence for caspases that many papers refer 
to is D/WEXD. (P4P3P2P1.P1’) with  being a small uncharged residue. Figure 1.9 offers a 
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detailed overview listing all residues for each caspase. It is conspicuous that the sequence 
specificity is very similar if not the same within subclasses such as inflammatory or 
executioner caspases. This fact urges the conclusion that caspase activity is to some extent 
redundant exhibiting overlapping substrate specificity in vivo. 
From this and other studies came the general idea of caspase-specific consensus recognition 
in order to predict natural substrates. In addition peptide substrates and inhibitors were 
developed and used for structural biology, enzyme kinetics, drug development and many 
other applications in molecular biology. These substrates or inhibitors have usually a 
tetrapeptide sequence matching a specific caspase coupled to a fluorogenic reporter or a 
warhead respectively. They are very useful in vitro to characterize individual purified 
caspases, but “they are by no means useful to distinguish between caspases in complex milieu 
such as cell lysates” [27]. This fact has to some extend been ignored in many studies in 
dissecting apoptotic pathways, leading to wrong conclusions. Caspase-7 exemplifies this 
problem very well, where it was shown that virtually any residue can bind at the P2 ,P3 and P4 
position although with varying affinities [79]. One can consequently say that there is a 
significant overlap between individual consensus sequences and the specificity highly 
depends on the concentration used. The promiscuity of the pseudo specific caspase substrates 
was further indicated by “showing that caspase-3 was able to cleave most substrates more 
efficiently than those caspases to which the substrates are reportedly specific” [80]. These 
finding suggest, that there are additional factors that determine the specificity and local 
concentrations of caspases.  
1.2.5.1 Exosites 
Caspase specificities between close homologous such as caspase-3 and -7 can often not be 
distinguished in vitro and all reported positional scanning methods of caspase substrates have 
only been obtained by in vitro techniques. The optimal tetrapeptide substrate for both 
caspases is DEVD or VEHD and caspase-3 has a significantly higher catalytic activity than 
caspase-7. A finding that contradicts this result is that PARP (poly[ADP-ribose]polymerase), 
42 INTRODUCTION 
 
 42 
a well described natural caspase substrate, possess a much higher affinity for caspase-7 than 
for the close homologue caspase-3 in vivo. This reverses the observed catalytic efficiency of 
caspases against small synthetic substrates. The enhanced affinity was found to be the result 
of specific interactions of the large caspase-7 subunit and PARP, which is not present in 
caspase-3 [81]. This example is the first description of an exosite that essentially determinates 
substrate recognition and processing. These exosites can to a certain extend explain the 
discrepancies of cleavage preferences in vitro and substrate cleavage found in vivo [82]. There 
is more evidence that implies the existence of exosites in caspase dependent substrate 
recognition and may to some extend overrule specificity requirements derived from studies 
with short synthetic peptides [53]. This does not mean, that all caspase cleavage events 
involve binding to exosites. It was found that caspase-1 cleaves heat denatured pro-IL-1 was 
cleaved as efficient as the folded precursor [83].  
1.2.5.2 Caspase phosphorylation 
The first evidence that caspases are regulated through phosphorylation was shown by Michael 
Cardone and colleagues in 1998, where they found that Caspase-9 was directly 
phosphorylated at Ser-196 by the kinase Akt, leading to inhibited protein activity [84]. Many 
more conserved phosphorylation sites have been assigned mainly in upstream caspases that 
obviously have a crucial role in regulation of apoptosis. A very illustrative example is the 
phosphorylation and dephosphoylation of caspase-8 regulating neutrophil survival [85]. 
Neutrophils are the most abundant type of white blood cells and are part of the innate immune 
system. The in vivo life span of neutrophils is 6 to 8 hours with a turnover of about 10
11
 cells 
per day. Delayed apoptosis in neutrophils is associated with several diseases and if one bears 
in mind, that apoptosis is a process that takes several hours to be complete it becomes 
obvious, that it has to be tightly regulated in neutrophils. Neutrophil survival is dynamically 
regulated through phosphorylation and dephosphorylation at Tyr310 which can consequently 
be recognized by the tyrosine phosphatase SHP-1 which dephosphoylates caspase-8, 
permitting apoptosis to proceed. The non-receptor tyrosine kinase Lyn can phosphorylate 
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caspase-8 on Tyr-397 and Tyr465, rendering it resistant to activational cleavage and 
inhibiting apoptosis. This mechanism represents a dynamic post translational regulation of 
apoptosis in neutrophils. Dysregulation of the mechanism is directly linked to tissue damage 
in sepsis [85].  
1.2.5.3 Allosteric mechanisms 
Allosteric regulation of proteins and especially enzymes leading to conformational changes is 
a common way to regulate enzymes independent from the active site. The clear advantage of 
this mechanism is that even enzyme families with highly conserved active sites gain 
specificity through regulation of their activity at positions other than the active site. First 
evidence that caspases are also to some extend regulated through allosteric mechanism was 
demonstrated for caspase-3 and -7. A conserved allosteric site was discovered in a deep cavity 
at the dimer interface about 14 Å from the active site [86]. A conserved cysteine in this 
allosteric site when coupled to a compound renders the caspase inactive. This allosteric site is 
functionally connected to the active site and binding of a compound traps a zymogen-like 
conformation. The active site cysteine is dislocated, the L2’ loop is pinned over the allosteric 
site to prevent proper folding of the active site and residues critical for substrate recognition 
are also dislocated [87]. It was later shown; that this allosteric site is located in a linear circuit 
of functional residues that connects both active site and a positive cooperativity has been 
revealed by kinetic analysis. Thus the formation of a dimer itself can be regarded as allosteric 
control of the active site since the dimer interface and the active site are connected. The small 
molecule binding site can functionally reverse the procaspase activation suggesting a common 
regulatory site for the allosteric control of inflammation and apoptosis [88]. 
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1.3 Targeting and analyzing caspases 
1.3.1 General strategies of caspase inhibitor design 
The intrinsic subsite preferences for all caspases has been extensively studied with positional 
scanning approaches [89]. Knowledge about substrate specificity has been used to develop 
caspases inhibitors which resemble the natural substrate. These inhibitors contain three 
structural components: the P2-P4 peptides, the P1 aspartic acid and a warhead electrophile 
(e.g.: fluoromethylketone) which reacts with the nucleophilic cysteine. However, peptide 
inhibitors for caspases are unspecific and have poor drug like properties due to charged 
peptides. This has prompted researchers to develop molecules that mimic their natural 
substrates, so called peptidomimetics (Figure 1.10). An alternative approach is the exploration 
of compound libraries to identify peptidase inhibitors since it does not require knowledge of 
subsite preferences. A prerequisite for this high throughput screening (HTS) however is the 
availability of large and chemically diverse compound libraries and requires extensive 
screening followed by lead optimization to obtain the desired bioavailability and specificity.  
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Figure 1-10: Caspase inhibitors 
A) Cartoon representation of the structure of caspase-3 (grey) in complex with the peptide inhibitor Ac-
DVAD.fmk (cyan) represented as sticks in the active site (PDB entry code 1CP3)[90] B) Cartoon representation of 
the structure of caspase-3 (grey) in complex with the irreversible inhibitor ‘compound-1’ (B92, magenta, PDB 
entry code 3KJF) [91] represented as sticks in the caspase-3 active site. C) Chemical diagram of the hydrogen 
bonding interactions of Ac-DEVD with caspase-3 D) Chemical diagram of the hydrogen bonding interactions of 
‘Compound-1’ with caspase-3 [C and D adapted from [91]] E) Surface representation of caspase-3 in complex 
with both inhibitors. F) Structural alignment of the two inhibitors (color coding as in A and B) Ac-DEVD and 
‘Compound-1’. 
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1.3.2 Alternative strategies for the development of caspase inhibitors 
Many conventional peptidase inhibitors have limited specificity and significant off target 
effects. This lack of specificity is often the result of highly conserved active sites within a 
protein family or even other families with similar catalytic mechanisms. This problem also 
accounts for other highly conserved protein families such as kinases, a class of proteins 
frequently implicated in many human diseases. 
An alternative approach involves inhibitors which target epitopes other than the active site. 
One example is the endogenous ‘X-linked inhibitor of apoptosis protein’ (XIAP), which 
inhibits caspase-3, -7 and -9 [92]. Caspase-3 and-7 are inhibited by the BIR2 domain (Figure 
1.11A), which has a binding site outside the active site (exosite) and an unstructured peptide 
which binds into the active site groove to prevent binding of the natural substrate. Caspase-9 
is inhibited by an allosteric mechanism with the BIR3 domain binding the dimerization 
interface to prevent activation (Figure 1.11B). An advantage of allosteric inhibition is that the 
inhibitor is not competitive with the substrate and is thus not affected by substrate 
concentrations. This is particularly compelling if one considers that most peptidases work in 
substrate saturated environments where inhibition of a competitive inhibitor is weakened.  
The same inhibition strategy can be pursued with antibodies or alternative scaffolds such as 
designed ankyrin repeat proteins (DARPins). These proteins scan larger surface areas and 
thus enhance the specificity of the interaction. Furthermore, interactions with allosteric sites 
such as dimer interfaces are possible, similar to the BIR3 domain of XIAP. Although large 
molecules have several distinct advantages over small molecules their scope of application is 
limited to extracellular applications until novel methodologies are developed to efficiently 
deliver proteins across cell membranes. The potential of both approaches would be best 
exploited if they were combined so that structural studies of large molecules in complex with 
caspases could provide insight for the rational design of small-molecule inhibitors that mimic 
the binding interactions [89]. 
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Figure 1-11: Caspase inhibition strategies by nature  
A) Schematic sketch of XIAP inhibiting caspase-3 or caspase-9. Color coding is according to 3D structures in (B). B) 
XIAP (green) inhibits caspase-3 (blue) with is BIR-2 domain with a long loop which binds into the active site cleft 
and thus competes with substrate binding. Caspase-9 is inhibited by the BIR3 domain which binds the 
dimerization interface and prevents dimerization. Dimerization is critical for full catalytic activity so inhibition by 
preventing dimerization is an allosteric mechanism used by nature. C) Domain organization of XIAP with the two 
BIR domains responsible for caspase inhibition. A caspase cleavages site at residue 242 (SESD) is not indicated. 
Figure was adapted from [53]. 
 
1.3.3 Specific inhibition of caspases 
Caspase-1 is involved in the onset of inflammation and is a major target for drug design. 
Based on the optimal substrate specificity WEHD, several highly specific peptidomimetic 
molecules have been developed. The most prominent caspase-1 inhibitor, pralnacasan (VX-
740 from Vertex Pharmaceuticals) and a derivative VX-765, possess an IC50 of 1.3 nM for 
caspase-1 which is 1000 fold higher than for any other caspase [93]. Although both inhibitors 
were well tolerated and exhibited strong anti-inflammatory effects in mice, they were 
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ultimately withdrawn from clinical trials due to liver toxicity [45, 94]. A limitation of caspase 
peptidomimetics is the absolute requirement of a charged aspartic acid in P1 which has a 
negative impact on drug like properties and cell permeability. In order to ameliorate drug like 
properties and obviate the requirement of an aspartic acid, researchers also used small-
molecule caspase inhibitors. However, none of the drugs developed so far have succeeded in 
clinical trials [45]. A new emerging strategy with high potential to increase the specificity of 
caspase targeting drugs are allosteric and exosite inhibitors. Allosteric regulators targeting 
caspase-3 and -7 were developed using tethering or disulfide trapping which revealed two 
compounds that bound in close proximity to the dimer interface [86]. When bound, these 
compounds displaced residues in the active site, thereby occluding substrate binding in this 
region. 
 
Figure 1-12: Specific allosteric inhibition of caspase-2 by a DARPin 
A) Crystal structure of caspase-2 (blue) in complex with the inhibitory DARPin F8 (red) (PDB entry code 2P2C). The 
DARPin binds loop4 in an inactive conformation leading to allosteric inhibition. B) Inhibition of caspase-2 (blue) 
DARPin F8 and the short peptide inhibitor VDVAD.fmk (green) is illustrated. The short peptide competes with the 
caspase-2 substrate while DARPin F8 stabilizes a conformation that is unable to cleave the natural substrate. D) 
Specificity profile of both the DARPin F8 and VDVAC-CHO inhibitor. The peptide inhibitor is relatively unspecific 
while DARPin F8 only inhibits caspase-2 but none of the other caspases. Figure is adapted from [95]. 
 
49 INTRODUCTION 
 
 49 
The advancement of novel techniques in protein engineering of antibodies and alternative 
scaffolds, such as nanobodies and DARPins, has added another promising means for 
developing allosteric protein inhibitors. Antibodies, scFv and especially DARPins have been 
shown to modulate the function of a diverse array of proteins such as kinases [96] and also 
caspases (Figure 1.12)[95]. In the latter study, DARPin_F8 was shown to bind to a flexible 
surface area which includes loop 381 and some residues of the large subunit. Furthermore, the 
authors revealed that DARPin_F8 inhibits caspase-2 via an allosteric mechanism. Loop 381 
appears to be crucial in active site formation and binding of DARPin_F8 stabilizes a distinct 
conformation in which essential residues in substrate recognition are misaligned. With a Ki of 
0.29 nM, this DARPin is a highly potent caspase-2 inhibitor and has an exceptional selectivity 
profile for other caspase family members. DARPin_F8 is highly specific because is interacts 
with caspase-2 through a large interface and binds a unique epitope close to the active site. 
Although it is unlikely this DARPin will make it into clinical trials, structural insights into the 
inhibition mechanism may assist in the development of small and cell permeable molecules 
[97].  
1.3.4 Specific activation of caspases 
Since many diseases, including cancer, occur due to a decreased activity of peptidases a valid 
therapeutic strategy is to activate peptidases such as procaspase-3 [45]. One approach would 
be to block endogenous inhibitors which are often up regulated in several diseases. For 
example, XIAP is up regulated in acute myeloid leukemia (AML) and contributes to chemo 
resistance [98]. An antisense oligonucleotide (AEG35156) that targets XIAP induces 
apoptosis in combination with chemotherapy, showing that inhibiting the inhibitors is a viable 
approach [99].  
Many types of cancer cells are resistant to apoptotic stimuli due to overexpression of 
regulatory proteins such as IAP’s or BCL2. However, a very promising finding was that 
activation of caspase-3 efficiently kills cancer cells despite XIAP overexpression [100]. There 
are in principle two ways to activate a caspase depending on whether they are executioner or 
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initiator caspase. Firstly, initiator caspases such as caspase-8 can be activated by induced 
dimerization via mimicry of the DISC. According to the current understanding of the DISC, 
caspase-8 can be activated simply be creating a high local concentration of two procaspase-8 
monomers leading to autoproteolysis and dimerization. Secondly, executioner caspases such 
as caspase-3 are believed to be in equilibrium between the active and the inactive state; it is 
thus necessary to find a compound which either stabilizes the active conformation or 
destabilizes the inactive conformation [100]. The first compound (PAC1) that activates 
caspase-3 was reported by BioLineRtx in 2006, yet it remains controversial whether PAC1 
directly activates caspase-3 or whether the observed effect is due to a secondary Zinc 
mediated mechanism [101]. An independent HTS screening led to the discovery of a small 
molecule (1541) which activates caspase-3 at a concentration of 2.4 M [102]. Compound-
1541 was found to induce apoptosis in cancer cells and a mutational study in the active site 
revealed that this compound activates caspase-3 through stabilization of the active 
conformation. 
1.3.5 Specific analysis of caspase activities 
Positional scanning of the intrinsic subsite preferences has determined the optimal substrate 
sequences of each caspase [28]. This knowledge provided the basis for the design of caspase 
substrates in order to profile caspase activity in apoptotic cells. These tetrapeptide sequences 
were combined with a functional group (7-amino-4-methyl coumarin (AMC)) at the C-
terminal. Cleavage of the peptide after the P1 residue AMC leads to a fluorescent red shift of 
125 nm (ex= 345 nm, em= 440 nm)[103]. This fluorogenic caspase substrate (e.g.: Ac-
DEVD.AMC) thus allows profiling of caspase activity by fluorescent measurements. 
However, because caspases have highly overlapping sequence specificities, this method is 
unable to determine the activity of a single caspase in complex mixtures such as cell lysates of 
apoptotic cells [80]. One approach to overcome this limitation would be the isolation of the 
desired caspase by a specific binding protein such as an antibody or DARPin followed by 
activity profiling using tetra peptide substrates. Here the specificity is achieved via interaction 
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of the binding protein with a less conserved surface of the caspase, followed by the addition 
of highly sensitive substrates capable of detecting the activity of very low enzyme 
concentrations. In order to realize this approach, it is necessary to have a panel of binding 
proteins specifically targeting each of the caspases with affinities below the actual 
concentration of the caspases in an apoptotic cell. 
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1.4 Designed Ankyrin Repeat Proteins and their applications 
1.4.1 Antibodies and the rise of alternative scaffolds 
Antibodies have evolved as molecules that recognize antigens specifically in the adaptive 
immune system. The immunoglobulin fold has proven to bind target molecules with high 
specificity and affinity in both, in vivo and in vitro applications. Antibodies can be generated 
using the immune system of a host animal or with screening approaches of a synthetic library 
using various display technologies. They are large, multidomain proteins and their disulfide 
bonds and glycosylation are both indispensable for immune effector functions [104]. 
Antibodies, especially the IgG format have proven to be very successful therapeutics and 
represent the most widely used binding molecules [105, 106]. Despite this success, antibodies 
are rather expensive to produce and often aggregate when fused to effector molecules. They 
possess disadvantageous biophysical properties including disulfide bonds, a complex 
molecular composition and are large molecules with a size of about 150 kDa. Research, 
development and industrial production of antibodies are obfuscated by the high production 
costs and elaborate screening procedures. Consequently smaller variants such as Fab or scFv 
fragments have been developed based on the IgG antibodies and can be produced at much 
lower costs, however they inherit many of the above mentioned limitations [107](Figure 
1.13A).  
These circumstances gave rise to the development of non-antibody scaffolds and have led to a 
multitude of alternative scaffolds. Some of the most successful alternative scaffolds include 
Immunoglobulin-Like -sandwich (FN3), -barrel (Lipocalins), single loop (aptamers), -
helical scaffolds (Affibodies) and repeat proteins (DARPins, LRR). Although these proteins 
differ significantly in their properties and fold, their design and selection are based on the 
same fundamental principles (Figure 1.13A). 
The concept of a molecular scaffold for binding protein was developed in 1993 and is the 
basic idea of a stable protein core that tolerates extensive surface mutations that allow it to 
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bind a ligand [108]. Natural evolution has derived many folds with such properties and most 
are involved in various protein-protein contacts. An alternative scaffold should ideally be 
highly stable in order to tolerate a large number of mutations forming a contiguous interface. 
In addition it is generally favorable to have a small protein with no disulfide bonds and with 
high solubility in order to improve its experimental handling. The choice of a scaffold then 
requires the design of a highly diverse library and an appropriate selection technique which 
agrees with the biophysical properties of the desired protein and future application.  
This Chapter gives an overview of the development and applications of an alternative scaffold 
based on the Designed Ankyrin Repeat Proteins (DARPins). A more detailed description of 
the many diverse alternative scaffolds that have been used to design binding protein is 
reviewed in [104]. 
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Figure 1-13: Overview of selected alternative scaffolds 
 
1.4.2 Design of DARPins based on ankyrin repeat proteins 
The rational for developing DARPins was to overcome all limitations of antibodies and its 
variants while not compromising on affinity and specificity [104]. The desired properties are 
high expression yields, stability and solubility, absence of disulfide bonds or free cysteines 
and favorable folding properties. 
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DARPins have been designed based on naturally occurring ankyrin repeat proteins which are 
known to be highly stable and versatile binding molecules with a modular architecture. The 
fundamental idea was to design a consensus repeat encoding self-compatible repeat modules. 
Some amino acid positions would be conserved and necessary for folding of the backbone, 
whereas other positions would be non-conserved surface exposed residues involved in the 
interaction interfaces [109]. Based on an alignment using sequence databases a consensus 
sequence was defined. Positions with no or very low sequence preference were chosen as 
randomized residues (Figure 1.14 D). A second important aspect is the capping of repeat 
proteins to shield the hydrophobic interface of internal repeats [109]. The capping repeats 
increase the solvent accessible surface significantly and lead to increased solubility and 
stability. Assembly of the selected framework leads to modular repeats that form a stable and 
self-compatible protein fold while allowing randomized residues at the surface [110]. 
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Figure 1-14: Architecture of a DARPin 
A) Transparent surface and cartoon representation of DARPin E3_5 (PDB entry code 1MJ0). The randomized 
positions which build the interaction with the respective side chains interface are shown in red. B) Each DARPin 
has a N- and C-terminal Cap colored in blue and red respectively. Several repeats (white), in this case three, can 
be inserted between both caps and form a continuous hydrophobic core which is shielded by the two caps. C) 
Modular architecture of caps, repeats and the randomized positions (skyred) is shown. D) Sequence of a DARPin 
with the respective randomized positions in red and the secondary structure. Color coding is adapted from (C). 
Parts from this figure are adapted from [109]. 
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1.4.3 Stability and folding of DARPins 
The first crystal structure of a consensus ankyrin protein was solved by A.Kohl and H.K.Binz 
et al. [111]. This DARPin (E3_5) showed very favorable biophysical properties with a free 
energy of unfolding (G) of 14.84 kcal/mol and a midpoint of unfolding of approximately 5 
M GdmCl. Further general studies of H.K.Binz et al. with randomly chosen library members 
[110] showed that the DARPin expression yielded up to 200 mg per liter. They could be 
purified by immobilized metal-ion affinity chromatography (IMAC) with a single step 
resulting in high purity. Only 1 of 6 selected binders showed a dimer peak indicating that 
DARPins are generally monomeric in solution. All DARPins showed cooperative unfolding 
while exhibiting substantial heat resistance with midpoints between 66 °C and more than 85 
°C. The G values for unfolding were calculated between 9.5kcal/mol and 21.1 kcal/mol. 
A folding study of a single consensus repeat with flanked capping repeats revealed that the 
AR is an autonomously folding domain following monoexponential kinetics with kfolding= 28 
sec
 -1
 and k unfolding=0.9 sec 
-1
. Specific unfolding enthalpy and entropy as well as the 
temperature slope of the heat capacity are typical for globular protein domains explaining the 
favorable properties of the consensus framework [112]. The hydrophobic interactions 
between the helices within a single AR are not well optimized, while hydrophobic stacking is 
more compact at inter-repeat interfaces. This finding explains the cooperative behavior of the 
number of internal repeats and thermodynamic stability [110].  
In order to address the folding and unfolding behavior of a DARPin as a function of the 
number of repeats S.K.Wetzel et al. designed a DARPin with identical repeats [113]. While 7 
out of 33 amino acids were randomized in the common DARPin library, defined residues 
were assigned to the variable positions according to sequence statistics and structural 
considerations [110]. This “averaged structure” revealed that DARPins with three repeats can 
only be entirely denaturated when boiled in 5 M GdmCl, whereas DARPin with four or more 
repeats did not denaturate when boiled in 8 M GdmCl. These findings highlight the 
cooperativity between stability and number of repeats and can be rationalized following the 
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Ising model. The stability of the AR protein is determined by unfolding rates rather than the 
folding rates which are monophasic (~400-800 s-1) and almost independent from the number 
of repeats. The unfolding rates in contrast decrease by a factor of 10
4
 with every repeat. This 
leads to the conclusion that the folding can be considered as a nucleation event where the 
folding of a single repeat triggers the folding of the entire molecule. The unfolding needs a 
progressive disruption of all repeats and is consequently dependent on the number of repeats 
[114]. 
A study by T.Merz et al. gave more insight to the intramolecular interactions that contribute 
to the stability of a DARPin by comparing two DARPins at atomic resolution [115]. His 
findings highlighted the almost crystal-like regularity of a network composed by salt bridges 
on the surface involving sulfate ions. This suggests that this regular charge network of surface 
exposed electrostatic interactions contributes to the stability of the protein next to the compact 
hydrophobic core. Although it is believed that this interaction network is a hidden design 
feature in this protein family, it can no longer be observed in naturally occurring AR proteins 
due to functional selection [115]. 
The contribution of the hydrophobic core and the surface exposed salt bridges are so 
tremendous that randomization of amino acids in specific positions can be easily tolerated 
without a critical loss of stability. This case highlights the interplay of stability and functional 
selection showing that stability is a prerequisite to functional selection. 
 
1.4.4 Target directed DARPin selection with display techniques 
The generation of specific binding proteins by immunizing animals is limited to proteins that 
can be evolved by the respective immune system. Although this approach offers different 
forms of antibodies or leucine rich repeat proteins (LRR) [116] depending on the host animal 
it does not allow the directed evolution of alternative scaffolds. This prompted researchers to 
develop in vitro techniques that mimic the classical selection procedure of the immune system 
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by physically coupling genotype with phenotype. The first display technique was developed 
in 1985, namely Phage display [117] providing a system of a viral phage which encapsulates 
DNA and presents the corresponding protein on the surface. Phage display is to date the most 
commonly used system for directed evolution and is especially attractive because of its high 
robustness and availability in different laboratories. Different display systems have emerged 
in recent years using different phages, cells or molecules such as proteins, DNA or RNA.  
One main limitation in cell or virus based systems is the absolute requirement of a 
transformation step in order to integrate DNA into the host. The relative low transformation 
efficiency that is obtained witch current techniques, limits the library size to less than 10
8
 
molecules [118]. In contrast one can obtain library sizes of up to 10
14
 molecules with cell free 
methods such as Ribosome Display (RD) which was first demonstrated by Hanes and 
Plückthun [119]. The phenotype-genotype coupling is achieved through a stable complex of 
mRNA, ribosome and the translated protein. The ribosome does not dissociate from the 
translated RNA due to the absence of a stop codon but allows the translated target protein to 
fold and exit the ribosomal tunnel owing to a tether sequence incorporated in the RNA library. 
The complex can then be panned against any target molecule that is usually immobilized on a 
surface followed by several washing steps. The genetic information of selected binding 
proteins is then recuperated and reverse transcribed into a more stable DNA library. A more 
detailed description is shown in figure 1.15. The most recent publication on RD offers an 
overview and a protocol including all aspects which have to be considered when performing 
RD selections [120].  
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Figure 1-15: Protein display technologies 
Both Phage Display (PD) and Ribosome display (RD) couple phenotype with genotype with Phages or Ribosomal 
complex respectively and allow selection of a protein for a specific binder. Both selection methods require a DNA 
library of a protein to be selected. In the case of PD, this library is transfected into E.coli and subsequently 
infected by phages. The amplified phages carry a single gene and present the according protein on the surface; 
this allows selection for a target protein which is immobilized on a surface. The DNA library in RD is transcribed 
into mRNA and then translated by a Ribosome. A tether sequence stops the translation and allows the formation 
of a stable complex of mRNA, ribosome and translated proteins which allows the selection against an 
immobilized target protein. The phage and the ribosome complex are eluted after selection in both PD and RD 
and the DNA and RNA are recovered respectively. This selection cycle can be repeated multiple times until 
sufficient enrichment of the library for a target is accomplished. Both selection techniques are followed by 
cloning of the selected library into E.coli with subsequent analysis of single clones by ELISA techniques. Ribosome 
display drawing was adapted from [121]. 
 
We have chosen RD to evolve DARPins against Caspase for several reasons. Firstly, the 
library based on the DARPin scaffold has a theoretical diversity of 10
23
 molecules, and RD 
represents the least limiting selection technique in terms of library size. Secondly, RD and 
DARPins libraries are compatible with high expression and stability of DARPins in the S30 
translation system. Finally DARPins show poor display levels using the conventional Phage 
Display system based on the Sec translocation system due to high folding rates that interfere 
with translocation to the phage surface. Only recently a novel variant named “SRP Phage 
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Display” yielded increased surface display of DARPins by exchanging the translocation 
signal sequence [122]. Third, RD has an additional diversification due to reverse transcription 
and multiple PCR amplification steps which increase the practical library diversity 
significantly. This may also lead to unpredictable but favorable framework mutations that can 
strongly impact affinity [123].  
It should be noted that each system has distinct advantages and disadvantages and the 
appropriate system should be selected carefully depending on the scaffold and the intended 
properties one aims to obtain. The DARPins scaffold combined with the designed library are 
highly compatible with RD and many studies have successfully combined the two 
technologies. 
1.4.5 Recent Applications of DARPins 
Since the development of the consensus ankyrin repeat protein and the combinatorial library 
[110], many studies have shown specific and high affinity binding of various target proteins. 
The first crystal structure of a DARPin in complex with its target protein maltose binding 
protein (MBP) at a resolution of 2.3 Å gave first insight on the interaction interface mediated 
by DARPins (Figure 1.16C) [124]. The selected DARPin (off7), a N3C molecule bound to 
MBP, exhibited a KD of 4.4 nM and was specific to its target protein. The interactions in the 
interface were only mediated by randomized surface residues with a total buried surface area 
of 1.267 Å
2
. This proof of principle work confirmed the feasibility and opened the door for 
many different studies and applications. 
The first tailor made protein inhibitor was selected against aminoglycoside 
phosphotransferase (3’)-IIIa (APH), and again showed high specificity and affinity and 
completely inhibited APH in vitro and lead to a gene knockout phenotype in vivo [96]. This 
study underlines the potential of DARPins for modulation of intracellular protein function. 
The crystal structure of APH in complex with its inhibitory DARPin AR_3a revealed an 
allosteric inhibition mode by binding three -helices in a displaced conformation. This shows 
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that DARPins are not limited to active site binding in contrast to small molecules, thus 
representing a powerful starting point for rational drug design in combination with allosteric 
inhibition by DARPins [125]. 
Another highlight was the first DARPin selected against the soluble domain of a membrane 
protein, the human epidermal growth factor receptor 2 (Her2). The selected DARPins bound 
to the same epitope as Herceptin with a KD of 7.3 nM. Her2 is an important target for cancer 
therapy and diagnosis thus the selected DARPins might be used for the development of 
diagnostic tests or in cancer treatment [126]. In a subsequent study, the affinity of the best 
selected Her2 binder was improved to 90 pM by error-prone PCR and affinity maturation. A 
single point mutation in the framework residue (H53T) leading to a conformational change in 
relative disposition of the repeat domains resulted in a 3000-fold affinity increase compared 
to the consensus sequence [123]. This DARPin (H10-2-G3) has the highest affinity so far 
reported of an AR protein [123, 127]. 
A central problem in targeting enzymes such as proteases is lack of specificity due to the fact 
that the binding hotspots are usually the active sites which are known to share homologous 
structures and overlapping specificities [97]. A study by A. Schweizer and H.Roschitzki-
Voser demonstrated the specific inhibition of Caspase-2 with DARPin AR_F8 by avoiding 
the actual active site and binding an exposed loop that is involved in the formation of the 
active site. Binding the loop freezes a nonproductive conformation and reveals a 
conformation of the active site that can be exploited for the design of inhibitory compounds. 
AR_F8 is the only specific caspases inhibitor to date [95].  
The first structure of a DARPin binding an integral membrane protein (AcrB) has been 
published by G. Sennhauser et.al [128] with a resolution of 2.5 Å, higher than any structure of 
AcrB before (Figure 1.16B). This study demonstrates that DARPins can be used as 
crystallization chaperones in order to improve resolution or help the crystallization process by 
extending the hydrophilic surface [129]. Next to the improved resolution, the selected 
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DARPin allowed functional studies of substrate transport by stabilizing an inactive 
conformation.  
In total, 18 reports have demonstrated the selection of DARPins against multiple targets 
including soluble and membrane proteins from various species. Taken together, this confirms 
that DARPins can in principle be selected against literally any protein for multiple 
applications. However, these studies represent only a fraction of possible applications that are 
imaginable for the future. 
 
 
Figure 1-16: Crystal structures of DARPins 
The DARPin is colored in blue (N-Cap) white (internal repeats) and red (C-Cap). A) The first DARPin selected was 
against MBP showing how the interaction is mediated by the randomized positions (PDB entry code 1SVX)[124]. 
B) First structure of a DARPin in complex with a membrane protein (green)(PDB entry code 2J8S [128]). The 
membrane protein AcrB is a trimeric protein and binds two DARPins only. C) Structure of the first N2C DARPin in 
complex with the wild-type PLK-1 kinase domain (green) (PDB entry code 2V5Q [127]). 
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1.4.6 Applications and future perspective 
Alternative scaffolds are expected to replace most applications that have previously been 
demonstrated by antibodies due to the amelioration of several features such as: stability, 
expression and purification as well as production costs. In addition, intracellular applications 
become feasible owing to the fact that most alternative scaffolds do not contain cysteine 
bonds. As described in several studies [104, 130], possible applications involve five areas: 
Therapeutic applications - The vast majority of therapeutic binding molecules on the market 
or in clinical studies are antibodies and alternative molecules are only slowly entering clinical 
trials. Antibodies have a long history of research and have clear advantages over other 
binding proteins. Their bivalent interactions leads to high affinities, they are fully human are 
well tolerated and have a long serum half-life. However antibodies also have limitations since 
it is a large multi domain protein with cysteine bonds and glycosylation and are thus rather 
difficult to handle at relatively high costs. The therapeutic effect that is achieved with 
antibodies is usually based on blocking a target or by "exerting effector functions" to activate 
a response of the immune system [131].  
DARPins represent an ideal protein class to complement antibodies in blocking or 
neutralizing target proteins. The absence of an effector domain (Fc) reduces the activation of 
the immune system and their significantly smaller size is expected to advance tissue 
penetration. It is further expected that antagonistic DARPins will have an enhanced ability to 
remove unwanted molecules such as toxins based on their short serum half-life. Although 
DARPins do not have effector functions, their mode of action is not limited to simply 
blocking or neutralizing a target. Their single domain architecture does not contain any 
cysteines, which allows the attachment of diverse molecules affecting their pharmacokinetic 
properties or even effector domains. Such a conjugated DARPin could thus deliver toxins, 
cytokines, enzymes or even a second DARPin domain for the recruitment of other effectors 
(Figure 1.17). This is indeed also possible with antibodies and other binding molecules but the 
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stability, ease of use and the possibility of introducing site-specific thiol groups constitute 
clear advantages for the DARPin fold [104, 131]. 
Chromatography and affinity purification based on specific antibodies is already applied and 
represents a well-established technique. The antibody is immobilized onto a surface and is 
able to purify the specific binding partner from complex mixtures such as cell lysates. Protein 
A is the most prominent example for standard purification of antibodies. Limitations in this 
field are mostly the high cost of antibody production and the sensitivity of antibodies to harsh 
washing or reducing conditions. Alternative scaffolds, especially DARPins are highly 
attractive due to their cheap production costs and the highly stable fold. We can expect 
significant progress in this field with an increasing number of specific binding proteins in the 
near future (Figure 1.17). 
Crystallization Chaperones facilitate crystallization and crystal packing of a desired target 
protein. This is in most cases given by reducing conformational heterogeneity, masking 
hydrophobic surfaces or by mediation of crystal contacts within the crystal lattice. In addition 
they may provide phase information by molecular replacement or the incorporation of heavy 
metal derivatives [132]. Immunoglobulins, Fab fragments and scFv’s have been successfully 
used as crystallization chaperones in the past and the potential and success stories of 
DARPins as crystallization chaperones has been recently reviewed [129] (Figure 1.17). 
Several structures of DARPins in complex with their target proteins have been solved, but the 
only example of a DARPin in complex with a previously unknown structure is the kinase Plk-
1 [127]. In order to reveal the true potential of DARPins in as crystallization chaperones many 
more structures and studies are needed. 
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Figure 1-17: Possible applications of DARPins.  
Applications as drugs are financially most attractive but many more applications as a technology in research are 
possible due to their favorable properties. 
 
Diagnostic applications such as ELISA, Flow cytometry and immunohistochemistry are 
mainly based on antibodies, alternative scaffolds may play a distinct role in the future because 
they can be produced at lower costs and might have a longer shelf half-life. Additionally 
cysteine free scaffolds allow specific immobilization to a surface or the attachment of 
functional groups such as fluorophore by introducing a specific cysteine. Whether alternative 
scaffolds will replace antibodies in the future will depend on the availability of such 
molecules in the scientific community. 
Intracellular applications could so far not be studied by antibodies due to their cysteine bonds 
that do not form in the cytoplasm. Alternative scaffolds are thought to have higher potential in 
this aspect as they can be expressed intracellularly (Figure 1.17). Several studies have shown 
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that selected synthetic molecules such as aptamers and DARPins can be used to perturb 
cellular functions [133, 134]. Despite its potential this approach still represents major 
bottlenecks, since synthetic proteins are not cell permeable and require expression in the host 
cell. 
In summary alternative scaffolds such as DARPins represent a complementary proposition to 
antibodies in almost all fields. Antibodies are still the most successful molecules in all 
applications but DARPins are an attractive alternative due to their favorable biophysical 
properties. While the majority of applications remain in their infancy, the most promising of 
these appear to target functions which are not possible for antibodies: intracellular 
applications, protein trafficking, dissection of pathways and sensors of biomarkers [130]. 
Their success as drugs will depend on the general immunogenic tolerance as therapeutics 
[135]. 
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Abstract 
Different strategies for the expression, purification and kinetic characterization of caspases 
have been described previously offering a vast number of protocols. In this work we have 
systematically revised these protocols and describe a comprehensive optimized expression 
and purification protocol for caspases 1-9 as well as improved assay conditions for their 
reproducible kinetic characterization. The here described studies on active site titration 
revealed that the accuracy is heavily influenced by the presence of DTT in the assay buffer. 
Furthermore it was found, that the activity of some caspases is not proportional to their 
enzyme concentration, explaining the discrepancy between the published values of specific 
activities. Our results contribute to overcome this problem leading to higher reproducibility in 
expression, purification and kinetic characterization of caspases. 
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Introduction 
Caspases are a conserved family of peptidases that play essential roles in inflammation and 
apoptosis. They employ a cysteine residue as the catalytic nucleophile and share a stringent 
specificity for cleaving their substrates after an aspartate in P1 position. To date twelve 
different human caspases have been identified and are classified into apoptotic or 
inflammatory caspases based on their sequence homology and substrate specificity 
(Figure 1).  Caspase-1, -4 and -5 are known to be involved in cytokine activation in the 
inflammatory response. Their main substrates are pro-interleukin-1-β and pro-interleukin-18 
which are activated upon caspase cleavage [136]. Caspase-12 which shares high sequence 
homology with caspase-1 is not expressed as a protease in the majority of the human 
population due to an early stop codon [137].  
The apoptotic caspases can be further subdivided into initiators (caspase-2, -8, -9 and -10) and 
executioners (caspase-3, -6, and -7). The main substrates for the initiator caspases are the 
executioner caspases, which once activated cleave many cellular proteins which are important 
for the integrity of the cell such as PARP, Lamins, various kinases an others to promote 
apoptosis [138-141]. Caspase-14 is a unique member of the caspase family which has been 
shown to be involved in proliferation and differentiation of keratinocytes [53, 142, 143]. 
In cells, caspases are expressed as pro-enzymes containing an N-terminal prodomain and a 
catalytic domain.  The catalytic domain consists of a large (17-20 kDa) and a small (10-
12 kDa) subunit connected by a short inter-domain linker (Figure 1). Processing of the 
caspase prodomain and the linker results in the formation of the active enzyme with two 
substrate-binding sites [48, 144]. All caspases share a highly conserved fold and have a high 
sequence homology, with the highest identities found within the family of inflammatory 
caspases (60-80 %). 
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Figure 1: Phylogenetic tree of the caspase family. 
The tree is organized based on the sequence similarity and substrate specificity. The sequence numbering 
highlighted in bold corresponds to the Swiss-Prot entries and numbering in grey represents the caspase-1 
nomenclature suggested by Fuentes-Prior and Salvesen 2004 [53].  
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Given the biological importance of caspases in apoptotic and inflammatory processes and 
their subsequent pharmaceutical potential, major research efforts in both academia and 
industry have been focused on investigating the structure and function of these enzymes.  
These studies have led to the functional classification and description of the role of individual 
caspases in apoptotic and inflammatory signaling. For the pharmaceutical industry the 
ultimate goal is to design small molecule substrates and inhibitors, selectively targeting 
individual caspases. The large scale production and handling of human caspases in their 
active form is absolutely essential to make further advances in this direction.  
Caspases were first isolated from natural sources. For example THP-1 cells, monocytes from 
human myeloid leukemia cell lines provided the source for caspase-1 and also caspase-3 [5, 
145]. Caspase-9 could be isolated from HeLa cells, a human uterine carcinoma cell line [18]. 
However, caspases could also be expressed in E.coli and purified as active enzyme resulting 
in significantly higher yields. The various procedures have been described in numerous 
publications all involving the heterologous expression of the catalytic domains.  
Here we describe optimized, detailed and consolidated expression and purification protocols 
for human caspases 1-9 that yield enzymes of equally high purity. Furthermore, we have re-
determined the enzymatic activities of all caspases in different conditions and propose optimal 
protocols for activity measurements and kinetic analyses. 
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Material and Methods 
 
Expression and purification of human caspases 
The plasmids for the expression of caspase-1, -2, -3 -4, -5, -6, -7, -8 and -9 are cloned as 
indicated in Table 1. 
Caspase Gene Vector 
Caspase-1 
Large subunit MA_N120 -- D297 pET28a(+)
kan
 
Small subunit MGS_A317-- H404_LEHHHHHH pET28a(+)
kan*
 
Caspase-2 
Large subunit MA_N150 -- D316 pET11d
amp
 
Small subunit M_A331 -- T435 pET11d
amp
 
Caspase-3 Full length       M-S1 – H277_ALEVLFQGPHHHHHHH pET28a(+)
kan
 
Caspase-4 
Large subunit  M_Q81 -- D270_LE pET21(+)
amp
 
Small subunit M_A290 -- N377_LEHHHHHH pET21(+)
amp
 
Caspase-5 
Large subunit M_A135 -- D311 pET11d
amp
 
Small subunit MGS_S331 -- N418_LEHHHHHH pET28a(+)
kan*
 
Caspase-6 Full length      M1-N293_LEHHHHHH pET21(+)
amp
 
Caspase-7 Full length      M1-Q303_LEHHHHHH pET23b(+)
amp
 
Caspase-8 
Large subunit MG_E218 -- D374 pET11d
amp
 
Small subunit M383 -- D479 pET11d
amp
 
Caspase-9 Full length     M1-S416_LEHHHHHH pET23b(+)
amp
 
 
Table 1: Constructs for the expression of human caspases. 
 
Expression and purification of caspase- 3, - 6, -7 and -9 (procedure A1a) 
The full length gene for caspase-3 was cloned into pET28a(+)
kan
 engineered to carry a C-
terminal His7-tag after a 3C cleavage site. The constructs for the expression of human 
caspase-6, -7 and -9 were obtained from Dr. Guy Salvesen, The Burnham Institute, La Jolla, 
USA [146]. The gene for caspase-6 was cloned into pET21(+)
amp
, caspase-7 into 
pET23b(+)
amp
 and caspase-9 in pET23b(+)
amp
 all containing a C-terminal His6-tag [146]. The 
caspase-6 construct was mutated at the cleavage site located between the large subunit and the 
linker (D294VVDNQ299  D294EVDAA299) because this cleavage site was only partially 
processed by bacterial proteases. The mutated construct yielded fully processed homogenous 
caspase-6 when expressed in E.coli. Expression and purification was carried out according to 
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the protocols established by Stennicke and Salvesen [146, 147]. The plasmids were 
transformed into BL21 (DE3). Single colonies were used to inoculate a 5ml 2×YT culture 
(0.5% NaCl, 1% Yeast Extract, 1.6% Tryptone), containing the appropriate antibiotic and was 
then grown at 37°C overnight (~210rpm). This culture was used to inoculate 500 ml of 
selective 2×YT medium in 2-liter baffled flasks at an OD600 of 0.02 and grown at 37°C. 
When the culture reached an OD600 of 0.6 – 0.8 the temperature was lowered to 30°C, 
expression was performed as listed in Table 2.  
 
Caspase E.coli Strain 
Temperatur
e 
[IPTG] Time OD600 
Caspase-3 BL21 (DE3) 30°C 0.2 mM 3h 0.6-0.8 
Caspase-6 BL21 (DE3) 30°C 0.02 mM 18h 0.6-0.8 
Caspase-7 BL21 (DE3) 30°C 0.2 mM 18h 0.6-0.8 
Caspase-9 BL21 (DE3) 30°C 0.2 mM 3h 0.6-0.8 
 
Table 2: Expression conditions for human caspase-3, -6, -7 and -9.  
 
Cells were harvested and washed in cell wash buffer (100 mM Tris-HCl, pH 8, 100 mM 
NaCl) subsequently resuspended in 50 ml lysis buffer (100 mM Tris-HCl, pH 8, 100 mM 
NaCl, 20 mM Imidazole, 10 units/ml DNaseI). Cells were broken using an EmusliflexTM 
homogenizer and further purified by immobilized metal ion affinity chromatography (IMAC). 
Lysate was cleared by centrifugation followed by filtration (0.22 mm syringe filter) and was 
loaded on a Ni
2+
-nitrilotriacetic acid (Ni-NTA) (Qiagen, Chatsworth, USA) gravity flow 
column previously equilibrated with wash buffer (100 mM Tris-HCl, pH 8, 500 mM NaCl, 20 
mM Imidazole). Nonspecifically bound protein was washed out with wash buffer and the 
protein was eluted with elution buffer (100 mM Tris-HCl, pH 8, 100 mM NaCl, 200 mM 
Imidazole). Fractions containing pure and active caspase were pooled. 
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Expression, refolding and purification of caspase-1, -2, -4, -5 and -8 (procedure B2a & b) 
For separate expression of the individual subunit, the plasmid of each subunit was 
transformed into BL21-Codon Plus (DE3)-RILtetr, pRareCodon
cam
. Single colonies were 
inoculated in 5 ml selective 2×YT medium and grown at 37°C overnight. Overnight cultures 
were transferred into 500 ml selective 2×YT medium in 2-liter baffled flasks and grown until 
an OD600 of 0.8 was reached. To express caspase subunits the cells were induced by adding 1 
mM IPTG and grown for 4 hours at 37°C. Under these conditions both caspase subunits were 
highly expressed and localized in the inclusion body fraction where they constituted more 
than 90% of the total protein. 
 
Cells from 500 ml culture were harvested, washed in 10 mM Tris-HCl, pH 8.0, resuspended 
in 50 ml lysis buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 10 units/ml DNaseI) and 
incubated for 1 hour at 4°C. The cells were broken using an Emusliflex
TM
 homogenizer and 
inclusion bodies were pelleted by centrifugation (17000×g for 20 min at 4°C). 
The pellets were washed twice in buffer 1 (50 mM Tris-HCl, pH 8, 300 mM NaCl, 1 M 
Guanidine Hydrochloride 0.1% Triton-X-100) and twice in buffer 2 (50 mM Tris-HCl, pH 8, 
300 mM NaCl, 1 M Guanidine Hydrochloride). Between each washing step the pellets were 
resuspended using an Ultra Turbax blender and pelleted by centrifugation for 20 min at 4°C 
and 17000×g. The washed inclusion bodies were solubilized by stirring the sample overnight 
at room temperature in a volume of 3 mL solubilization buffer (6.5 M Guanidine 
Hydrochloride, 25 mM Tris-HCl, pH 7.5, 5 mM EDTA, 100 mM DTT).  
 
Refolding of active caspases was achieved by rapid dilution. Equimolar amounts of both 
subunits were combined to a total volume of approximately 6 ml and rapidly diluted in 250 ml 
of refolding buffer (Table 3) to a final concentration of 200-500 µg/ml. Refolding was 
performed overnight at 20°C, with gentle stirring under nitrogen to avoid oxidation. Unfolded 
and aggregated protein was removed by centrifugation for 20 min at 4°C, 5000× g and 
subsequent filtration (0.22 mm syringe filter). 
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Following refolding, caspase-4 and 5 were further purified by IMAC (B2a), caspase-2 and 8 
by anion exchange chromatography and caspase-1 by cation exchange chromatography (B2b). 
 
 
Caspase Buffer pH 
Caspase-1 
100 mM HEPES, 100 mM NaCl, 100 mM Sodium Malonate, 20% 
Sucrose, 0.5 M NDSB-201, 10 mM DTT 
8.0 
Caspase-2 100 mM HEPES, 20% Sucrose, 10 mM DTT 7.5 
Caspase-4 
100 mM HEPES, 100 mM NaCl, 100 mM Sodium Malonate, 20% 
Sucrose, 0.1 M NDSB-201, 10 mM DTT 
7.5 
Caspase-5 
100 mM HEPES, 100 mM NaCl, 100 mM Sodium Malonate, 20% 
Sucrose, 0.1 M NDSB-201, 10 mM DTT 
8.0 
Caspase-8 100 mM HEPES, 10% Sucrose, 0.1% CHAPS, 10 mM DTT 7.5 
 
Table 3: Refolding conditions for human caspases.  
 
 
Expression and purification of human caspase-4 and -5 (procedure B2a) 
After refolding and filtration caspase-4 and -5 were dialysed against IMAC wash buffer (50 
mM Tris-HCl, pH 7.5, 250 mM NaCl, 10% Sucrose, 20 mM Imidazole) in order to reduce the 
DTT concentration. 
The protein solution was loaded on a Ni2+-NTA gravity flow column previously equilibrated 
with IMAC wash buffer (50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 10% Sucrose, 20 mM 
Imidazole). The protein sample was loaded twice and the column was subsequently washed 
with washing buffer (total volume 100x of the bead volume) to remove nonspecifically bound 
protein. The protein was eluted with 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% Sucrose, 
250 mM Imidazole. Fractions containing pure and active caspase are pooled and stored at -
80°C. 
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Expression and purification of human caspase-2 and -8 (procedure B2b) 
 
The refolding solution of caspase-2 and -8 was concentrated 10 fold by ultrafiltration using an 
stirred cell (Model 8200, Amicon) and a PLG cellulose membrane, 10-30 kDa molecular 
weight cutoff at 4°C, under nitrogen. The concentrated refolding solution was dialyzed 
overnight against buffer A (20 mM HEPES pH 7.5, 10% Sucrose) at 4°C in order to reduce 
the salt concentration and to facilitate binding to the column. Subsequent purification was 
carried out by anionic exchange chromatography at 4°C using a MonoQ HR 5/5 column (GE 
Healthcare Life Sciences, Uppsala, Sweden). The protein was eluted with buffer B (20 mM 
HEPES, pH 7.5, 10% Sucrose, 500 mM NaCl) using a gradient from 0-200 mM NaCl in 20 
column volumes. Fractions containing pure and active caspase were pooled. 
 
 
Expression and purification of human caspase-1 (procedure B2b) 
 
To prevent autoproteolysis, the refolding buffer for caspase-1 was supplemented with 100 
mM Sodium Malonate (Table 3). The refolding solution was concentrated 10 fold by 
ultrafiltration (10 kDa molecular weight cutoff) and dialyzed against buffer A (30 mM Na-Ac, 
pH 5.9, 10% glycerol) in order to facilitate binding to the column. Subsequent purification 
was carried out by cation exchange chromatography at 4°C using a ResourceS column (GE 
Healthcare Life Sciences, Uppsala, Sweden) and the protein was eluted with 25% buffer B 
(72 mM Na-Ac, pH 5.9, 400 mM NaMalonate, 10% Glycerol) corresponding to a final 
NaMalonate concentration of 100 mM. Fractions containing pure and active caspase-1 were 
pooled. 
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Size exclusion chromatography 
 
Size exclusion buffer 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 
 5 mM DTT, 10% Sucrose 
 
For analytical purposes and for buffer exchange after IMAC, all caspase were further purified 
by size 
exclusion chromatography using a Superdex 200 5/150 GL or a Superdex 200 10/30 GL 
column respectively (GE Healthcare Life Sciences, Uppsala, Sweden) previously equilibrated 
with size exclusion buffer.  
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Kinetic characterization of caspases 
 
Standard caspase assay buffer 20 mM PIPES, pH 7.5, 100 mM NaCl, 1 mM EDTA, 
 5 mM DTT, 0.1% (w/v) CHAPS, 10% Sucrose  
 
High citrate assay buffer 50 mM Tris-HCl, pH 7.5 (6.5 for caspase-2) 
 1 M NaCitrate, 5 mM DTT, 10% Sucrose 
 
Caspase-2 assay buffer 100 mM MES, pH 6.5, 10% (w/v) PEG600,  
 5 mM DTT, 0.1% (w/v) CHAPS 
 
Caspase activity assay 
The caspase activity was determined in a fluorometric assay using substrates with the general 
structure Ac-Xaa-Xaa-Xaa-Asp↓AMC incorporating the sequence previously determined to 
be optimal for each caspase [28] (Table 4). In order to ensure linearity, caspases were assayed 
at protein concentrations such that not more than 10% of substrate was converted during the 
measurements. Appropriate dilutions of enzymes (Table 4) were added to the reaction 
mixture containing buffer and substrate at concentrations of 0.2·Km to 5·Km in a total assay 
volume of 100 μl. To analyze the effect of kosmotropic salt on the kinetic properties, the 
individual caspases were assayed in standard caspase assay buffer as well as in high citrate 
assay buffer. 
AMC release was monitored by measuring the fluorescence at λex = 360 nm and λem = 465 
nm using a spectrofluorometer (Tecan Infinite M-1000). Kinetic constants were computed by 
direct fits of the initial velocity data to Equation 1, where ν is the initial velocity, V the 
limiting rate and Km the Michaelis constant. An AMC standard curve was determined for each 
experiment. Caspase activity was expressed in units per mg active protein (one unit 
corresponds to the conversion of 1μmol caspase substrate per min). 
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For qualitative analysis of enzyme activity during protein purification, 5 μl of peak fractions 
were diluted in standard assay buffer, the reaction started by adding DMSO-dissolved 
substrate to a final volume of 100 μl and initial rates of substrate hydrolysis were calculated. 
 
Caspase 
Protein 
Concentration 
pH 
Preferred 
Substrates 
Caspase-1  10-50 nM 7.5  Ac-WEHD↓AMC 
Caspase-2  5-20 nM 6.5 
 Ac-
VDVAD↓AMC 
Caspase-3  1-10 nM 7.5  Ac-DEVD↓AMC 
Caspase-4  50-100 nM 7.5  Ac-WEHD↓AMC 
Caspase-5  50-100 nM 7.5  Ac-WEHD↓AMC 
Caspase-6  10-100 nM 7.5  Ac-IETD↓AMC 
Caspase-7  10-100 nM 7.5  Ac-DEVD↓AMC 
Caspase-8  10-100 nM 7.5  Ac-DEVD↓AMC 
Caspase-9  50-100 nM 7.5  Ac-LEHD↓AMC 
 
Table 4: Optimized assay conditions for activity measurements of caspases.  
 
 
SDS-PAGE analysis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 15 % was used to 
separate the caspase subunits by their size. 15 l of caspase (~1 mg/ml) was mixed with 5 l 
of 4x loading buffer containing 1% -mercaptoethanol. The samples were boiled at 95°C for 
10 min and 10 l were loaded per lane in a gel (Protean, BioRad). 
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Enzyme activity in dependence of initial caspase concentrations  
The dependence of the enzyme activity on the caspase concentration was determined in 
standard assay buffer, except for caspase-9, which was assayed in high citrate assay buffer. 
The individual caspases were analyzed at three different concentrations (1x, 2x and 4x), the 
lowest (1x) concentrations were: 20 nM caspase-1, 3 nM caspase-2, 1 nM caspase-3, 50 
nM caspase-4, 50 nM caspase-5, 100 nM caspase-6, 10 nM caspase-7, 10 nM caspase-8 and 
25 nM caspase-9. The substrate concentrations were kept constant at 140 µM. Ac 
WEHD↓AMC was the substrate used for caspase 1, -4 and -5, Ac-DEVD↓AMC for caspase-
3, 7 and -8, Ac-IETD↓AMC for caspase-6, Ac-LEHD↓AMC caspase 9 and Ac-
VDVAD↓AMC for caspase-2. 
Product formation at different caspase concentrations were plotted against time multiplied by 
the concentration factor. 
 
Active site titration 
In order to obtain reliable kinetic data, active enzymes concentrations were first determined 
accurately by active site titration, where the caspases were titrated with increasing 
concentrations of covalent and preferentially irreversible inhibitors and decreasing enzyme 
activity was measured. A plot of the residual activity versus inhibitor concentrations revealed 
the active site concentration. 
In order to analyze the reversibility of the covalent enzyme-inhibitor complex under reducing 
conditions, caspase-8 was used as a case study. 75 nM enzyme were titrated with Ac-DEVD-
CMK in 3 different assay buffers either without DTT or supplemented with 10 mM and 12 
µM, respectively. 
The following inhibitors were used for active site titration: Ac-YVAD-CMK (Peptanova, 
Sandhausen, Germany) for caspase 1, -Ac-WEHD-CHO (Peptanova, Sandhausen, Germany) 
for 4 and -5,  Ac-VDVAD-CHO (Peptanova) for caspase 2, and Ac-DEVD-CMK (R&D 
Systems, Palo Alto, USA) for caspase 3, -7. -8 and -9. 
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Results and Discussion 
 
Expression and purification of human caspases 
Expression and purification protocols of human caspases have been described in numerous 
studies and mainly employ two different approaches: (i) the expression of the full length gene 
in order to obtain soluble protein which is activated upon expression in E.coli (Figure 2, A) 
and (ii) the expression of inclusion bodies followed by refolding (Figure 2, B). The genes 
encoding the catalytic domain are cloned either in one single vector (Figure 2, I) or in the 
case of inclusion body formation the two genes encoding the individual subunits are cloned in 
two different vectors (Figure 2, II). Expression of caspases as inclusion bodies requires 
refolding, processing and/or autoprocessing in order to obtain full catalytic activity and 
subsequent purification by ion exchange- or affinity chromotography  (Figure 2, a/b). We 
have systematically tested the optimal expression and purification strategy for each caspase. 
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Figure 2: Expression and purification of human caspases at a glance.  
A) The strategies for the soluble expression and subsequent purification of caspases. B) The expression of 
inclusion bodies followed by refolding and purification. The genes encoding the catalytic domain are cloned 
either in one single vector (I) or as two genes encoding the individual subunits in two vectors (II). The protein, 
independent of the expression strategy, is subsequently purified using affinity (a) or ion exchange 
chromatography (b) followed by size exclusion chromatography. The strategies corresponding to the optimized 
expression and purification protocols applied in this work are highlighted (in green the strategies for the soluble 
expression and in blue the expression of inclusion bodies). 
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Soluble expression and purification of caspases  
Soluble expression of a caspase is the method of choice if the respective caspase undergoes 
maturation in the bacterial host cell. By employing the AIa strategy (Figure 2) several mg of 
the desired protein can be produced and only one purification step is necessary to obtain 
highly pure caspase. In the procedures AIa and A1b, the full length construct (lacking the N-
terminal peptide) is expressed in the cytosol of E. coli. The expressed protein undergoes 
‘maturation’ by cleavage of bacterial proteases. It is crucial that the caspase is entirely 
cleaved otherwise a heterogenous protein sample will be obtained. We found that caspase-6 is 
only partially cleaved at the first cleavage site in the inter subunit linker (D294VVDNQ299) 
resulting in two p20 subunits species of slightly different size. We therefore mutated this site 
to (D294EVDAA299) which resulted in fully processed caspase-6. The protein can either be 
purified by immobilized metal ion affinity chromatography (IMAC) loaded with Ni
2+
 or by 
ion exchange chromatography. IMAC represents a straight forward purification strategy and 
thus is the most desired approach, granted the tag does not interfere with downstream 
applications.   
Although the procedure of soluble expression has been proposed for all human caspases [18, 
29, 90, 147-151], we find it most suitable for the production of non-autocatalytic executioner 
caspases-3, -6, -7 and -9 [152] (Table 5). Soluble expression of inflammatory caspases results 
in considerable degradation products due to their autocatalytic activity, especially in the case 
of caspase-1. 
Caspase Procedure 
1 BIIb 
2 BIIa 
3 AIa 
4 BIIb 
5 BIIb 
6 AIa 
7 AIa 
8 BIIa 
9 AIa 
 
Table 5: Optimal expression and purification strategy for human caspase-1 to -9. 
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Expression of caspases in inclusion bodies and purification 
Inclusion body formation is a very common occurrence during heterologous protein 
expression in E.coli. Since inclusion bodies are highly homogeneous their isolation is usually 
the first purification step [153]. Various protocols for the refolding of human caspases have 
been described [28, 154, 155] and all approaches yield active enzymes (procedure B) [103]. 
Full length caspase-8 and -10 constructs (lacking the N-terminal domain) can be expressed as 
inclusion bodies (procedure BI) followed by refolding and autocatalytic processing. The fully 
processed active caspase is further purified either by affinity chromatography (a) [156], ion 
exchange chromatography (b) or it can be directly loaded on a size exclusion column [157]. 
This approach is limited to caspase-8 and -10 and may lead to heterogeneous protein due to 
incomplete processing.  
 
We favor the more commonly used strategy for the production of recombinant caspases 
(procedure BII) because it yields higher protein concentrations and very homogenous 
samples. Both subunits are separately expressed in E.coli and subsequently refolded by rapid 
dilution overnight. The refolded caspase can then be purified by ion exchange 
chromatography [103] (procedure BIIb), which is our method of choice for caspase-8 and -2 
(Table 5). However, purification by ion exchange chromatography is not straight forward 
which accounts especially for the inflammatory caspases. They bind to the anionic exchange 
column (MonoQ HR 5/5) at a conductivity of the buffer below 1.2 mS/cm which requires 
extensive dialysis after refolding leading to accumulation of degradation products because of 
their autoproteolytic activity. Therefore, we have developed a new protocol for caspase-1, -4 
and -5 based on the study published by Scheer et al. [158]. The addition of a malonate ion 
during refolding and purification prevents the autoproteolysis of the enzyme. Although these 
caspases can be purified by ion exchange chromatography (BIIb), we obtained significantly 
higher yields by using IMAC purification. The purification by IMAC is therefore preferred 
(Table 5) because it is faster, reduces the risk of protein degradation and it increases the yield 
of purified protein. 
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SDS-PAGE analysis of purified caspases 
 
Purified caspases 1-9 were analyzed by SDS-PAGE, as shown in Figure 3. For each caspase 
the small and the large subunit are visible which appear around 10 kDa and 20 kDa 
respectively. The size can vary by several kDa due to the different molecular composition of 
each subunit in size. The large subunit of Caspase-9, which contains a CARD domain, 
appears at a molecular weight of about 30 kDa. Due to their particular amino acid 
composition the small subunits appear less stained than the large subunits for most caspases. 
For all caspases, a purity of over 95% was achieved thus allowing the application of protein 
crystallography and functional and kinetic assays.  In the case of caspase-1, degradation 
products were observed due to autoproteolysis, which could not be entirely prevented by the 
addition of sodium malonate. 
 
 
 
Figure 3: SDS-PAGE analysis of human caspase-1 to -9. 
SDS-PAGE (15%) analysis showing purified samples of caspase 1 to 9. The small and large subunits of each 
caspase are seen as predominant bands. 
 
 
 
Size exclusion chromatography analysis of purified caspases 
The oligomeroc state of caspases influences their specific activity. Independent of 
concentration, executioner caspases and caspase-2 exist as stable dimers [159-161] in 
solution, while caspase-6 can form tetramers [162]. In contrast, initiator and inflammatory 
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caspases exist in a monomer-dimer equilibrium; however, only the dimeric form has catalytic 
activity. The oligomeric state of each caspase was therefore analyzed by size exclusion 
chromatography. The inflammatory caspases (Figure 4, left column) appear as monomers, 
but a shoulder representing a higher molecular weight was observed in the case of caspase-5 
due to the detergent NDSB supplemented during purification. On the other hand, the 
executioner caspases (Figure 4, middle lane) were found to be stable dimers as previously 
described, caspase 6 is partially present as a tetramer [162]. The initiator caspase-2 (Figure 4, 
right column) is a stable dimer and caspase-9 is monomeric, the latter runs at a higher elution 
volume due to the CARD domain at the amino terminus of the large subunit. As expected, the 
oligomeric state of caspase-8 is highly dependent on ion and protein concentration and thus 
occurs in a monomer-dimer equilibrium [161]. 
 
 
 
Figure 4: Size exclusion profile of human caspase-1 to -9.  
50-100 µg protein was injected onto an analytical Superdex 200 (5/150 GL) column. The absorbance signal at 
280nm has been normalized. 
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Functional analysis of human caspases 
 
 
In the past, caspases have often been characterized in standardized conditions, which is not in 
agreement with their biochemical nature leading to a false interpretation of their kinetic 
properties and specificities. This particularly concerns the correlation of their oligomeric state 
and their specific activity. Here we pinpoint the described problem for each individual 
caspases and offer a broad biochemical and kinetic characterization leading to an improved 
assay protocol for the determination of the enzyme activity. Furthermore we would like to 
emphasize the importance of a reproducible and accurate determination of the protein 
concentration. We critically depict active site titration to determine the amount of active sites 
which are essential for kinetic analysis.  
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Active site titration 
Absorption spectrometry is an inadequate method to determine accurate enzyme 
concentration since the total amount of both active and inactive protein is measured. To 
obtain precise concentration values of active protein we used active site titration. This method 
is based on the titration of the active sites with an irreversible inhibitor; increasing 
concentrations of a covalent and preferentially irreversible inhibitor are incubated with the 
enzyme and its activity is recorded. A plot of the residual activity versus inhibitor 
concentration reveals the active site concentration. Caspase activity is routinely analyzed 
under reducing conditions to keep the active site cysteine reduced.  Therefore, the standard 
caspase assay buffer is typically supplemented with DTT or another reducing agent such as - 
mercaptoethanol or L-cysteine. However, we observed that the presence of DTT is 
problematic for the determination of the exact protein concentration by active site titrations. 
Significant enzyme activity was detected even in the presence of a 150-fold excess of 
inhibitor (Figure 5A), indicating reversibility of the covalent enzyme-inhibitor complex 
under reducing conditions. A similar but less pronounced effect occurred at low DTT 
concentrations (12 µM), yet the inhibition remained hyperbolic (Figure 5B). A linear 
inhibition curve, which is essential for the accurate titration of the enzyme, was obtained only 
when DTT free assay buffer was used (Figure 5C). 
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Figure 5: Active site titration of caspase-8 at different DTT concentrations.  
Relative hydrolysis rate against the ratio of inhibitor concentration to enzyme concentration are shown at 10 mM 
(A), 12 µM (B), and no DTT (C). The substrate (Ac-DEVD-AMC) was used at final concentration of 12.3 µM.  
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Dependence of enzyme activity on caspase concentration 
Loss of Enzyme activity due to instability of the protease is commonly observed under in 
vitro assay conditions. To establish the optimal assay conditions and determine the time range 
in which a particular enzyme is stable, M.J. Selwyn developed a time-course assay to 
systematically monitor enzyme stability over time [163]. This procedure involves plotting 
product formation at different enzyme concentrations against time multiplied by the initial 
enzyme concentration. These progress curves superimpose during the time course where the 
enzyme is stable.  
By applying this method, we systematically analyzed the activity of all caspases at different 
enzyme concentrations. Relative fluorescence was plotted against time multiplied by the 
respective enzyme concentration. It is evident from the initial velocity graphs (Figure 6) that 
the dependence of enzyme activity on  caspase concentration is not linear for all caspases. In 
the case of caspase-2, -3, -7 and -9, doubling the enzyme concentration yielded a twofold 
enzyme activity increase. In contrast, an increase in enzyme activity for caspase-1, -4, -5 and -
8 resulted in higher activity (Figure 6).  
Our results are in agreement with the observed oligomeric state of active caspases described 
above (Figure 4). Caspases which are monomeric in solution or occur in monomer-dimer 
equilibrium show an exceeding increase of enzyme activity at higher protein concentrations, 
suggesting that the equilibrium is shifted to the dimer at higher protein concentrations. This 
hypothesis is supported by the observation that dimeric caspases fail to exhibit this effect. It 
can also be hypothesized that the tetrameric form of caspase 6 is less active than the dimer. 
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Figure 6: Selwyn-Test of human caspase-1 to -9.  
Product formation at different initial caspase concentrations (1x, 2x and 4x enzyme concentrations) were plotted 
against time multiplied by the concentration factor.  The lowest concentrations (1x) were: 20nM caspase-1, 3nM 
caspase-2, 1nM caspase-3, 50nM caspase-4, 50nM caspase-5, 100nM caspase-6, 10nM caspase-7, 10nM caspase-
8 and 25nM caspase-9. The substrate concentrations were kept constant at 140µM. Ac-WEHD↓AMC was the 
substrate used for caspase-1, -4 and -5, Ac-DEVD↓AMC for caspase-3,-7 and -8, Ac-IETD↓AMC for caspase-6, Ac-
LEHD↓AMC caspase-9, and Ac-VDVAD↓AMC for caspase-2. Initial velocities were determined in standard assay 
buffer except for caspase-9, which was assayed in citrate buffer. 
 
 
These findings have important implications for the setup and analysis of enzymatic assays for 
initiator and inflammatory caspases. Catalytic efficiencies should be determined in high 
citrate assay buffer or at high enzyme concentration using standard assay buffer. Therefore, 
values that have been obtained in different conditions in the past need to be interpreted with 
caution. 
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The effect of kosmotropic salts on caspase activity and specificity 
Kosmotropic solutes contribute to the stability of proteins; furthermore, such salts are able to 
stabilize the dimerization of caspases. Boatright et al.  previously demonstrated, that 
kosmotropes significantly enhance the activity of recombinant procaspases-8 and -9 but do 
not enhance the activity of the executioner procaspases-3 and -7 [59]. This is in line with our 
observation, that apical caspases are disproportionally more active at higher concentrations. 
We set out to systematically analyse the effect of kosmotropic salts on the kinetic properties 
of caspase-1 to -9.  Substrate affinities (Km values), specific activity and substrate specificity 
were determined under standard assay conditions and in the presence of high concentrations 
of kosmotriopic salt (Table 5 and Figure 7). 
 
 
 Km Value kcat Specific Activity 
 (µM) (s
-1
) (U/mg) 
 
Standard 
Buffer 
Citrate 
Buffer 
Standard 
Buffer 
Citrate 
Buffer 
Standard 
Buffer 
Citrate 
Buffer 
Casp-1 8.6 18.9 1.4 3.7 26’553 77’209 
Casp-2 19.9 24.5 0.8 0.7 15’665 13’573 
Casp-3 29.8 23.1 8.7 5.7 170’326 111’943 
Caps-4 228.1 188.8 0.3 0.5 5’717 8’378 
Casp-5 33.9 57.4 0.5 1.3 9’689 24’731 
Casp-6 98.7 75.9 0.5 0.4 10’260 7’142 
Casp-7 40.3 55.4 3.2 1.0 55’625 18’250 
Casp-8 9.7 41.4 0.3 0.4 5’563 7’444 
Casp-9 n.d. 189.0 n.d. 0.1 n.d. 1'171 
 
Table 5: The catalytic properties of human caspases.  
The assay concentrations of the different enzymes were:  8nM caspase-1, 12nM caspase-2, 5nM caspase-3, 84nM 
caspase-4, 41nM caspase-5, 180nM caspase-6, 90nM caspase-7, 135nM caspase-8, 125nM caspase-9. Ac-
WEHD↓AMC was the substrate used for caspase-1, -4 and -5, Ac-DEVD↓AMC for caspase-3, -7 and -8, Ac-
IETD↓AMC for caspase-6, Ac-LEHD↓AMC caspase-9, and Ac-VDVAD↓AMC for caspase-2. One unit (U) 
corresponds to the conversion of 1μmol substrate per min. 
 
 
In the presence of sodium citrate a decrease in substrate affinity (slightly higher Km values) 
was observed for caspase-1, -5 and -8 and a clearly improved cleavage efficiency (kcat values), 
resulting in significantly higher specific activities, was measured for caspase-1, -4, -5 and -8. 
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Although the presence of kosmotrophic salts did not affect the catalytic properties of caspase-
2,-3, -6 and -7, a decrease in cleavage efficiency was observed (Table 5). 
 
 
 
Figure 7: Substrate specificities of human caspases.  
Substrate specificities were determined in standard assay buffer (white bars) and high sodium citrate buffer (grey 
bars). The protein concentrations were: 8nM caspase-1, 12nM caspase-2, 5nM caspase-3, 84nM caspase-4, 41nM 
caspase-5, 180nM caspase-6, 90nM caspase-7, 135nM caspase-8, 125nM caspase-9. 
 
 
We further analyzed the effect of kosmotropic salts on substrate specificity for caspase-1 to -9 
(Figure 7). Here we also noticed that the substrate specificity does not change for dimeric 
caspases (caspase-2, -3, -6 and -7). However, for all monomeric caspases (caspase-1, -4, -5, -8 
and -9) we observed an increase in cleavage efficiency not only for the preferred substrates 
but also for additional substrates. This effect was found to be particularly pronounced for 
caspase-4 and -5, which showed significantly increased substrate specificity for LEHD in the 
presence of sodium citrate (Figure 7).   
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Conclusions 
 
 
In this study we have refined the established protocols for the expression and characterization 
of human caspases. Several buffer conditions and constructs have been screened and the 
optimal conditions for each caspase are herein described. Our study on active site titration, to 
reliably determine caspase concentration, revealed that the presence of DTT leads to a 
hyperbolic inhibition curve and thus inaccurate fitting results. Another finding is that the 
specific activity and specificity of caspases is dependent on their concentration. However, we 
demonstrated that the activity of some caspases is not proportional to their enzyme 
concentration. This property accounts in particular for inflammatory caspases (-1, -4, -5), but 
to some extend also for caspase-8 and caspase-9 which are monomeric in solution but 
dimerize at higher concentrations. Since a dimer is required for the full enzymatic activity we 
observe that the specific activity increases at higher concentrations or in presence of 
kosmotropic salts such as sodium citrate. Furthermore, the presence of kosmotropic salts was 
found to affect substrate specificity. We thus recommend determining the specific activity of 
these caspases at high enzyme concentrations or in sodium citrate buffer. In contrast, the 
executioner caspases (-3, -6, -7) and caspase-2 are dimeric in solution and their specific 
activity is not dependent on enzyme concentration and can therefore be determined using the 
standard caspase assay buffer.  
In conclusion we show that the protocols described in this study allow for optimal expression, 
purification and characterization of caspase-1 to -9. Enzyme activities are often cited as 
specific activities and these values can vary tremendously between laboratories, most likely as 
a result of different assay conditions and methods used for the determination of caspase 
concentration. Our results help to overcome this issue leading to a more reproducible 
characterization of caspases. 
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3. Development of a caspase specific microarray using DARPins 
as capture reagents 
 
Introduction 
Apoptosis can be monitored with a variety of techniques such as flow cytometry, microscopy 
and western blot. These techniques visualize the apoptotic phenotype of the cell, formation of 
membrane complexes or cleavage of apoptotic target proteins. In contrast, it is technically 
challenging to monitor the activity if a single caspase in the apoptotic pathway. Attempts to 
dissect the apoptotic pathways are mainly based on western blot analysis and short peptide 
substrates [29]. The available caspases substrates are unspecific and one substrate is cleaved 
by several caspases [164]. It is thus not possible to dissect the apoptotic pathway simply by 
measuring their activity using caspases substrates. 
We thus aimed to develop a caspase specific array that allows us to monitor the following 
aspects:  (i) activity of each caspase in different apoptotic stages, (ii) expression levels of 
caspases during apoptosis and (iii) caspases activity in relation to different apoptotic stimuli. 
This would allow us to dissect the apoptotic pathway and monitor the contribution of a single 
caspase to the apoptotic pathway. We regarded the protein microarray setup as very promising 
as it allows high throughput analysis of a large number of samples while only a small amount 
of sample and material is required [165]. We thus developed a protein microarray with 
caspase specific DARPins as capture reagents. Since DARPins are highly selective binding 
proteins (similar to antibodies) they are ideal molecules to target individual enzymes in a 
family of homologous proteins. 
We have combined a multitude of techniques and protocols to establish a standard procedure 
of DARPin selection and characterization. We improved current protocols for the 
characterization of selected DARPins so that a large number of DARPins can be handled with 
minimal use of material in a time efficient manner. By combining state of art machines and 
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novel protocols we were able to handle large numbers of DARPins while obtaining highly 
quantitative data (Figure 3.1). Furthermore we describe the production and optimization of 
DARPin microarrays and offer possible applications for this technology. 
 
 
 
 
Figure 3-1: Workflow of the selection and characterization of DARPins.  
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Results 
Selection of DARPins against caspases using ribosome display 
We used ribosome display for the selection of DARPins based on a library that was described 
previously [110]. Nine caspases (caspase-1 to -9) were used as target proteins. The selection 
for each target protein was performed under varying conditions such as addition of inhibitor, 
chemical additives or koff-maturation. Typically the selection included 4 selection rounds, 
however in some individual cases three or five selection rounds have been performed (Figure 
3.2A). For each caspase we now have an enriched DARPin sub-library which is stored at -
20°C. These libraries were further used to identify caspase specific DARPins binders. The 
analysis of individual clones by Crude Cell Extract ELISA (CEE) (Figure 3.2 B and C) 
revealed a set of potential binders that were further characterized. We improved several 
technical aspects during the DARPin characterization this included the use of a colony picker, 
ELISA washer, liquid suspender and pipetting robot. Furthermore we up scaled the ELISA 
from a 96 to a 386 well format which significantly reduces the amount of target protein to 1/5 
compared to the previous setup. This represents a crucial improvement because the 
purification of the target protein is often a bottleneck. The usage of auto inducing media 
increased the expression rate to 99 % compared to previously used media 2YT where only 
approximately 80 % of the selected constructs expressed the DARPin. Each DARPin obtained 
a unique name after selection (DX.Y) with X indicating the caspase it binds and Y stands for 
the succession of discovery; e.g. D1.10 is the tenth DARPin that was identified to bind 
caspase-1. 
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Figure 3-2: Selection of DARPins against caspases  
(A) The enrichment of the DARPin library after four RD selection rounds analyzed on a 1% Agarose Gel. C4 
indicates selection against caspase-4. (+) indicated selection against the target (-) indicates selection against the 
surface only. Buffer conditions are indicated by a, b and c with a=WBT, b= WBT + z-WEHD.cho, c= WBT + 30mM 
NaMalonate (WBT stands for Wash buffer + Tween as indicated in the material and methods section). (B) 15% 
SDS-PAGE showing N3C and N2C DARPin expression in Crude Cell Extract. (C) Crude Cell Extract ELISA of DARPins 
selected against caspase-3. Blue bars show the signal against caspase-3 and red bars show signal against the 
negative control MBP.   
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High throughput expression and characterization of DARPins 
Positive hits from CEE ELISA were expressed in larger volumes to obtain sufficient material 
and purity for further analysis. Because different DARPins show very different behavior in 
recombinant E.coli cell cultures we used auto-inducing media for high throughput expression. 
A parallelized expression and purification setup in 24-well plates allowed the purification of 
96 different DARPins in one day with a yield of usually more than 1mg per culture (5ml) 
followed by IMAC purification. The purified DARPins were stored at 4 °C with the 
antimicrobial additive sodium azide (NaN3) at a final concentration of 0.03% for further 
characterization. DARPins stored in these conditions retained their binding capabilities for at 
least one year. In contrast storage at -20 °C even when cryoprotectants such as sucrose or 
glycerol were used resulted in precipitated protein after thawing.  
Since the strength of a signal in CEE experiments does not directly correlate with binding 
affinity we further analyzed the selected DARPins by surface plasmon resonance (SPR) after 
purification by size-exclusion chromatography (SEC). We used the Proteon XPR36 (BioRad 
[166]) because it allows analysis of up to 24 DARPins within one day. Binding at 8 different 
concentrations usually in the range from 0.17 to 128 nM was measured. Figure 3.3 shows the 
SPR kinetics of six different DARPins (DARPin_3.7 to DARPIN_3.13), that were selected 
against Caspase-3 and expressed in a 5 ml cell culture followed by IMAC purification. From 
this screen we were able to determine an approximate KD by equilibrium analysis. 
Furthermore other kinetic constants such as kon and koff of each individual DARPin could be 
estimated. Based on this screen we could exclude DARPins with unfavorable kinetic 
properties. Binders that show slow dissociation rates, as it is the case for DARPIN_3.8 and 
DARPIN_3.13 (Figure 3.3) were sequenced and used for further analysis. We repeated SPR 
analysis with selected DARPins which were purified by IMAC and SEC followed by a 
precise determination of the protein concentration. The results of all SPR screens that have 
been performed are shown in the comprehensive summary in Table 1. We classified the 
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DARPins according to their affinity estimated by equilibrium binding measurements of the 
saturated phase. DARPins with KD values lower than 10 nM are marked with (+++), 
DARPins with KD lower than 100 nM and 1M were marked with (++) and (+) respectively. 
No kinetic constants (kon and koff) can be determined from equilibrium measurements and are 
thus not included in Table 3.1. We were not able to determine the kinetic constants for each 
DARPin often due to the absence of a fitting equation that was in agreement with the 
experimental data. A list of the kinetic data of the best DARPins we selected is listed in Table 
3.2. 
 
 
Figure 3-3: SPR analysis of DARPins 
High-throughput analysis of selected DARPins. SPR signal for eight concentrations of six DARPins was measured 
against a surface that was coated with caspase-3. 
 
To measure specificity of the particular DARPin we used the Proteon XPR36 as well. It 
allows independent coating of 6 lanes with different caspases. The analyte (DARPin) can thus 
be tested against 6 caspases simultaneously. DARPin_3.8 was particularly interesting for us, 
because it was found to inhibit caspase-3 (Chapter3). In order to test the specificity of 
DARPin_3.8 caspase-3 and five other homologous caspases were coated on the SPR chip. 
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DARPIN_3.8 showed binding to caspase-3 only, indicating that this DARPin is very specific 
(Figure 3.4). 
We initially anticipated to have a least two DARPins that bind different epitopes of the same 
caspase for sandwich ELISA applications. To confirm this we tested DARPins from different 
sequence families by competition ELISA. Interestingly we found that literally all DARPin 
bound to one, or overlapping epitopes (Andreas Flütsch). For caspase-7 as an example we 
selected 43 different DARPins, but none of them showed uncompetitive behavior to other 
caspase-7 DARPins.  
 
 
Figure 3-4: SPR specificity analysis 
Six different ligands were coated and one DARPin (DARPIN_3.8) was analyzed for binding against each caspase 
simultaneously. 
 
 
Due to the overwhelming number of selected DARPins we listed only the most important 
DARPins for each caspase. As an example, over 130 caspase-1 specific DARPins have been 
characterized in search for an inhibitor, but not all of them are listed also because they often 
have almost identical sequences. For every caspase, except for caspase-4 we found specific 
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and high affinity binders. For completeness we have listed four DARPins that were selected 
against caspase-4 but SPR experiments have shown that they possess affinities in the low M 
range, three orders of magnitude higher than the best binders we have found against the other 
caspases. Next to binding properties we have also screened for DARPins which either activate 
or inhibit a caspase. For caspase-1 we found DARPin 1.81 which inhibits the activity 
significantly. However, even at 1000 fold excess the DARPin reduced the activity by only 
50%. From the DARPin library selected against caspase-3 we identified two DARPins which 
inhibit caspase-3 (DARPin_3.4 and DARPin_3.8), which are described in Chapter 4 in more 
detail. Furthermore the selection of DARPins against caspase-8 revealed a DARPin which 
increases the activity of caspase-8, as described in Chapter 5. 
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DARPin Properties Results 
Name repeats MW ExtCoef pI Sequenced SPR Array properties 
D1.1 N3C 18371.5 16960 5.54 Yes  - - 
D1.4 N3C 18371.5 15470 5.61 Yes ++ +++ - 
D1.7 N3C 18341.5 16960 5.54 Yes ++ +++ - 
D1.9 N3C 18385.5 16960 5.54 Yes ++ +++ - 
D1.10 N3C 18375.5 15470 5.61 Yes  - - 
D1.15 N3C 18320.4 15470 5.54 Yes + +++ - 
*D1.16 N3C 18371.5 16960 5.54 Yes ++ +++ - 
D1.17 N3C 18384.6 16960 5.44 Yes  - - 
D1.19 N3C 18427.6 16960 5.54 Yes ++ +++ - 
D1.21 N3C 18418.6 18450 5.54 Yes  + - 
D1.39 N3C 18371.5 16960 5.54 Yes  + - 
D1.44 N2C 16037.9 16960 5.87 Yes  ++ - 
D1.53 N3C 18381.6 16960 5.54 Yes  n.d. - 
D1.70 N3C 18165.2 11000 5.4 Yes  n.d. - 
*D1.73 N3C 18358.4 9970 5.34 Yes +++ n.d. - 
D1.74 N3C 18262.3 12490 5.4 Yes  n.d. - 
D1.75 N3C 18390.4 9970 5.49 Yes  n.d. - 
D1.76 N3C 18227.4 8480 5.34 Yes  n.d. - 
D1.77 N2C 14652.4 6690 5.29 Yes  n.d. - 
D1.81 N3C 18353.5 24980 5.18 Yes + n.d. Inhibitor 
D1.85 N3C 18416.5 12490 5.51 Yes + n.d. - 
D1.93 N3C 18440.6 15470 5.27 Yes  n.d. - 
D1.97 N3C 18406.5 20970 5.35 Yes  n.d. - 
D1.100 N3C 18140.2 4470 5 Yes  n.d. - 
*D2.1 N3C 18417.5 18450 5.28 Yes +++ + Inhibitor 
D2.2 N2C 14773.7 6990 5.27 Yes + + - 
D3.1 N2C 14327.90 0.00 5.64 Yes - n.d. - 
D3.2 N2C 14812.60 6990.00 5.55 Yes - n.d. - 
D3.3 N2C 14726.50 11000.00 5.45 Yes + n.d. - 
D3.4 N2C 14676.40 5500.00 5.84 Yes +++ n.d. Inhibitor 
D3.4_S76R N2C 14676.40 5500.00 5.84 Yes +++ n.d. Inhibitor 
D3.4_I78S N2C 14676.40 5500.00 5.84 Yes - n.d. No inhibition 
D3.5 N2C 14545.20 2980.00 5.55 Yes - n.d. - 
D3.6 N2C 14468.20 6990.00 5.29 Yes +++ n.d. - 
D3.7 N2C 14551.20 5500.00 5.55 Yes + n.d. - 
*D3.8 N3C 17964.10 8480.00 5.51 Yes - n.d. Inhibitor 
D3.9 - - - - No + n.d. - 
D3.10 - - - - No + n.d. - 
D3.11 - - - - No - n.d. - 
D3.12 - - - - No - n.d. - 
*D3.13 N3C 18257.40 9970.00 4.92 Yes +++ n.d. - 
D4.1 N3C 18096.1 9970 4.99 Yes - - - 
D4.2 N3C 18410.5 16960 5.09 Yes - - - 
D4.3 N3C 18108 6990 4.95 Yes - - - 
D4.4 N2C 14659.2 2980 5.15 Yes - - - 
D4.5 N3C 18286.4 5960 5.01 Yes - - - 
D5.1 N3C 18598.9 22460 5.7 Yes  + - 
D5.2 N3C 18598.9 22460 5.7 Yes  + - 
D5.3 N3C 18521.6 12950 5.49 Yes  - - 
D5.4 N3C 18280.5 8480 5.39 Yes + +++ - 
*D5.5 N3C 14794.5 12490 5.38 Yes ++ + - 
D5.6 N2C 14794.5 12490 5.38 Yes  + - 
*D5.7 N3C 18356.4 13980 4.89 Yes ++ +++ - 
D5.8 N3C 18405.7 17990 4.99 Yes  - - 
D5.11 N2C 14853.4 9970 5.04 Yes - +++ - 
*D5.15 N3C 18324.5 19480 4.99 Yes +++ +++ - 
D5.16 N3C 18324.5 19480 4.99 Yes  +++ - 
D5.25 N3C 18324.5 19480 4.99 Yes  +++ - 
D6.1 N3C 18374.4 7450 5.54 Yes ++ n.d. - 
D6.2 N3C 18088.3 6990 5.35 Yes + - - 
D6.3 N3C 18469.7 14440 5.08 Yes + - - 
D6.4 N3C 14690.4 4470 5.03 Yes + - - 
D6.5 N3C 18469.7 14440 5.08 Yes + - - 
D6.6 N3C 18329.7 12950 5.51 Yes + - - 
D6.7 N3C 14846.5 8480 5.41 Yes + - - 
D6.8 N3C 18209.5 11460 5.41 Yes ++ + - 
D6.9 N3C 18064.3 4470 5.51 Yes ++ + - 
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DARPin Properties Results 
Name repeats MW ExtCoef pI Sequenced SPR Array properties 
D6.10 N3C 14697.4 6690 5.44 Yes  - - 
*D6.11 N3C 18300.4 9970 5.46 Yes ++ +++ - 
D6.12 N3C 18345.3 7450 5.44 Yes + - - 
D6.14 N3C 18345.3 7450 5.44 Yes + - - 
D6.15 N3C 18088.3 6990 5.35 Yes + n.d. - 
D6.16 N3C 18283.6 11460 5.54 Yes + n.d. - 
D6.20 N3C - - - No + ++ - 
*D6.21 N3C 18381.5 15470 5.4 Yes + +++ - 
*D7.1 N3C 18023.1 2980 4.99 Yes +++ +++ - 
D7.2 N2C 14928 17990 5.79 Yes n.d. - - 
D7.3 N2C 14873.6 19480 5.51 Yes ++ +++ - 
D7.4 N3C 18211 13980 5.53 Yes n.d. - - 
D7.5 N2C 14741.4 5500 5.72 Yes n.d. - - 
D7.7 N2C 14930 15470 5.79 Yes ++ ++ - 
D7.10 N2C 14725 12490 5.43 Yes + - - 
D7.14 N2C 14961 15470 5.72 Yes +++ ++ - 
D7.17 N2C 15013 17990 5.85 Yes n.d. ++ - 
D7.18 N3C 18273.2 15470 4.74 Yes ++ +++ - 
D7.20 N2C 14780.5 12490 5.52 Yes n.d. +++ - 
D7.31 N3C 18363.5 13980 5.51 Yes n.d. - - 
D7.33 N2C 14983.7 17990 5.85 Yes + +++ - 
D7.40 - - - - No ++ +++ - 
*D7.43 N3C 14812.6 6990 6.68 Yes +++ +++ - 
D8.1 N3C 18157.4 5500 5.28 Yes +++ n.d. - 
D8.2 N3C 18122.4 6990 5.38 Yes +++ n.d. - 
D8.3 N3C 18157.3 6990 5.48 Yes +++ n.d. - 
*D8.4 N3C 18190.5 5500 5.3 Yes +++ n.d. Activation 
D8.7 N3C 18157.4 5500 5.28 Yes +++ n.d. - 
D9.2 N3C - - - - - - - 
 
Table 3-1: DARPins selected against human caspases. The best DARPin binders for each caspase are labeled 
with an asterix (*) in front of the DARPin name. 
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Protein microarray 
The microarray technology has proven to offer a highly parallelized and reproducible setup 
for diagnostic applications using DNA and RNA molecules as capture reagent [167]. 
However, in contrast to well-established DNA microarrays, the automation and robustness of 
protein microarrays needs to be demonstrated before they can be reliably used for diagnostic 
high-throughput applications [168]. These applications include the identification of 
biomarkers, screening large numbers of patient samples or the detection of protein expression 
levels in the cell [169]. The greatest limitation in producing protein microarrays is the 
availability of capture reagents which are able to bind a molecule in a complex sample even if 
it is expressed at low concentrations. DARPins are very promising in this regard because they 
are exceptionally stable and can bind their target protein with high specificity. We describe 
here the first production of microarrays with DARPins as capture reagents. 
For the production of the microarray we used a Piezoelectric non-contact spotter S11 
(Scienion, Berlin as illustrated in Figure 3.5A). We developed a very reproducible technique 
that allows us to screen up to 500 different DARPin with six replicates on one array to screen 
for binding and specificity. We found that epoxysilane coated slides are most effective and 
offer a good signal to noise ratio at low costs. The DARPins were covalently immobilized 
(PBS, pH 7.4) by reacting with epoxysilane via their reactive amino groups. Figure 3.5C 
shows a schematic overview of DARPin coating and signal readout. Coated microarray slides 
were stored at 4 °C and saturated humidity for up to one month. The microarray showed an 
inferior performance after storage longer than one month.  
After the immobilization of DARPins on the surface we applied the biotinylated caspase 
using a hybridization station (2xHS 4800, Tecan Figure 3.5 B). This device allows microarray 
handling including pre-hybridization, blocking, washing and drying for up to twelve different 
microarrays in parallel. The caspase which was used for hybridization has been covalently 
linked to a Cy5 fluorophore. For signal readout of the hybridized microarray we used a 
confocal laser scanning microscope LS4000 (Tecan, Austria). Figure 3.5D shows a 
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microarray with fluorescent intensity represented in color, with black being no signal and red 
being the strongest signal. On this microarray we coated 150 different DARPins that were 
selected against caspase-1 to caspase-9 and hybridized the slide with caspase-5. As indicated, 
32 DARPins that have been selected against caspase-5 have been coated. The majority of 
those DARPins show a significant signal for caspase-5, whereas two DARPins that have been 
selected against other caspases (blue box) also show a signal for caspase-5, indicating that 
they are not specific. Figure 3.5E shows the signal intensity of the average of six replicates 
that were coated on the chip. Bars in blue or red, are DARPins that were selected against 
caspase-5. We have set a threshold of 2.5 (Ratio of net intensity/background) to select specific 
binders with a strong signal. DARPins that excel this threshold can be regarded as specific 
caspase-5 binders under the given conditions.  
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Figure 3-5: Production of protein microarrays 
A) Piezoelectric non-contact spotter S11 (Scienion, Berlin). B) Hybridization station (2xHS 4800, Tecan). (C) 
Schematic view of the microarray interactions. DARPins are immobilized to the epoxysilane coated slides and 
bind caspases. The caspases are labeled with a Cy5 fluorophore which is used for signal readout. (D) A microarray 
coated with 150 different DARPin each spotted in replicates of six. The microarray was then incubated with 
caspase-5 to test DARPin for specificity against caspase-5. (E) Quantification of signal intensity with a confocal 
scanning laser microscope. Ratio net intensity/background is assigned to each DARPin. A threshold of 2.5 was set 
to distinguish between specific and non-specific DARPins. 
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Optimization of microarray printing and readout 
Microarray experiments aim to handle large numbers of samples with minimum consumption 
of material. At the same time, the experiments need to be highly reproducible with optimal 
results in terms of signal to background ratio. For this we screened several conditions during 
the procedure of microarray including printing, hybridization and readout. We found that, 
DARPins are successfully printed in PBS pH 7.3 which is compatible with previously used 
buffers for DARPin purification. Any additives such as Sucrose increased the viscosity and 
led to higher failure rates during printing of the protein spots. Addition of sodium azide to a 
final concentration of 0.03 % did not affect printing or the interaction with a caspase. The 
ideal protein concentration was 0.5 mg/ml, since higher concentrations also increased the 
viscosity and lower concentrations decreased the density and thus the resulting signal. As 
mentioned before we found epoxysilane coated glass slides (Schott Nexterion) are most 
favorable for our application and offer a good signal to noise ratio at low cost of five CHF per 
slide. We tested several other slides from different manufacturers; however they did not 
increase the signal to noise ratio but were significantly more expensive. We also tested which 
caspase concentration is best for optimal signal. Starting with a concentration of 0.1 mg/ml 
caspase-1 we used four different dilutions in PBS as illustrated in Figure 3.6A. Increasing 
concentrations led to increasing background signal, the optimal ratio was found at a dilution 
of 1:1500 with an average signal intensity over background of approximately eight (Figure 
3.6B).  
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Figure 3-6: Optimization of protein microarrays 
(A) Caspase-1 was incubated with the previously coated microarray at different dilutions. Relative fluorescent 
intensity and mean background are shown. (B) Signal intensity/background of 57 DARPins is shown. Position 49 
to 57 are caspase-1 specific DARPins. Caspase-1 was incubated with the microarray at a dilution of 1:1500. 
 
Specificity test of DARPins using  protein microarrays 
To test the specificity of the selected DARPins we used the microarray technology. Caspases 
have high sequence homologies thus we were interested whether the selected DARPins 
distinguish between the homologous proteins. An example is shown for binders of caspase-6 
and -7 (Figure 3.7). In total 46 DARPins were coated in replica of 12 spots. This screen 
indicates that the DARPins are overall very specific. None of the DARPins shows a 
significant signal against the close homologue. For example D7.18 shows an intense signal 
for caspase-7, but no signal is visible for caspase-6 (Figure 3.7). The signal intensities that are 
observed on the microarray are in line with other experimental setups such as SPR and 
ELISA. As an example D6.11 is the best binder according to the kinetic properties we 
measured by SPR which is in agreement with the microarray experiment, where D6.11 has the 
highest signal intensity and thus affinity to caspase-6. 
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Figure 3-7: Specificity of DARPins tested on microarrays 
A set of caspase-6 and caspase-7 DARPin was coated on a microarray and then hybridized with (A) caspase-6 and 
(B) caspase-7. The intensity of the signal is represented by a rainbow color-coding with black being no signal, red 
a strong and white an oversaturated signal. 
 
 
Characterized set of binders against all caspases 
With the described DARPin selection and characterization we selected a pool of DARPins 
against caspase-1 to caspase-9. This set of DARPins can be regarded as a “toolbox” of 
caspase binders for various applications such as caspase localization, depletion or protein 
microarrays. An overview of these binders including their kinetic properties is presented in 
Table 3.2 and the amino acid sequence of the corresponding DARPin is listed in the appendix. 
For most caspases the kinetic data were evaluated based on the heterogeneous ligand model 
[170] which gives two possible kinetic values as indicated in Table 3.2. The only case where 
we could apply the langumir model is DARPin_8.4 which has a KD of 5.2 nM. 
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 Kinetic constants Equilibrium 
Binder kon1(M
-1s-1) koff1(s
-1) Kd1(M) kon2(M
-1s-1) koff2(s
-1) Kd2(M) Kd(M) 
D1.16 1.41E+05 1.22E-03 8.63E-09 2.89E+06 2.82E-03 9.78E-10 - 
D1.73 1.03E+05 4.70E-04 4.54E-09 1.20E+06 1.88E-03 5.87E-09 - 
D2.1 n.d. n.d. 4.1E-09 - - - - 
D3.8 1.77E+05 2.49E-03 1.41E-08 2.44E+06 1.11E-04 4.57E-11 3.4E-09 
D3.13 2.74E+05 1.24E-03 4.51E-09 2.31E+06 7.86E-03 3.41E-09 7.69E-09 
D5.15 1.05E+06 1.01E-02 1.00E-08 2.85E+05 5.97E-04 2.10E-09 1.10E-08 
D5.16 6.05E+05 1.05E-02 2.13E-08 1.55E+05 9.66E-04 6.23E-09 3.37E-08 
D6.11 1.32E+05 0.01 8.99E-08 4.70E+04 3.70E-04 7.88E-09 - 
D7.1 1.55E+06 1.10E-02 6.90E-09 1.03E+05 8.41E-04 8.14E-09 - 
D7.43 1.90E+06 9.63E-03 5.06E-09 2.21E+05 6.54E-04 2.95E-09 - 
D8.4 1.8E+05 9.31E-04 5.2E-09 - - - - 
D9.2 - - - - - - -18E-09 
 
Table 3-2: Association, dissociation kinetics and KD-values  of selected DARPins for each caspase.  
The affinity of DARPins with two indicated kinetic constants were determined applying the heterogeneous ligand 
model [170]. D8.4 kinetics were determined using the langumir model. 
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Discussion 
We successfully selected and characterized DARPins against nine human caspases. Several 
tight binding DARPins were characterized for each caspase with the exception of caspase-4, 
where the interaction was only observed in the ELISA format but could not be shown in SPR 
measurements. In the selection and characterization workflow we have optimized several 
steps based on existing protocols allowing us to handle large sample numbers in one 
experiment. This included the use of auto-inducing media that resulted in higher expression, 
higher cell densities and more reproducible expression during DARPin expression in 96-well 
plates and 100 mL flasks. Furthermore we assisted several steps during the characterization 
with state of the art machines such as a colony picker and liquid suspender. We based all 
screens on 384 well plates which led to higher throughput while only a fifth of proteins 
material was required compared to previously common ELISA screens. The hits we obtained 
by Crude Cell Extract ELISA screens were analyzed by high throughput SPR measurements 
which provided high quality data within a short time. This allowed the elimination of most 
DARPins that do not possess the required kinetic properties. Only DARPins with KD values 
lower than 50 nM and slow dissociation rates from their target protein were considered for 
further characterization. 
Our high-throughput selection and characterization yielded a large number of specific 
DARPins which bind caspases and few also have a functional phenotype when bound to the 
caspase as described in chapter 4 and 5. We have found DARPins that inhibit caspase-3 
(DARPIN_3.4 and DARPIN_3.8) and caspase-1 (D1.81), D1.81 however only inhibited 
caspase-1 by 50% and we were not able to elucidate the basis of this inhibition. A caspase-8 
specific DARPin (D8.4) increased the activity of caspase-8 which is described in chapter 5. 
These DARPins in complex with their caspase also led to well diffracting crystals for 
structural studies. Furthermore the selected DARPins are used by Andreas Flütsch as caspase 
specific binding molecules for the visualization of apoptosis in fixed and living cells. 
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Figure 3-8: Potential formats for a caspase specific DARPin microarray  
A) Antigen microarray. The antigen (orange circle) is coated on the surface of the slide. A fluorophore (green star) 
labeled DARPin is used to detect and quantify the amount of antigen concentration B) DARPin microarray. The 
DARPin is coated on a microarray followed by addition and incubation with the antigen (orange). A secondary 
DARPin labeled with a fluorophore is used to detect the antigen. The two DARPins have to detect non-
overlapping epitopes. C) DARPin-substrate coupled microarray. As described in B, the antigen is captured by a 
coated DARPin. The caspase is then quantified by a enzymatic assay, monitoring cleavage of a caspases substrate. 
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Our initial goal was to select two DARPins against each caspases with high affinity and if 
possible different binding epitopes. Competition ELISA however showed that most, if not all 
DARPins bind to the same or overlapping epitope on a particular caspase. This suggests that 
DARPins in one selection process tend to favor one dominant epitope of the target protein 
which excludes the application of DARPins in a sandwich assay approach (DARPin 
microarray) in ELISA or microarray applications (Figure 3.8 B). Other possible microarray 
setups based on DARPins as capture or detection reagents would be an antigen- or DARPin-
enzyme coupled microarray (Figure 3.8 A and C). The DARPin-substrate coupled microarray 
has the advantage that caspases can be isolated from complex cell lysates of apoptotic cells 
followed by standard enzyme substrates. The specificity is given by the DARPin-caspase 
interaction which is quantified by fluorogenic substrates. 
In order to use DARPins as capture reagents, we investigated whether they retain their 
binding properties that have been elucidated in solution. A number of different slide surfaces 
can be used with the criteria that one maintains the conformation and functionality while 
achieving maximum binding capacities at low costs. We found that epoxy-derived glass slides 
fulfill these criteria best and developed our microarrays based on this format in combination 
with a non-contact spotter.  
We were able to print more than 150 different DARPins on one slide and classified the 
DARPins according to their signal strength, specificity and stability. We saw a clear 
correlation between affinities that we determined in SPR experiments and signal strength on 
the microarray indicating that the DARPin fold is generally suitable for array technologies. 
The compact fold with its extraordinary stability represents a promising alternative to the 
commonly used antibodies in protein microarrays. We further conducted several experiments 
to determine specificity of DARPin sets for their target protein and their closest homologs 
(Table 3.1). Since we had to handle a large amount of DARPins we optimized the purification 
for microarray experiments. After Ni-NTA purification of each DARPin we exchanged the 
buffer to PBS, pH 7.3 on a desalting column. The addition of glycerol to prevent dehydration 
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on the slide was not necessary but complicated the printing process due to the high viscosity. 
We found that a concentration of 0.5 mg/ml was optimal and we obtained the best signal to 
noise ration at a 1:1500 dilution of the caspase for incubation with the slides. 
Our initial goal was to develop a caspase specific array to dissect the apoptotic caspase 
pathway because no appropriate techniques are available. Due to the lack of DARPin binders 
targeting different epitopes for a sandwich based approach for detection we adapted our 
strategy to a general proof-of-principle of DARPins as capture reagents. Furthermore 
apoptotic cells in a cell culture are highly heterogeneous and cannot be synchronized. 
Apoptosis occurs around four hours after the apoptotic stimulus and transmission of the 
apoptotic signal leading to the activation of executioner caspases is then completed within 
minutes. This timeframe in a heterogeneous sample is very short and complicates 
development and application of a caspase specific microarray. Consequently we decided to 
establish DARPins as capture reagents on microarrays without performing experiments with 
apoptotic samples.  
In summary we have shown, that DARPins can be selected against a whole protein family 
with high specificity and affinity. DARPins retain their functionality on a surface and are very 
promising proteins for microarray applications. We were able to use our microarray to 
classify the selected DARPins according to their specificity and affinity. DARPins in 
combination with microarrays is an excellent high-throughput method that can be used to 
characterize an entire collection of proteins for a specific function or biochemistry [165]. 
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Material and Methods 
Caspase purification and biotinylation 
All caspase have been purified as described in chapter 1 [171]. For ribosome display selection 
and ELISA experiments we biotinylated the caspase prior to the experiment. For chemical 
biotinylation of the caspase we used the linker EZ-Link Sulfo-NHS-LC-LC-Biotin (21338, 
Pierce), containing a reactive group, a 3.05 nm long linker and a biotin moiety. After 
purification, 1ml of the caspase (10 M) was either in PBS pH 7.3 or 50 mM HEPES pH 7.5, 
150 mM NaCl and was incubated with a seven fold molar excess (1 ml of a 70 M solution) 
of biotin on ice for 30 minutes. The reaction was quenched by adding 10 l of 5M Tris, pH 
7.5. The biotinylated protein was then purified by size exclusion chromatography, using a 
Superdex 200 10/300 GL (GE Healthcare) in PBS at 4 °C. The fractions containing the 
biotinylated caspase were pooled and frozen in liquid nitrogen after adding sucrose to a final 
concentration of 10 %. The samples were stored at -80 °C for up to one year until further 
usage.  
Ribosome display selection of DARPins 
Cloning and amplification of the N3C DARPin library has been described previously [110]. 
The library contains N3C and N2C DARPins. The principle of ribosome display selection has 
been described elsewhere [119, 120]. However, Figure 3.6 shows a schematic drawing of the 
selection strategy that was developed for selection with focus on specificity and low koff rates. 
We performed four selection rounds for each caspase and maltose-binding protein (MBP) was 
coated for pre panning (22 nM) in each round. Furthermore the two most homologous 
caspases (22 nM) were included into pre-panning in round n°1 and n°3. koff maturation was 
done in round n°2 and n°4 by adding a 1000 fold excess of unbiotinylated caspase (final 
concentration of 22 M, if the caspases was coated at a concentration of 22 nM) for 5 or 10 
minutes respectively. After each round we washed the unbound DARPin-Ribosome complex 
with increasing stringency as indicated in Figure 3.8. 
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After four selection rounds we cloned the library into a pQE30 vector and this library was 
used to transfect competent XL-1Blue E.coli cells (Stratagene). Single colonies were used for 
Crude Cell Extract ELISA experiments. 
 
Figure 3-9: Overview of the RD selection strategy 
An strategy with alternating conditions each round was used to prevent unspecific enrichment under one 
condition. The number in the box stands for the respective caspase, with ‘3’ representing caspase-3. Yellow boxes 
represent pre-panning with MBP, white box pre-panning against other caspases and gray background indicates 
the target protein for selection. Off-rate selection was done in round n °2 and n°4. 
 
 
 
Crude cell extract ELISA 
Single colonies each containing one DARPin clone of the selected library were picked and 
inoculated in 0.9 ml auto-inducing media [172] containing deep 96-well plates (Abgene, UK). 
The cells were grown over night at 37 °C while shaking at 300 rpm in a shaker (TH15, 
Edmund Bühler GmbH). Then 200 l of each well were transferred into a sterile 96 well plate 
(Nunc) as a backup for further protein expression and plasmid preparation. The remaining 700 
l of cell-suspension was harvested by centrifugation and the cell pellet was lysed with 50 l 
B-PER II (78260, Pierce) per well for 30 minutes shaking at room temperature. The lysed 
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cells were resuspended by adding 950 l PBS, pH 7.3 and cell debris was removed by 
centrifugation (20 min, 4500 rpm at 4°C) in a table top centrifuge 5414 (Eppendorf). We took 
20 l of the supernatant an added it to 384 ELISA plate (Nunc) where MBP or a caspases has 
been coated previously. This plate has been coated with 20 l of a 22 nM Neutravidin 
solution (Pierce, 31000), followed by extensive washing. We then added 20 l of a 100 M 
protein solution representing the caspases or MBP as control. After 1h of incubation of the 
supernatant at room temperature and 3 washing cycles the plate was incubated with mouse 
anti-RGS-H4 antibody (34650, Qiagen) at a dilution of 1:2000 in PBS 1% BSA. We then 
added the secondary antibody (goat--mouse IgG alkaline phosphatase conjugate (Sigma, 
A3562)) followed by four washing cycles and added the substrate di-sodium 4-nitrophenyl 
phosphate (pNPP; 3 mM di-sodium 4-nitrophenyl phosphate, 50 mM NaHCO3, 50 mM 
MgCl2.6H2O). The OD was measured at 405 nm using a multi-well plate reader (Infinite 
M1000, Tecan). 
Large scale expression and purification of DARPins 
DARPins were expressed in 100 ml media using either 2YT or auto-inducing media starting 
from a glycerol stock or the 200 l backup culture after Crude Cell extract ELISA. When 
expressed in 2YT media we induced expression at an OD600nm between 0.6 - 1 with 0.5 mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) followed by 3h of expression at 37 °C under 
continuous shaking. Cells were harvested by centrifugation for 7 minutes at 8000rpm, 4°C 
(Biofuge primo R, Hereaus) and lysed by sonification. The expressed DARPin was purified 
with common His-tag purification methods using a self-made gravity column consisting of a 
plastic column (57024, Supelco) and 0.5 ml bead volume of Ni
2+
-NTA agarose (30210, 
Qiagen). The DARPins were eluted in PBS, 200 mM Imidazole pH 7.4 and the Imidazole was 
removed with a PD-10 desalting column (17-0435-01, GE Helthcare). We added sodium 
azide (NaN3) to a final concentration of 0.03% to prevent growth of bacteria and fungi. The 
DARPins solution was further stored at 4 °C. 
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Kinetic Analysis of DARPins with Surface Plasmon Resonance  
For SPR experiments we used the Proteon XPR36 (Bio-Rad Laboratories, Inc.) and all kinetic 
analysis were made on a NLC sensor chip (Bio-Rad Laboratories, Inc.). We used sterile 
filtered PBS pH 7.3, 0.005% Tween-20 as a standard buffer for coating and all kinetic 
measurements. The biotinylated ligand (caspase) was coated on the sensor chip at a 
concentration of 5 nM and a flow rate of 30 l per minute. The coating procedure was 
interrupted once a total of 1000 relative units (RU) were reached on the Proteon monitoring 
system. We started by coating lane six and continued with lane five and used lane one at last. 
Twelve different analytes (DARPin) were prepared prior to the experiment and a dilution 
series was pipetted in the 96 well storage plates, which were sealed to prevent evaporation or 
contamination with dust particles. For Kinetic analysis we measured every analyte at eight 
different concentration (0, 0.176, 0.52, 1.58, 4.47, 14.2, 42.6, 128 nM) starting with the 
lowest concentration.  All experiments were performed at 20 °C. Due to the heterogeneity of 
the system we did not regenerate the chip surface in between every concentration but 
dissociated the analyte with a long dissociation phase of up to 300 minutes. We used a flow 
rate of 100 l per minute, an association phase of 5 minutes and a dissociation phase of 20 
minutes. The data were recorded and further processed with the ProteOn Manager 2.1.1 
(BioRad). Data evaluation and curve fitting was performed with the same program to 
determine kinetic and equilibrium constants [166].  
Microarray production 
Prior to coating the DARPin samples were adjusted to a final concentration of 0.5 mg/ml in 
PBS, pH 7.4 and filtered (0.22 m). 15 l of each DARPin was pipetted into a 384-well plate 
(Nunc) which was connected to the microarray printer. We used a piezoelectric non-contact 
spotter S11 (Scienion, Berlin) for microarray slide production. Each spot was printed by 
shooting three drops of 1.5 nl on the slide surface, with six to twenty replicates. We used 
epoxysilane coated glass slides (Schott, Nexterion) for most of the experiments. After printing 
the microarray was stored at 4 °C in saturated humidity for up to one month. The microarray 
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was hybridized with a diluted biotinylated caspase solution (0.1 mg/ml in PBS pH 7.3) for 1h 
at room temperature in a hybridization station (2xHS 4800, Tecan). Four different dilutions 
were used; 1:500, 1:1500, 1:5000 and 1:20000. Hybridization was followed by four washing 
cycles. In a second step we incubated a fluorophore-conjugated Streptavidin (Alexa-633) 
followed by four more washing cycles. The microarray was then dried and stored at room 
temperature protected from light. For scanning of the slides we used a confocal laser scanning 
microscope LS4000 (Tecan, Austria) with an excitation wavelength of 633 nm and 
fluorescent detection at 670 nm. Data extraction and image processing and were performed 
with ArrayPro 4.5 (Media Cybermetics, Bethesda, USA) and Origin (Microcal, Northampton, 
USA). 
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Abstract 
Dysregulation of apoptosis is associated with several human diseases including cancer, 
autoimmune diseases and stroke. The main mediators of apoptosis are cysteine proteases 
(caspases) which propagate death signals to downstream targets. One of the main 
executioners is caspase-3 which is responsible for the majority of cleavage events in the cell. 
The potential of caspase 3 as a therapeutic target is an area of high interest and to date, several 
potent active site peptide inhibitors have been synthesized. However, all these molecules do 
not only inhibit caspase-3, but also homologous caspases. Here we describe caspase-3 specific 
inhibitors which have been selected from a library of designed ankyrin repeat proteins 
(DARPins). The crystal structures presented describe how the high specificity and inhibition 
is achieved and the kinetic data reveal a competitive inhibition mechanism. We further 
demonstrate that the mode of inhibition of the DARPins has similarities with that of the 
natural caspase inhibitor XIAP. However, unlike XIAP, the DARPin inhibitor is specific for 
caspase-3 alone and therefore does not bind the highly homologous caspase-7.  
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Introduction 
Programmed cell death (apoptosis) is a central process for the development and tissue 
homeostasis of metazoans. It is characterized by morphological changes such as nuclear 
fragmentation, membrane blebbing or the formation of apoptotic bodies [1]. In multicellular 
organisms including humans, improper regulation of apoptosis leads to a variety of 
pathologies such as cancer, autoimmune diseases and neurodegenerative disorders [2]. 
Apoptosis is triggered by various internal- and external stimuli, which are propagated by 
different pathways. Common to all apoptotic pathways are cysteine Asp-specific peptidases 
(caspases) [3-5]. These proteins are synthesized as inactive pro-enzymes and upon triggering 
of the cell death machinery they are activated by proteolytic cleavage on the C-terminal side 
of a well-conserved aspartic acid. Active caspases are dimers of two catalytic subunits and 
each subunit consists of a p12 and a p17 chain.  
Of the eleven known human caspases, caspase-3 occupies a prominent position in the 
apoptotic cascade. Caspase-3 is activated by intrinsic- or extrinsic death signals and it 
executes cell death by the cleavage of downstream targets such as PARP-1 [6]. Since 
apoptosis is a dangerous process for the cell, caspase activation is strictly controlled and all 
apoptotic signaling pathways are tightly regulated. All caspases recognize tetrapeptide 
sequences, which are characterized by an aspartic acid at the C-terminus (P1 position) and 
either tryptophan, aspartic acid or leucine residues at the N-terminus (P4 position) conferring 
selectivity for caspase-1, -3 and -8, respectively. The P4 selectivity has been attributed to 
different interactions with residues in loops flanking the P4 binding pocket [7, 8]. However, 
the selectivity of short peptidic substrates remains controversial. It has been reported that the 
in vitro selectivity of caspase-3 for a substrate harboring a P4 aspartic acid is at least 100-fold 
higher than for a glutamate or an asparagine [9]. Despite this finding, commercially available 
peptide substrates failed to exhibit the expected caspase selectivity [10]. Caspase-3 is the most 
promiscuous and efficient caspase and is more active in cleaving short peptide substrates than 
the caspase it was originally designed for. [10]. This analysis raised doubt regarding the use 
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of short peptides to dissect signaling cascades leading to apoptosis. The observation that 
naturally occurring caspase inhibitors, such as X-linked inhibitor of apoptosis (XIAP), are 
highly specific for caspase-3 and -7 [11, 12] suggests that specificity can be gained by 
extending the size of the inhibitor. Caspases are attractive drug targets since they are 
implicated in various diseases. Selective and potent caspase-specific inhibitors are therefore 
highly desirable. 
In order to develop a caspase-3 specific inhibitor we used the Designed Ankyrin Repeat 
Protein (DARPin) technology [13]. From a highly diverse library of DARPin molecules, 
binders that recognize the target molecule can be selected by either ribosome- or phage 
display [14, 15]. DARPins consist of a N- and C-terminal capping repeat and two or three 
internal repeats that recognize the target molecule through selected amino acids in 
randomized positions. DARPins possess several beneficial properties that make them 
attractive for biotechnological applications. They are thermodynamically stable, easily 
produced and do not contain cysteine residues allowing intracellular applications [16]. Highly 
selective DARPins have been successfully selected and described for a variety of different 
target proteins such as kinase inhibitors [17], crystallization chaperones [18], HIV inhibitors 
[19] and tumor targeting binding molecules [20]. 
Here, we report the selection and characterization of DARPins that bind to active caspase-3. 
Kinetic and binding experiments revealed that DARPins D3.4 and D3.8 are competitive 
caspase-3 inhibitors that do not recognize other members of the caspase family. The structure 
of the caspase-3/D3.4 complex provides insight into the inhibition mechanism and presents an 
analogy to XIAP inhibition. 
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Results 
Selection of caspase-3 specific DARPin binders 
A DNA library containing NI2C and NI3C DARPins was used to select caspase-3 binders by 
ribosome display [15]. After four selection rounds, 768 putative binders were screened by 
crude-cell extract ELISA yielding 29 clones that possessed submicromolar affinities for 
caspase-3. These high affinity binders were individually expressed, purified and their binding 
affinities for caspase-3 were determined by surface plasmon resonance (SPR) analysis. Four 
of the selected DARPins showed affinities below 10 nM (Supplementary Figure 1). Their 
sequences were aligned and are shown in Figure 1. Although DARPins D3.4 and D3.8 
contain 2 and 3 internal repeats, respectively, they possess the highest sequence similarity. Of 
the 14 randomized positions of the internal repeats 7 residues are identical. When comparing 
the sequences of DARPin D3.6 and D3.13 only 4 residues in a total of 21 randomized 
positions are identical. Despite the different numbers of internal repeats all four DARPins 
possess very high affinities for Caspase-3. SPR analysis revealed that D3.4, D3.6, D3.8 and 
D3.13 bind caspase-3 with KD values of 9.6±1.1 nM, 8.8±2.0 nM, 3.4±0.4 nM, and 7.69±0.4 
nM, respectively (Table 1). These KD values were determined based on equilibrium analyses 
of the SPR signal. We used the heterogeneous ligand model to determine the kinetic values 
(Table 1), which suggests two epitopes with substantially different binding affinities [21]. 
Inhibition of Caspase-3 by DARPins D3.4 and D3.8 
The inhibitory properties of the purified DARPins were analyzed using two different 
approaches. Initially the ability of the DARPins to inhibit the hydrolysis of the short 
chromogenic caspase-3 substrate Ac-DEVD-AMC was measured. These initial tests revealed 
that D3.4 and D3.8 inhibit the hydrolysis of the standard caspase-3 substrate with Ki values of 
16.8±0.3 nM and 6.37±0.2 nM respectively, whereas D3.6 and D3.13 showed no detectable 
inhibitory activities (Table 1). To characterize the mode of inhibition (competitive versus 
uncompetitive), specific velocity plot (Supplementary Figure 2) [22] analysis was performed, 
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which yields the ratio between competitive and uncompetitive inhibitor constants () and the 
turnover rate of free enzyme to inhibited enzyme (). For both DARPins we determined equal 
values of ∞and  = 0 demonstrating that D3.4 and D3.8 are purely competitive inhibitors 
of caspase-3 (Table 1). 
In the past, short peptide substrates have been extensively used for the characterization of 
proteases, because the determination of rate constants is straight forward in those 
experiments. On the other hand, short peptide substrates represent a rather artificial situation, 
since these substrates utilize a very limited number of binding interactions. Natural protease 
substrates are significantly larger and consequently their binding is guided by a broader set of 
interactions. Therefore, we tested whether the selected DARPins also inhibit the processing of 
PARP-1, one of the best characterized caspase-3 substrates. The 116 kDa PARP-1 is 
specifically cleaved by caspases-3 and -7 on the C-terminal side of Asp216 into an 85 kDa 
and a 31 kDa fragment [23]. The addition of three fold molar excess of D3.4 or D3.8 over 
caspase-3 inhibited the cleavage of PARP-1 by ~50%, whereas the addition of E3_5, a 
DARPin that does not bind caspase-3, showed no effect on the cleavage of PARP-1 (Figure 
2). However, the addition of a 150 fold molar excess of the caspase-3 DARPin inhibitors did 
not abolish PARP-1 cleavage completely in contrast to the peptide inhibitor Ac-DEVD.fmk 
which inhibited cleavage of PARP-1 completely (Figure 2).  
Specificity of DARPins D3.4 and D3.8 
All commercially available caspase inhibitors are capable of inhibiting both caspases-3 and -7 
equally well [10]. We investigated the caspase selectivity of D3.4 and D3.8 by measuring the 
binding affinity and inhibitory activity against caspase-7 (56% sequence identity with 
caspase-3) and the more distantly related caspase-6 (41% sequence identity). SPR analysis did 
not show any detectable binding of the caspase-3 directed DARPins D3.4 and D3.8 to 
caspases-6 or -7 (Supplementary Figure 3), suggesting that both DARPins are highly specific 
for caspase-3. These results are consistent with the activity measurements where D3.4 and 
D3.8 were also unable to inhibit PARP-1 cleavage by caspase-7 (Figure 2). Probing the ability 
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of D3.4 and D3.8 to inhibit the hydrolysis of chromogenic tetrapeptide substrates by caspases-
1, -2, -4, -5, -6, -7, -8, and -9 revealed that only D3.8 has a moderate inhibitory activity 
against caspase-7 (Figure 3, and Supplementary Figure 4). Addition of 1000 fold excess of 
D3.8 decreases the activity of caspase-7 to approximately 40%. 
Crystal structure analysis of the caspase-3/DARPin D3.4 complex 
To understand the inhibition mechanism of caspase-3 by DARPins the crystal structure of the 
caspase-3/D3.4 complex was determined at 2.1 Å resolution. The details of the structure 
determination (data collection and refinement) are listed in Table 2. In the crystal structure the 
asymmetric unit contains one (p12, p17)2 caspase-3 heterotetramer and two D3.4 molecules 
(Figure 4A). In the complex a surface area of 876 Å
2
 is buried and a surface complementarity 
index of 0.74 indicates a very good fit between D3.4 and caspase-3 (Table1). The interface 
involves residues from the N-terminal capping repeat and the two internal repeats from the 
DARPin, which form specific hydrogen bonds and hydrophobic interactions with the caspase 
(Figure 4A). The crystal structure reveals first of all that D3.4 binds in the active site pocket 
of caspase-3 and prevents substrate molecules from accessing the catalytic residues (Figure 
4A). The -turns of D3.4 point towards the -strand of caspase-3 that is responsible for the 
recognition of the substrate by main chain hydrogen bonds (residues 205 to 207). This 
observation agrees very well with the kinetic analysis of the inhibition mechanism, where also 
no uncompetitive contribution was observed (∞). Therefore, structural and kinetic 
analyses consistently classify D3.4 as a purely competitive caspase-3 inhibitor 
(Supplementary Figure 2). Furthermore, the concave side of the DARPin binds to loop-4 of 
caspase-3 (L4, residues 246 to 258) with the residues in the randomized positions. 
When comparing the structure with the previously published caspase-2 inhibitor 
(DARPin_F8) structure [24] and the natural caspase-3 inhibitor XIAP structure [25] (Figure 
4B and C) the following features can be highlighted: (i) DARPin_F8 also binds to loop-4 
(also termed 381-loop) however from the backside, (ii) DARPin F8 does not occupy the 
active site and inhibits caspase-2 specifically by an allosteric mechanism (Figure 4B) (iii) The 
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BIR2 domain of XIAP inhibits caspase-3 with its N-terminal extension loop and binds in the 
active site of caspase-3 in the opposite direction when compared to the substrate (Figure 4C). 
Interestingly, the binding mode of D3.4 shows similarities to the binding of natural substrates 
(based on inhibitor structures) and the natural inhibitor XIAP. Asp45 of D3.4 is located in the 
-turn that connects the N-terminal capping repeat and the first internal repeat of D3.4 and its 
side chain occupies the S4 pocket of caspase-3 (Figure 5A). It forms a direct hydrogen bond 
with Asn208-ND2 and two water-mediated hydrogen bonds with Trp214-NE1 and Phe250-N 
(Figure 5A and Supplementary Figure 5). The main chain carbonyl oxygen of Asp45 forms 
another water-mediated (Wat10) hydrogen bond with Arg207-N of caspase-3. This atom is 
normally involved in the formation of an anti-parallel -sheet with the substrate peptide. 
Wat10 forms a third hydrogen bond with Tyr204-OH. As a consequence, Thr166 moves 
towards the active site pocket and forms hydrogen bonds with Trp79-NE1 and Lys111-NZ of 
D3.4 (Figure 5A and Figure 6A). 
The tip of loop-4 of caspase-3 is recognized by the DARPins concave surface (Figure 5B and 
C). The side chain of Asp44 of D3.4 is buried in the interface and forms two hydrogen bonds 
with Ser251-OG and Phe252-N. In contrast, the side chains of Lys56 and Arg81 of D3.4 are 
solvent exposed and form salt bridges with the side chain Asp253 of caspase-3. Hydrophobic 
interactions seem to play equally important roles. The side chain of Phe256 of caspase-3 
nicely fits into a pocket that is formed by Ala46, Val48, Ile78 and Trp79 of D3.4 where the 
benzyl ring of Phe256 of caspase-3 forms T-stacking interactions with the indole ring of D3.4 
Trp79 (Figure 5C). Although the Phe256 binding pocket is mainly hydrophobic, the side 
chain of Asp77 is located at the bottom of this pocket and forms an intra-molecular salt bridge 
with Arg81 and a hydrogen bond with Wat26 (Figure 5C).  
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Comparison of the caspase-3/D3.4 structure with caspase-3 in complex with XIAP and 
DEVD 
The overall structure of caspase-3 is identical to several other caspase structures with rmsd 
values of 0.39 Å and 0.352 Å, respectively, when comparing the caspase-3/D3.4 structure 
with the 1.06 Å resolution caspase-3/z-DEVD-cmk (2DKO, [26]) and the caspase-3/XIAP 
complex structures (1I3O, [25]). Differences between caspase-3/D3.4 and the caspase-3/z-
DEVD-cmk structures are observed in the active site pocket. In the caspase-3/D3.4 structure 
loop-4 of caspase-3 has moved approximately 1 Å out of the active site, whereas Thr166 has 
moved into the active site compared to the caspase-3/z-DEVD-cmk structure (Figure 6A). 
The movement of Thr166 is a consequence of the 120° rotation of the Tyr204 side chain. In 
the caspase-3/z-DEVD-cmk structure Tyr204 points towards Thr166, whereas in the caspase-
3/D3.4 complex the Tyr204 side chain occupies the P2 pocket (Figure 6A).  
Interestingly, the conformations of Tyr204, Thr166 and loop-4 in the caspase-3/D3.4 complex 
structure resemble the conformations in the caspase-3/XIAP structure (1I3O) (Figure 6B). In 
both complexes Tyr204 occupies the S2 pocket and consequently the side chains of Thr166 
superimpose well [25]. Furthermore, Tyr204 rests against a hydrophobic patch of the 
inhibitor, which is formed by Leu141 and Val146 in XIAP and by Ala46 and Ile78 in D3.4 
(Figure 6B).  
Modeled structure of the caspase-3/D3.8 complex 
Based on the sequence alignment and the competitive inhibition we assume that both D3.4 
and D3.8 bind to the same epitope with similar interactions. We were not able to crystallize 
the caspase-3/D3.8 complex and thus calculated a homology model of D3.8 based on a N3C 
DARPin structure (DARPin E3_5, 1MJ0, [27]). This homology model was aligned with the 
caspase-3/D3.4 crystal structure (Figure 6C). D3.4 lacks the first internal repeat so that the N-
cap of D3.4 was superimposed with the first internal repeat of D3.8 (Figure 6C). D3.8 has two 
mutations (L56S and S76R) in the interface which are possibly involved in the interaction 
with caspase-3. All other amino acid changes between D3.4 and D3.8 are located more than 4 
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Å away from caspase-3. The homology model showed that the Lys56…Asp253 salt bridge is 
missing in the D3.8/caspase-3 complex (Figure 6D). In D3.8, Lys56 is replaced by serine, 
which is unable to form a salt bridge as observed in the caspase-3/D3.4 structure. The positive 
charge of Lys56 in D3.4 may also lead to repulsive interactions with His255 of caspase-7 at 
the top of loop-4 (Figure 6D). D3.8 in contrast, possesses a weak affinity for caspase-7 which 
is possibly caused by the L56S mutation. The deletion of a positive charge in caspase-7 is 
compensated by the positive charge of His255 in caspase-7. 
Mutant D3.4_S76R 
D3.8 binds caspase-3 with higher affinity and has a lower inhibition constant (Ki= 3.42 nM). 
Residue Ser76 in D3.4 is located in proximity to the interface but does not interact with 
caspase-3. Because a bulkier side chain such as Arg, as it is observed in D3.8, could 
participate in an extended DARPin/caspase-3 interface, we generated the D3.4_Ser76Arg 
(D3.4_S76R) mutant and characterized its functional and structural properties. The 
D3.4_S76R mutant has a dissociation and inhibitory constant of KD
S76R
 = 5.99 ± 0.47 nM and 
Ki
S76R
 = 3.49 ± 0.03 nM, respectively. Thus, D3.4 Ser76Arg shows an even lower inhibitory 
constant for caspase-3 compared to D.3.8 (Table 1). 
The 2.1 Å resolution crystal structure of the caspase-3/D3.4 Ser76Arg complex revealed that 
although the overall structure is identical to the caspase-3/D3.4 structure (rmsd of 0.198 Å), 
the C-terminal capping repeat has shifted by approximately 2 Å (Figure 6E). The newly 
introduced Arg76 forms two intra-molecular hydrogen bonds with Gly80-O and Gln109-O of 
the C-terminal capping repeat and an inter-molecular hydrogen bond with Gly60-O of the 
caspase (Figure 6E). In addition, the weak hydrogen bond between Lys111 and Thr166 as it is 
seen in the parent structure is broken and Lys111 points into the active site forming an intra-
molecular hydrogen bond with Ile78-O and a water-mediated hydrogen bond with Gly165-O 
of caspase-3. The mediating water molecule is located in direct vicinity of the active site 
Cys163 (Figure 6E). 
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Discussion 
The development of specific caspase inhibitors has remained a challenging task, due to the 
similarity between the active sites of caspases. Although the selectivity of caspases for short 
peptide inhibitors that differ in the P4 positions is well established [28], their selectivity is 
often insufficient considering the different amounts of active caspases in cells undergoing 
apoptosis [29]. In 2007 Schweizer et al. published the first truly specific caspase inhibitor 
(AR_F8) which inhibits caspase-2 with an allosteric mechanism by interacting with loop-4 
[24].  
Using the same technology [13], we identified four caspase-3 DARPins of which two 
specifically inhibited the enzyme. Kinetic analysis characterized D3.4 and D3.8 as purely 
competitive inhibitors, corresponding well with the structural findings that show how D3.4 
recognizes loop-4 of caspase-3 and occupies the active site substrate binding pocket. The 
caspase-2 directed DARPin AR_F8 also recognized loop-4, but demonstrated a significant 
part of uncompetitive inhibition. The different inhibition modes of D3.4 and AR_F8 can be 
explained by the different epitopes on the caspases. AR_F8 recognizes caspase-2 from the 
backside of loop-4 and stabilizes a distinct conformation which is not able to bind the 
substrate, whereas D3.4 binds straight into the active site of caspase-3. Our analysis further 
showed that D3.4 prevents substrates from accessing the catalytic Cys163 and leaves the 
conformation of loop-4 almost undisturbed when compared to the caspase-3 inhibitor 
structure. 
Another finding of our study was the superior inhibition of caspase-3 by the closely related 
D3.8 which inhibits caspase-3 even better than D3.4, however, D3.8 was found to have some 
residual affinity for caspase-7, probably resulting from Ser56.  
DARPin molecules D3.6 and D3.13 bind caspase-3 but do not inhibit hydrolysis and were 
thus not further analyzed. The IC50 value for the inhibition of caspase-7 by D3.8 can be 
estimated to be in the lower micro-molar range, based on data given in Figure 2. Thus, even 
inhibitors with a significantly extended interaction surface compared to tetrapeptide inhibitors 
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can in principle be recognized by the closely related caspases-7, albeit with affinity constants 
that differ by at least three orders of magnitude. Our inhibition studies using PARP-1 as a 
caspase substrate revealed that the selected DARPins inhibit the cleavage of PARP-1 
specifically. However, the irreversible peptide inhibitor Ac-DEVD.fmk inhibited caspase-3 
completely in contrast to the DARPins which reduced the activity of caspase-3 by 
approximately 50 % even in a 150 fold excess. This can be explained by the fact, that the 
caspase-3/DARPin complexes exist in an equilibrium and a small fraction of unbound active 
caspase-3 is sufficient to cleave PARP-1 over a relatively long incubation time of 20 minutes. 
Our data suggest that D3.4 and D3.8 bind to the same caspase-3 epitope, since residues that 
seem to be crucial for the recognition of this epitope, such as Asp45, Ala46, Val48, Ile78, 
Trp79 and Arg81, are conserved in both molecules. Our crystal structure revealed that D3.4 
recognizes caspase-3 by a set of specific hydrogen bonds, salt bridges and hydrophobic 
contacts. Particularly interesting are the interactions formed by Asp45, which occupies the S4 
pocket. So far all structurally characterized caspase-3 specific peptide inhibitors harbor an 
aspartic acid that occupies this pocket (Figure 7). Although the hydrogen bonding networks 
are different in the structures of caspase-3 in complex with D3.4, z-DEVD-cmk or XIAP, the 
positive electrostatic potential explains the preference for a small and negatively charged 
hydrogen bonding partner like aspartate. Further similarities between the complex structures 
of caspase-3 with D3.4 and XIAP are seen for Tyr204 (Figure 7). In both structures the 
Tyr204 side chain points towards Arg341, placing the phenyl ring at van der Waals distance 
to Cys163-S. On the opposite side the Tyr204 phenyl ring rests against a hydrophobic core, 
which is composed of caspase-3 residues Leu168 and Phe256 and the side chains of Ala46 
and Ile78 from D3.4 or Leu141 and Val146 from XIAP. D3.4 and XIAP are both lacking an 
aspartic acid that could occupy the S1 pocket of caspase-3, which consequently is filled by 
water molecules. The same conformation of Tyr204 is also seen in several other structures of 
caspase-3 in complex with low molecular weight inhibitors that are lacking a P1 aspartate [30, 
31]. Conversely, this conformation is different from classical tetrapeptide inhibitors, where 
the Tyr204 side chain rests against the side chain of Thr166 [26]. 
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The small molecule inhibitor z-DEVD.cmk and D3.4 both run anti-parallel to caspase-3 
residues 204-208. The S4 pocket of caspase-3 is occupied by Asp1 and Asp45 of z-
DEVD.cmk and D3.4 respectively and the S3-S1 pockets are occupied by residues continuing 
towards the C-terminus. The main chain of XIAP in contrast runs parallel to caspase-3 with 
Val 146 and Asp148 binding into the S2 and the S4 pocket respectively. Although the main 
chains of D3.4 and XIAP run in opposite directions, both inhibitors use very similar 
interactions to inhibit caspase-3 (Figure 7). Thus, the comparison of the caspase-3/D3.4 
crystal structure with the caspase-3/XIAP crystal structure provides an interesting example for 
the molecular mimicry of natural and designed caspase-3 inhibitors. 
In summary, our study presents the development and characterization of a caspase-3 
inhibitory DARPin with implications for specificity and inhibition mechanism. D3.4 and the 
improved variant D3.4_S76R are the first truly specific caspase-3 inhibitors and do not bind 
its close paralog caspase-7 or any other caspase. The selected DARPin is entirely competitive 
and prevents substrate binding by directly competing with the substrate. A remarkable finding 
was that this DARPin inhibits caspase-3 with a similar mechanism compared to XIAP, the 
natural caspase-3 inhibitor which also inhibits caspase-7. It has previously been postulated 
that specificity is achieved by two key factors, allosteric regulation and scanning of large 
volumes of conformational space [32]. While the second aspect holds true, we demonstrate 
here that specificity can be achieved even when the conserved active site is targeted, provided 
this is combined with specific surface recognition outside the active site.   
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Methods 
DARPin selection with Ribosome Display 
We performed 4 rounds of ribosome display to enrich caspase-3 specific binders based on a 
N3C and N2C library as described before [15, 33]. Prior to each selection the DARPin-
ribosome-mRNA complex was incubated with the closest homologous of caspase-3 (caspase-
6 and -7) and Streptavidin for 30 minutes at 4 °C to avoid selection of unspecific DARPins. 
Biotinylated caspase-3 was immobilized on magnetic particles (Dynabeads, Invitrogen) for 
solution panning. The DARPin-ribosome-mRNA complex was incubated with 20 l of beads 
for 30 minutes at 4 °C in a tube that was previously blocked with TBST-BSA (50 mM 
TrisHCl pH 7.4, 150 mM NaCl, 0.05 % Tween-20, 0.1 % BSA). The incubation was followed 
by 4 washing cycles in WBT (50 mM Tris acetate pH 7.4, 150 mM NaCl, 50 mM Magnesium 
acetate, 0.05 % Tween-20). The RNA was eluted in EB (50 mM Tris acetate pH 7.4, 150 mM 
NaCl, 25 mM EDTA) and purified and reverse transcribed for amplification for the next 
selection round. In round three and four we added a 1000 fold excess of unbiotinylated 
caspase-3 for 10 minutes during the selection to favor the enrichment of DARPins with slow 
koff rates. After four rounds of selection, we cloned the library in a pQE30 vector (Qiagen), 
transformed competent XL1 blue cells (Stratagene) and continued with crude cell extract 
ELISA.  
 
Crude cell extract ELISA 
Single colonies each containing one DARPin clone of the selected library were picked and 
inoculated in 0.9 ml auto-inducing media 5052 [34] containing deep 96-well plates (Abgene, 
UK). The cells were grown over night at 37 °C while shaking at 300 rpm in a shaker (TH15, 
Edmund Bühler GmbH). Then 200 l of each well were transferred into a sterile 96 well plate 
(449824, Nunc) as a backup for further protein expression and plasmid preparation. The 
remaining 700 l of cell-suspension was harvested by centrifugation and the cell pellet was 
lysed with 50 l B-PER II (78260, Pierce) per well for 30 minutes shaking at room 
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temperature. The lysed cells were resuspended by adding 950 l PBS, pH 7.3 and cell debris 
was removed by centrifugation (20 min, 4500 rpm at 4°C) in a table top centrifuge 5804 
(Eppendorf). We now took 20 l of the supernatant of four 96 well plates and transferred it to 
one 384 well ELISA plate (464718, Nunc). This plate has been previously coated with 20 l 
of a 22 nM Neutravidin solution (Pierce, 31000) and biotinylated caspase-3, followed by 
extensive washing. After 1h of incubation at room temperature and 3 washing cycles the plate 
was incubated with mouse anti-RGS-H4 antibody (34650, Qiagen) at a dilution of 1:2000 in 
PBS 1% BSA. We then added the secondary antibody (goat--mouse IgG alkaline 
phosphatase conjugate (Sigma, A3562)) followed by four washing cycles and added the 
substrate di-sodium 4-nitrophenyl phosphate (pNPP; 3 mM di-sodium 4-nitrophenyl 
phosphate, 50 mM NaHCO3, 50 mM MgCl2.6H2O). The OD was measured at 405 nm using 
a multi-well plate reader (Infinite M1000, Tecan). 
 
Expression, purification and biotinylation of Proteins 
All DARPins were expressed in auto-inducing media [34] or lysogeny broth media (LB) [13]. 
The expressed DARPin was purified with common His-tag purification methods using a self-
made gravity column consisting of a plastic column (57024, Supelco) and 0.5 ml bead volume 
of Ni
2+
-NTA agarose (30210, Qiagen). The DARPins were eluted in PBS, 200 mM Imidazole 
pH 7.4 and the Imidazole was removed with a PD-10 desalting column (17-0435-01, GE 
Helthcare). We added sodium azide (NaN3) to a final concentration of 0.03% to prevent 
growth of bacteria and fungi. The DARPins solution was further stored at 4 °C. Protocols on 
expression, purification and characterization of human caspase-1 to caspase-9 are published 
elsewhere [35].  
For chemical biotinylation of the caspase we used the linker EZ-Link Sulfo-NHS-LC-LC-
Biotin (21338, Pierce), containing a reactive group, a 3.05 nm long linker and a biotin moiety. 
After purification, 1ml of the caspase (10 M) in PBS pH 7.3 was incubated with a seven fold 
molar excess (1 ml of a 70 M solution) of biotin on ice for 30 minutes. The reaction was 
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quenched by adding 10 l of 5M Tris-HCl, pH 7.5. The biotinylated protein was then purified 
by size exclusion chromatography, using a Superdex 200 10/300 GL (GE Healthcare) in PBS 
at 4 °C. The fractions containing the biotinylated caspase were pooled and frozen in liquid 
nitrogen after adding sucrose to a final concentration of 10 %. 
 
Crystallization, Data Collection and structure modeling 
Crystallization 
The caspase/DARPin complexes were formed by incubating caspase-3 with a two-fold molar 
excess of each DARPin for 10 minutes on ice. The complex was purified by size exclusion 
chromatography (Superdex 200 HR 10/30, Amersham Pharmacia, Sweden) in 50mM Tris pH 
8.0 (4 °C), 50 mM NaCl. The samples containing the caspase/DARPin complex were 
concentrated to 5 mg/ml and 10 mg/ml for D3.4 and D3.4_S76R respectively, using a 
centrifugal filter device with a molecular weight limit of 15 kDa (Amicon Ultra, Millipore). 
Crystals were grown at room temperature using the vapor-diffusion method. 2 l of 
concentrated protein solution (5 mg/ml and 10 mg/ml for D3.4 and D3.4_S76R respectively) 
were mixed with 1 l of reservoir solution containing 100 mM HEPES buffer, pH 7.3, 70% 
(v/v) 2-Methyl-2,4-pentanediol (MPD). The mixture was stored at 20 °C and crystals 
appeared within 24 hours. 
 
Data Collection, Structure Determination and Refinement 
Crystals were flash frozen in liquid nitrogen for diffraction analysis and data collection at 
100K. No cryoprotectant was necessary for data collection. X-ray diffraction data were 
collected at the Swiss Light Source (SLS) at the X06SA beamline equipped with a Pilatus 6M 
fast readout pixel detector (Dectris, Switzerland). XDS was used for data processing and data 
were scaled with XSCALE [36]. Structure factors were calculated with IDXREF [37]. Both 
complexes crystallized in the space group P3121. Unit cell dimensions are listed in Table 2. 
The structures were solved by molecular replacement with the program PHASER [38] using a 
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high resolution structure of caspase-3 (2DKO, [26]) and a modeled N2C DARPin. The N2C 
DARPin was generated by homology modeling (MODELLER 9v8 [39]) using the N3C 
DARPin E3_5 (1MJ0, [27]) as a template. The crystals have a solvent content of 59 % 
(Matthews coefficient = 3) [40] with two caspase-3 heterodimers bound to two DARPins in 
the asymmetric unit. Alternating rounds of manual building using COOT [41] and restrained 
refinement with TLS groups using REFMAC 5.5.01.09 [42]. Water molecules were 
introduced in the last phase of refinement. The final refinement step we obtained Rfree/Rwork 
values of 0.185/0.217 for the caspase-3/D3.4 complex and 0.174/0.214 for the caspase-
3/D3.4_S76R complex. Data collection and structure refinement statistics are listed in Table 
2. Structural superposition was done using COOT [41] and figures were prepared using 
PyMOL [43]. 
 
Site directed Mutagenesis 
We used the QuikChange® Site Directed Mutageneis Kit (Stratagene) to incorporate 
mutations in the DARPin sequence. The following Primers were used to mutate D3.4 to 
D3.4_S76R fwd: 5'-GGT GCT GAC GTT AAC GCT CGT GAC ATT TGG GGT CGT ACT-
3' rev: 5'-AGT ACG ACC CCA AAT GTC ACG AGC GTT AAC GTC AGC ACC-3'. Codon 
which is underlined indicates the mutation. 
 
SPR measurements 
For SPR experiments we used the Proteon XPR36
TM
 (Bio-Rad Laboratories, Inc.) and a NLC 
sensor chip (Bio-Rad Laboratories, Inc.). We used sterile filtered PBS pH 7.3, 0.005% 
Tween-20 as a standard buffer for coating and all kinetic measurements. The biotinylated 
ligand (caspase) was coated on the sensor chip at a concentration of 5 nM and a flow rate of 
30 l per minute. The coating procedure was interrupted once a total of 1000 relative units 
(RU) were reached on the monitoring system. A dilution series of the analyte (DARPin) was 
pipetted in 96 deep well microplates (176-6023, Biorad), which were sealed to prevent 
evaporation or contamination with dust particles. For Kinetic analysis we measured the 
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analyte at eight different concentrations (0, 0.176, 0.52, 1.58, 4.47, 14.2, 42.6, 128 nM) 
starting with the lowest concentration.  All experiments were performed at 20 °C. We used a 
flow rate of 100 l per minute, an association time of 3 minutes and a dissociation time of 20 
minutes. The data were recorded and further processed with the ProteOn Manager 2.1.1
TM
 
(BioRad). The KD, kon and koff values were determined using the data analysis tool provided 
by the ProteON Manager
TM
 2.1.1 using the heterogeneous ligand model and equilibrium 
constants [44].  
 
Caspase activity measurements 
Specific inhibition of caspase-1 to caspase-9 was measured using peptide substrates from 
PEPTIDE INSTITUTE Inc. We used AC-DEVD-AMC for caspase-3, -6, -7 and -8, AC-
WEHD-AMC for caspase-1, -4 and -5, AC-VDVAD-AMC for caspase-2 and AC-LEHD-
AMC for caspase-9. Enzyme and substrate concentrations in the assay were as following 
considering each caspase as a dimer: caspase-1 (10 nM enzyme; 150 M substrate), caspase-2 
(25 nM; 150 M), caspase-3 (0.5 nM; 150 M), caspase-4 (200 nM; 600 M), caspase-5 (10 
nM; 150 M), caspase-6 (10 nM; 600 M), caspase-7 (2 nM, 400 M), caspase-8 (10 nM; 
150 M and caspase-9 (25 nM, 600 M). DARPin was added in the according molar ratio 
calculated per caspase active site. For caspase-2 we used 100 mM MES, pH 6.5, 10% 
PEG600 (w/v), 0.1% CHAPS (w/v), 10 mM DTT and caspase-9 activity was monitored in 50 
mM Tris, pH 7.5, 10% Sucrose (w/v) and 1.3 M NaCitrate.  For all other caspases we used 20 
mM PIPES, pH 6.5, 10% Sucrose (w/v), 0.1% CHAPS (w/v), 10 mM DTT, 150 mM NaCl, 
1mM EDTA. AMC release was monitored by measuring the fluorescent at ex = 360 nm and 
em = 465 nm using a spectrofluorometer (Infinite M-1000, Tecan). 
 
Specific velocity plot 
Inhibition mechanism and Ki values of D3.4, D3.8 and D3.4_S76R have been determined 
using the specific velocity plot [22] and inhibitor titration. The concentration of caspase-3 was 
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determined by active site titration as described previously [9]. The caspases inhibitor AC-
DEVD-CMK (0-7.6 nM), caspase-3 (~0.5 nM) and the substrate AC-DEVD-AMC (100 M)  
were prepared in activity buffer containing no DTT [20 mM PIPES, pH 6.5, 10% Sucrose 
(w/v), 0.1% CHAPS (w/v), 10 mM DTT, 150 mM NaCl, 1mM EDTA]. Concentrations of 
DARPins have been determined using amino acid analysis at the Functional Genomic Center, 
Zurich. The initial velocities of substrate hydrolysis with 0.5 nM caspase-3 (Dimer) have been 
measured with different DARPin concentrations (D3.4: 8-32 nM, D3.4_S76R: 4-10 nM, 
D3.8: 2-8 nM) and substrate concentration between 0.2 – 0.8 times Km (Km = 24.7 ± 1.8 M). 
Graphical analysis of the velocity plot was done with Prism5 (GraphPad Software). The 
inhibitor titration has been performed using 0.5 nM caspase-3 (Dimer), different DARPin 
concentrations (D3.4: 0-1000 nM, D3.4_S76R: 0-1000 nM, D3.8: 0-100 nM) and 24 M 
substrate. Initial velocities have been fitted according to tight binding inhibition equation 
which has been described previously [45] to determine Ki values of inhibitor DARPins. 
 
PARP-1 inhibition and Western Blot analysis 
A 0.15 M solution of PARP-1 [50 mM Tris pH 7.5, 150 mM NaCl] was obtained by Prof. 
Hottiger (University of Zurich) and mixed with caspase-3 or -7 (1.5 M) and the according 
DARPin (4.5 to 225 M) as indicated in Figure 2. The reaction was incubated for 20 minutes 
at 37°C in 50 mM Tris pH 7.5, 150 mM NaCl, 0.5 mM DTT and stopped by adding SDS 
sample buffer and heating to 95°C for 5 minutes. The samples were further analyzed by 
Western Blot analysis. 
 
Western Blot analysis 
The sample was subjected onto a 12% SDS-PAGE under reducing conditions for separation 
and transferred to a nitrocellulose membrane (iBlot®, Invitrogen). The membrane was 
blocked in High-TBS [50 mM Tris pH 7.5, 500 mM NaCl] containing 5 % w/v nonfat dry 
milk over night at 4° C. The primary antibody anti-PARP (Cell Signalling, 9542) was 
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incubated with the membrane in a 1:1000 dilution in High-TBS-T [50 mM Tris pH 7.5, 500 
mM NaCl, 0.1 % Tween-20] at 4°C over night. After intensive washing in High-TBS-T we 
incubated the membrane with anti-rabbit HRP conjugated antibody (Cell Signalling, #7074) 
for 1 h at room temperature in TBS [50 mM Tris pH 7.5, 150 mM NaCl]. For the 
chemiluminescent detection we used the SuperSignal West Pico Chemiluminescent Substrate 
(Piercenet) and recorded the emitted light with a CCD camera. 
 
Modeling of D3.8 
Based on inhibition measurements and the sequence alignment, we hypothesized that D3.8 
binds to the same epitope as D3.4. We therefore calculated a model of D3.8 in complex with 
caspase-3. The N3C DARPin E3_5 (PDB entry code 1MJ0) [27] was used as a template to 
calculate a homology model of D3.8 using the program MODELLER 9v8 [39]. The model of 
D3.8 was then aligned and superimposed with the structure of the caspase-3/D3.4 crystal 
structure based on the sequence alignment shown in Figure 1.  
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Figure legends 
Figure 1. Sequence alignment of caspase-3 specific DARPin binders 
The general DARPin sequence is shown with the consensus (black) and the randomized 
amino acid positions (red x, any of the 20 natural amino acids except cysteine, glycine or 
proline; z, any of the amino acids asparagine, histidine or tyrosine). Four DARPin sequences 
are aligned to the consensus sequence with identical residues represented as a dot and 
different residues are highlighted by the respective residue acronym. Amino acids involved in 
the interaction with caspase-3 are colored in orange and differences in the sequence of 
DARPin_3.4 and DARPin_3.8 (green) are highlighted. A mutation we introduced in this 
study (DARPin_3.4S76R) is marked by a red box. The sequence number is based on 
DARPin_3.4, a N2C DARPin which lacks the first internal repeat. 
Figure 2. Inhibition of caspase-3 dependent PARP-1 cleavage by DARPin inhibitors 
The cleavage of PARP-1 by caspase-3 and -7 was observed on a 12 % SDS-PAGE (upper 
panel). PARP-1 and cleaved PARP-1 (cPARP-1) was detected by a specific antibody which 
recognized both forms. Cleavage of PARP-1 could be prevented by pretreating caspase-3 and 
-7 with a peptide inhibitor (DEVD.fmk). None of the selected DARPins cleave PARP-1. 
Caspase-3 and -7 have been pretreated with DARPin inhibitors to test the effect on PARP-1 
cleavage. The DARPin was added with a 3, 15 or 150-fold molar excess and cleavage was 
monitored by SDS-PAGE. The selected DARPins do not inhibit the reaction of caspase-7. 
The catalytic efficiency of caspase-3 in contrast is clearly reduced and approximately 50 % of 
PARP-1 is cleaved after 20 minutes. 
Figure 3. Specificity and inhibition of selected DARPins for caspase-3, -6 and -7 
(A) The relative activity of caspase-3 in presence of four different DARPins (D3.4, 
D3.4_S76R, D3.8 and control DARPin E3_5) is shown. Each DARPin was added in three 
different concentrations indicated as X-fold molar excess per active site; 10x (black), 100x 
(light grey) and 1000x (grey). All DARPins inhibit the activity of caspase-3 with the 
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exception of the control DARPin E3_5. (B) and (C) The relative activity of caspase-6 and -7 
in presence of four different DARPins as described in (A). The 1000-fold molar excess of 
DARPin was not measured for caspase-6 because no effect was visible at a 100-fold excess. 
D3.8 has a moderate inhibitory affect on caspase-7, all other DARPins are highly specific for 
caspase-3. 
 
Figure 4. Structure of the caspase-3 in complex with different inhibitors 
(A) Stereo view of a cartoon representation of the caspase-3/D3.4 complex. The two subunits 
of caspase-3 are colored in dark grey (large subunit) and light grey (small subunit), the active 
site forming loops L1 to L4 (red) and the catalytic residues (green) are highlighted. The D3.4 
consists of two capping repeats (N-cap and C-cap; dark blue) and two internal repeats (1
st
 and 
2
nd
 repeat, light blue). D3.4 binds in the active site and mainly interacts with loop-4 of 
caspase-3. (B) The caspase-2 specific DARPin AR_F8 (green, 2P2C) caspase-3/D3.4 
structure has been superimposed, caspases are shown in a surface representation (grey). D3.4 
(blue) and DARPin AR_F8 (green) both bind to active site loop-4 (red) covering different 
epitopes. (C) The BIR2-XIAP/caspase-3 structure (yellow, 1I3O) has been superimposed with 
the caspase-3/D3.4 structure. The C-terminal BIR2 domain of XIAP binds to an exosite on 
caspase-3 and inhibits the enzyme with the hook, line and linker substructures at the N-
terminal. The DARPins repeats, XIAP substructures and loop-4 (red) are indicated. 
Figure 5. Molecular Basis of the Interaction 
Stereo view of the caspase-3/D3.4 interaction. D3.4 (blue) interacts with caspase-3 (large 
subunit, dark grey; small subunit, light grey) via hydrogen bonds (dotted line) and 
hydrophobic interactions. DARPin amino acid side chains are labeled with an additional (‘). 
The position of the active site cysteine (green) is shown. (A) Asp45’ forms several hydrogen 
bonds in the active site and binds in to the S4 pocket of caspase-3. Thr166 which is located 
close to the active site Cys163 forms two hydrogen bonds with the second repeat of the 
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DARPin (B) The concave site of DARPin_3.4 binds the tip of loop-4 through several 
hydrogen bonds. (C) Hydrophobic interactions of both molecules. Phe256 binds into a 
hydrophobic pocket formed by DARPin residues and forms T-stacking interactions with 
Trp79.  
Figure 6. Structural Basis of DARPin_3.4 Binding and Inhibition 
With the exception of caspase-3, the labels of all amino acid side chains contain a unique 
identifier (D3.4(‘), DEVD(°), XIAP(*), D3.4_S76R(^), D3.8(), caspase-7(#)). (A) 
Superposition of the caspase-3/z-DEVD.fmk (green, 2DKO) structure and the caspase-3 (dark 
grey)/3.4 (blue) structure. Several structural differences can be observed. Tyr204 is rotated by 
approximately 120° in the DARPin bound structure. The position of Thr166 is shifted away 
from the active site due to the Tyr204 rotation.  (B) Superposition of the caspase-3 (light 
grey)/XIAP_BIR2 (yellow, 1I3O) structure and the caspase-3 /D3.4 (colored as in A) 
structure. Both caspase-3 inhibitors use similar interactions for the inhibition. The 
conformation of Tyr204 is very similar in both structures and occupies the P2 pocket of 
capase-3. This is also the case for Asp45 which occupies the P4 pocket and forms a hydrogen 
bond with Asn208. (C) Model of D3.8 (dark red, salmon) is superimposed with D3.4 (blue, 
light blue) which binds to loop-4 (red) of caspase-3 (surface representation, grey). (D) The 
first internal repeat of D3.4 (blue) is superimposed with the second internal repeat of the 
modeled D3.8 (salmon) binding to loop-4 of caspase-3 (grey) and caspase-7 (green). Lys56’ 
forms two hydrogen bonds with Asp253 and causes repulsive interactions with His255
#
. 
Ser56

 in D3.8 lacks the hydrogen bonds to Asp253 and repulsive interactions to His255
#
. (E) 
Superposition of the caspase-3/D3.4 structure with the mutated D3.4_S76R. Surface (grey) 
and ribbon (black) representation of caspase-3 in complex with both DARPins (D3.4, dark 
blue; and D3.4_S76R green) is shown. Newly formed hydrogen bonds are indicated with 
white dotted lines (grey). The mutated residue Arg76^  forms a new hydrogen bond to Gly60-
O (see also Table 3). Ile78^ and Lys111^ form new hydrogen bonds leading to structural 
changes in the flexible C-terminal capping repeat of D3.4. 
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Figure 7. Schematic representation of caspase-3 inhibition by different inhibitors 
(A) The peptide inhibitor Ac-DEVD.fmk occupies the four substrate binding pockets (S1 – 
S4) of caspase-3 similar to binding of the natural substrate. (B) The BIR2 domain of XIAP 
occupies the S4 pocket of caspase-3 and Val146 (V) keeps Tyr204 in a position which 
occupies the S2 pocket. P1 is filled with water and binding of the hook leads to steric 
hindrance of substrate binding. The BIR2 domain runs in the opposite direction with the N-
terminal at the S1 pocket and the C-terminal at the S4 pocket. (C) DARPin_3.4 (blue) uses a 
similar mechanism to inhibit caspase-3 compared the XIAP. Asp45 binds in the S4 pocket, 
Ile78 keeps Tyr204 in a locked conformation and S1 is filled with water. Steric hindrance of 
the 16 kDa DARPin prevents binding of the substrate. 
Table 1. Kinetic constants and characteristics of the interaction 
Table 2. X-ray data collection and model refinement statistics 
Table 3. Hydrogen bonds of the caspase-3 interaction with DARPin_3.4 
 
Supplementary Figures 
Supplementary Figure 1.  
SPR analysis of the five DARPins binding to caspase-3. Eight different concentrations (0, 
0.176, 0.53, 1.6, 4.5, 14.2, 42.7, 128 nM) have been measured by the Proteon XPR on a NLC 
sensor chip. The relative units (RU) were recorded for the association (3 minutes) and 
dissociation phase (20 minutes). 
Supplementary Figure 2. Characterization of the inhibition type of caspase-3 DARPins 
Initial velocities and the specific velocity plot (small figure) are shown. The specific velocity 
plot shows the behavior of a competitive inhibitor with ∞and  = 0. 
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Supplementary Figure 3. SPR analysis of selected DARPins 
Caspase-3 specific DARPins have been tested on binding against the close homologs caspase-
6 and -7. All three caspases have been coated on a Proteon XPR36 NLC chip followed by 
testing of five DARPins. DARPin_6.21 and DARPin_7.1 are DARPins that have been 
selected against caspase-6 and -7 respectively. They were used a positive control, to show that 
the caspases are functional on the surface on the chip. All DARPins that were analyzed how a 
signal to their devoted caspase only, indicating how specific DARPins interact with their 
target proteins. 
Supplementary Figure 4 Inhibition assay of different caspases 
Inhibition assay of the selected DARPins against different caspases (caspase-1, -2, -4, -5, -8 
and -9) as described in Figure 3. 
Supplementary Figure 5. Binding of Asp45 in the S4 pocket of caspase-3 
Surface representation of caspase-3 in complex with three different inhibitors superimposed 
in the active site. The peptide inhibitor DEVD (green), XIAP (yellow) and DARPin_3.4 (red) 
share a common mechanism and occupy the S4 pocket with an aspartic acid. Asp45 from the 
DARPin forms a hydrogen bond with Asn-ND2 and two water mediated hydrogen bonds. 
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Footnotes 
Abbreviations Ac: Acetyl, AMC: 7-amino-4-methyl coumarin, BIR: Baculovirus 
IAP repeat, cmk: Chloromethyl ketone, LBHB: Low-barrier 
hydrogen bond, p12: Small subunit of caspase-3, p17: Large 
subunit of caspase-3, SMAC: Second mitochondrial activator of 
caspases, XIAP: X-linked inhibitor of apoptosis, Z/Cbz: 
Benzyloxycarbonyl 
Coordinates Coordinates and structure factors have been be deposited to PDB 
under accession codes 2XZD, 2Y0B. 
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Table 1: Kinetic constants 2 
 Kinetic Equlibrium 
 
Inhibition Interaction
DARPin kon1(M
-1s-1
) koff1(s
-1
) KD1(M) kon2(M
-1s-1
) koff2(s
-1
) KD2(M) KD(nM) KI(nM)   SC Å
2
 iG kcal/mol 
D3.4 2.85E+05 8.81E-03 3.09E-08 1.12E+06 1.13E-03 1.01E-09 9.6 ± 1.1 16.76 ∞ 0 0.740 875.95 -6.1 
D3.4_S76R 1.74E+05 4.20E-03 2.42E-08 1.62E+06 7.45E-04 4.61E-10 5.99±0.47 3.49 ∞ 0 0.725 907.55 -7.1 
D3.6 1.48E+05 1.13E-03 7.63E-09 1.46E+06 1.00E-02 6.88E-09 8.8±2.0 - - - - n.d. n.d. 
D3.8 1.77E+05 2.49E-03 1.41E-08 2.44E+06 1.11E-04 4.57E-11 3.4±0.4 3.42 ∞ 0 n.d. n.d. n.d. 
D3.13 2.74E+05 1.24E-03 4.51E-09 2.31E+06 7.86E-03 3.41E-09 7.69±0.4 - - - - n.d. n.d. 
 3 
 4 
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Table 2: Data and refinement statistics 
Structure* C3/D3.4 (2XZD) C3/D3.4_S76R (2Y0B) 
Data collection 
Oscillation [°] 0.25 0.2 
Space Group P3121 P3121 
Unit cell parameter a=98 Å a=98 Å 
 b=98.0 Å 
 
b=98.0 Å 
  c= 193.6 Å 
 
c= 192.9 Å 
  ==90.0° =120.0° ==90.0° =120.0° 
Resolution [Å] 49.0 – 2.1 49.0 – 2.1 
Wavelength [Å] 1.000 0.92 
RMEAS 
A
[%] 
 
4.9 (69.6) 
 
5.8 (72.2) 
 ROBS 
B
[%] 4.2 (60.4) 4.9 (60.9) 
Completeness 
B
[%] 99.3 (99.5) 99.2 (99.5) 
I/(I)B 15.59 (1.92) 12.94 (1.96) 
Refinement 
Resolution [Å] 2.1 2.1 
RWORK/RFREE 18.5/21.8 19.1/21.7 
No. of protein atoms 5616 5622 
No. of water atoms 247 345 
B-Factor [Å
2
] 35.29 ± 11.29 35.75 ± 11.36 
Root mean square deviations 
Bond length [Å] 0.011 0.006 
Bond angles [°] 1.192 0.941 
* Given are the names of caspase-3 DARPin inhibitor complexes and the PDB entry  
codes in brackets.  
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Table 3: Hydrogen bonds  
DARPin Distance Caspase-3 
D:ARG 23 [NH1] 3.19 C:PHE 252 [O] 
D:ASP 44 [OD2] 2.69 C:SER 251 [OG] 
D:ASP 44 [OD2] 2.97 C:PHE 252 [N] 
D:ASP 45 [OD1] 3.1 C:ASN 208 [ND2] 
D:ASP 45 [O] 2.5/2.8 C:Wat 10 - TYR 204 [OH] 
D:ASP 45 [OD2] 2.6/2.7 C:Wat 12 - Phe 250 [N] 
D:ASP 45 [OD2] 2.6/2.9 C:Wat 11 - Trp 214 [NE1] 
D:LYS 56 [NZ] 3.38 C:ASP 253 [OD1] 
D:LYS 56 [NZ] 
 
C:ASP 253 [OD2] 
D:TRP 79 [NE1] 2.87 C:THR 166 [O] 
D:ARG 81 [NH2] 2.79 C:ASP 253 [OD2] 
D:LYS 111 [NZ] 3.75 C:GLU 167 [OE2] 
* D:LYS 111 [NZ] 2.68 C:THR 166 [OG1] 
* not present in DARPin_3.4_S76R 
DARPin_3.4_S76R 
D:Arg 76 [NE] 3.3 C:Gly 60 [O] 
D:Lys 111 [NZ] 2.7/3.2 C:Wat - Gly 165 [O] 
 
 
 
 
 
 
 
 
 
171 Specific inhibition of caspase-3 by a competitive DARPin 
 
 
 
171 
Supplementary Figure 1 
 
172 Specific inhibition of caspase-3 by a competitive DARPin 
 
 
 
172 
Supplementary Figure 2A 
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5. A DARPin activator of caspase-8 
 
Introduction 
Peptidases are involved in various regulatory pathways in which the signal is relayed by limited 
proteolysis making the process irreversible [173]. Peptidases control a large number of physiological 
processes such as cell proliferation, DNA replication, tissue remodeling, homeostasis, apoptosis and 
inflammation. The deregulation of these highly controlled processes can lead to too little or too much 
proteolysis and is implicated in many human diseases. Limited proteolysis of a protein can lead to 
gain, loss or switch of function. An interesting and extensively studied protease cascade that 
exemplifies these alterations of function is the caspase mediated pathway of cell death and 
inflammation. Apoptotic initiator caspases, once activated, cleave downstream caspases that are 
present in the zymogenic inactive form. Once processed, downstream caspases are activated and 
cleave multiple substrates resulting in most cases in a loss of function of the target protein ultimately 
leading to cell death [3]. Caspases are present in the cell as inactive zymogens (procaspases), similar 
to literally all peptidases and require several maturation steps to be active. Initiator caspases such as 
Caspase-8 and -9 require recruitment to macromolecular activation platforms via their N-terminal 
prodomains. The high local concentration leads to dimerization and subsequent autocatalytic cleavage 
of the interdomain linker [62]. Executioner caspases in contrast are constitutively dimeric and are 
activated by upstream proteolysis of the intra domain linker. 
Dysregulation of apoptosis plays a crucial role in many human pathologies and targeting caspases for 
inhibition or activation are viable strategies to overcome these diseases. MacKenzie et.al. have 
comprehensively addressed this topic and point out general problems and opportunities on how to 
manipulate caspase activity [45]. While most approaches focus on the inhibition of peptidases, a recent 
study has highlighted the potential of activating peptidases and their potential in drug discovery [102]. 
Caspase-8 plays a central role in apoptosis and other signaling pathways (e.g. suppressing or 
potentiating tumor malignancy [174]) and is therefore a target of high interest.  
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In this work we have selected a specific caspase-8 binder (DARPin_8.4) from a highly diverse library 
of designed ankyrin repeat proteins (DARPins) using ribosome display (RD). A crystal structure of the 
caspase-8/ DARPin_8.4 protein complex revealed that the DARPin binds to helix 2 of caspase-8. 
Enzymatic characterization showed that this DARPin_8.4 increases the activity of caspase-8 through 
specific interactions with the active site forming loop1. 
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Results 
Ribosome display selection of DARPins against caspase-8. 
DARPins were selected against purified and biotinylated caspase-8 under physiological conditions. 
We performed two independent selections with four ribosome display rounds. In round one and three 
we included a pre-panning step against the two closest homologs, namely caspase-2 and caspase-9 
(Figure 5.1 A). Both caspases have a sequence homology with caspase-8 of approximately 50% and 
are also involved in activation of executioner caspases. We additionally included koff maturation 
during selection to increase selection pressure for DARPins with favorable binding kinetic (Figure 
5.1A). In the first RD selection we obtained 4 hits from 192 colonies screened and in the second 
selection we identified 32 hits from 384 colonies based on a crude cell extract ELISA. We sequenced 
the 14 strongest hits and the alignment of these DARPins sequences shows that all DARPins have one 
common ancestor because they differ in only one or two amino acids (Figure 5.1 B).  
 
 
Figure 5-1: DARPin selection against caspase-8 
A) The selection strategy consisted of four selection rounds with alternating conditions. Yellow boxes indicate prepanning 
on MBP, caspase-2 and -9.The grey box shows selection against the target protein caspase-8, followed by washing as 
indicated. Off-rate selection is shown by the green box.  B) Sequence alignment of DARPins DARPin_8.1 from the first 
selection and DARPin_8.4 and DARPin_8.6 from the second selection by ribosome display. Variable positions in the DARPin 
consensus sequence (red) are indicated by either X or Z. Amino acids that differ from the other DARPins (green) are shown. 
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All sequence variation appeared to be either in the C- or N-terminal capping repeat of the DARPin, 
while all randomized positions were conserved. A DARPin which occurred repeatedly in this pool was 
DARPin_8.4. This DARPin was also found to be the strongest binder and therefore was further 
characterized. 
DARPin 8.4 binds caspase-8 with high affinity and specificity 
In order to determine the thermodynamic properties and binding kinetics of the caspase-
8/DARPin_8.4 interaction we applied several techniques. First we revealed that both proteins interact 
with a 1:1 binding stoichiometry (N= 0.95) with one DARPin binding one caspase-8 monomer using 
isothermal titration calorimetry (ITC). Binding of both proteins reduced the enthalpy (H=-8477) and 
is entropically favoured (S= 5.09 kcal/mol) since the Gibbs free energy deceases (Table 5.1). The KD 
of the interaction was 47 nM according ITC measurements at 25 °C (Table 5.1). 
 
 
 Kinetics DARPin_8.4  
S
P
R
 
kon(M
-1s-1
) koff(s
-1
) KD(M) 
i
G [kcal/mol] 
1.8E+05 9.41E-04 5.2E-09 - 
IT
C
 
KD(M) H [kcal/mol] S [kcal/mol] 
i
G [kcal/mol] 
4.7E-08 -8477 5.09 n.d. 
 
Table 5-1: Kinetic data obtained by ITC and SPR 
 
Surface plasmon resonance (SPR) measurements with a Proteon XPR36 allowed precise determination 
of the kinetic characteristics of the interaction including kon and koff rates. The KD of the interaction is 
5.2 nM at 20 °C based on a fit using the Langmuir model (Table 5.1 and Figure 5.2 C). The high 
affinity is owing to the slow koff value with 9.41 x 10
-4
. The resulting kon value is 1.8 x 10
5
. We were 
further interested in the specificity of DARPin_8.4 and thus tested whether it is able to bind other 
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caspases such as caspase-9, -2, -3 and -7. No interaction was detectable (data not shown) with any 
other caspase coated on the SPR chip, indicating that DARPin_8.4 is highly specific for caspase-8.  
We further analyzed the pH dependency of the caspase-8/DARPin_8.4 interaction by ELISA in 
different buffers from pH 4 to pH 9.5. DARPin_8.4 binds caspase-8 in a broad pH range (pH 5 – 10) 
unlike most DARPins that have been selected to date (Figure 5.2 B). The strongest binding was 
observed between pH 7.5 to 9; binding remains at a significant level between pH 7.5 and pH 5 and 
becomes insignificant below pH 5. 
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Figure 5-2: Analysis of DARPin binding to caspase-8 
A) Top, raw ITC data: eighteen injections of the ligand have been measured and recorded. Bottom, complete binding 
isotherm: One site model was used to fit the data resulting in values for stoichiometry and enthalpy (black box). B) ELISA 
profile of the influence of pH on DARPin binding. DARPin_8.4 was compared with DARPin_7.1 which binds caspase-7. 
Twelve different buffers have been prepared, ranging from pH 4 to pH 9.5. C) SPR profile of DARPin_8.4 against caspase-8 
showing eight different concentrations with the according fit. Data were fitted using the Langmuir model with the deviation 
shown in the lower panel. 
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Crystal structure of the DARPin_8.4/caspase-8 complex 
The DARPin_8.4 caspase-8 complex crystallized in acidic conditions at pH 4.8 showing that the 
interaction remains intact even at low pH at high protein concentrations. The crystals diffracted to 1.8 
Å, the highest resolution for a DARPin structure in complex with its designated target protein so far. 
The complex crystallized in the space group P212121 and the crystals have a solvent content of 38.2 %. 
Crystallographic data are presented in Table 5.2.  
Structure DARPin_8.4 (2Y1L) 
Data collection 
Space Group P212121 
Unit cell parameter a=61.0 Å 
b=81.60 Å 
c= 163.2 Å 
==90.0° =120.0° 
Resolution [Å] 48.86 – 1.8 
Wavelength [Å] 1.000 
RMEAS 
A
[%] 
ROBS 
B
[%] 
11.1 (58.0) 
4.2 (51.5) 
Completeness 
B
[%] 99.4 (98.9) 
I/(I)B 13.29 (3.67) 
Refinement 
Resolution [Å] 1.8 
RWORK/RFREE 18.0/21.8 
No. of protein atoms 6246 
No. of water atoms 685 
B-Factor [Å
2
] 18.4 ± 9.66 
Root mean square deviations 
Bond length [Å] 0.009 
Bond angles [°] 1.2 
 
Table 5-2: Crystallization and refinement statistics of the caspase-8/D8.4 crystal structure. Values in parentheses 
represent the highest resolution shell. 
A 
R MAES=Σhkl(N/(N-1))Σ1¦I1(hkl)-I(hkl)¦ΣhklΣ1I1(hkl). 
B
 ROBS=ΣhklΣ1¦I1(hkl)-
I(hkl)¦/ΣhklΣ1I1(hkl). 
 
The asymmetric unit cell (asu) contains a caspase-8 dimer which consists of two small and two large 
subunits as it was found in the previous caspase-8 structure (1QTN) [148] and is bound by two 
DARPins (Figure 5.3 A and B). The crystal has a tight packing and the protein complex is arranged in 
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layered sheets (Figure 5.3 A). Crystal contacts are mediated mainly by DARPin-DARPin and 
DARPin-caspase interactions (Figure 5.3 A). One crystal contact is observed between symmetry 
related caspases. All previously solved structures of caspase-8 crystallized in the space group P3121 
with the highest resolution being 1.2 Å [175]. The DARPin/caspase interface has a buried surface area 
of 934 Å
2
, this represents one of the largest interfaces observed for DARPin interaction with their 
target protein [129]. A surface complementarity index of 0.7 indicates a good fit between both 
proteins. The structure reveals that DARPin_8.4 mainly binds to an extended -helix (termed -helix 
2) which involves ten residues from Tyr288 to His304 (Figure 5.3 C and Figure 5.4). DARPin_8.4 
forms three hydrogen bonds with residues located in the -helix2 (Glu290, Asp294 and Lys297) 
which point away from the protein surface (Figure 5.4). It further interacts with residues of the -
strand2, namely Lys282 and Glu280. The C-terminal capping repeat of DARPin_8.4 binds to residues 
of the active site forming loop1 (Lys246 and Lys250) by forming two hydrogen bonds (Figure 5.4 and 
Figure 5.5 C). All three internal repeats of the DARPin are involved in the binding interface (Figure 
5.3 C); in addition five residues of the C-Cap of DARPin_8.4 also contribute to the interaction. In 
total, we observe 16 hydrogen bonds (H-bonds) which span the entire interface (Table 5.2 and Figure 
5.4). 
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Figure 5-3: Crystal structure of caspase-8 in complex with DARPin_8.4 
(A) Crystal packing of the caspase-8/DARPin_8.4 complex (space group P212121). One complex is shown in cartoon 
representation and the neighboring complexes are shown in ribbon representation. The caspase-8 dimer is shown in blue 
(large subunit: dark blue, small subunit: light blue) bound by the active site inhibitor z-IETD.fmk (yellow). Crystal contacts 
are mediated mainly by DARPin-DARPin and DARPin-caspase interactions but also caspase-caspase interactions. (B) 
Overview of the caspase-8/DARPin_8.4 complex in a transparent surface and cartoon representation. Color coding as 
described in (A), residues of the catalytic dyad (Cys285 and His237) are shown in green and the active site is circled (dotted 
circle). Two DARPin_8.4 (red) molecules bind one caspase-8 dimer. The interface is largely formed by -helix 2 of caspase-8 
and the three internal repeats and the C-Cap (C). DARPin_8.4 interacts with three secondary structure features of caspase-8 
(surface representation, blue), -helix 2 (orange), -strand 2 and loop 1 (both orange). (D) Surface representation of the 
DARPin_8.4 surface (red) forming a hydrophobic core (green) with residues and the helix2 of caspase-8 (blue). 
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The H-bond network surrounds the hydrophobic core which is formed by the amino acids F56, Leu86, 
Leu89, Phe90 and Phe123 of DARPin_8.4 and Tyr293, Ile295 and Ile298 of caspase-8 (Figure 5.3 C 
and Figure 4). Residue Ile298 of caspase-8 binds to a pronounced hydrophobic pocket which is formed 
by Leu86, Leu89 and Phe90 in the core of the caspase-8/DARPin interface (Figure 5.3 D). 
 
Figure 5-4 Hydrogen bond network of the caspase-8/DARPin_8.4 interaction 
Stereo view of Caspase-8 (blue, cartoon representation) and the interacting residues of DARPin_8.4 (red) are shown. H-
bonds are indicated by dotted black lines between the two respective side chains.  
In total, fifteen residues of caspase-8 are involved in the interaction with DARPin_8.4 of which ten are 
located in the -helix2, three in the -strand2 and two in loop1. A sequence alignment of these 
residues with ten other caspases revealed that none of the residues is conserved. This finding explains 
why DARPin_8.4 recognizes caspase-8 with high specificity when binding to an epitope which is 
unique to caspase-8.  
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DARPin_8.4 Distance Caspase-8 
D:ARG 23 [NH1] 2.78 C:TYR 235 [OH] 
D:ARG 23 [NH1] 2.54 C:GLU 280 [OE1] 
D:ASN 57 [ND2] 3.30 C:GLU 280 [OE2] 
D:ASN 156 [ND2] 2.62 C:GLU 290 [OE1] 
D:ARG 85 [NH2] 2.94 C:GLU 294 [OE1] 
D:SER 46 [OG] 2.40 C:LEU 301 [O] 
D:ALA 45 [N] 2.69 C:ASP 303 [OD2] 
D:ASN 57 [OD1] 2.94 C:TYR 235 [OH] 
D:ASN 158 [OD1] 3.12 C:LYS 246 [NZ] 
D:ASN 156 [O] 2.55 C:LYS 246 [NZ] 
D:ILE 154 [O] 3.09 C:LYS 250 [NZ] 
D:ASN 156 [OD1] 2.44 C:THR 288 [OG1] 
D:GLU 112 [OE1] 2.95 C:LYS 297 [NZ] 
D:SER 45 [OG] 3.04 C:ASP 303 [N] 
D:MET 122 [O] 2.60 C:GLN 291 [N] 
D:ASN 57 [ND1] 2.3 C:LYS 282 [N] 
 
Table 5-3: Hydrogen bonds formed in the caspase-8/DARPin_8.4 interface 
 
Comparison with previously solved caspase-8 crystal structures 
Crystal structures in complex with selected protein binders such as antibodies or DARPins often reveal 
novel structural conformations that are stabilized by the respective binder [176]. In order to investigate 
whether caspase-8 in complex with DARPin_8.4 shows a novel conformation we compared the 
structure with previously published structures of caspase-8 alone. The superposition with the highest 
resolved crystal structure of caspase-8 in complex with the inhibitor z-IETD.fmk (pdb code: 1QTN) 
[175] shows that DARPin_8.4 binds to a previously observed conformation (Figure 5.5 A). No 
significant differences can be observed in the overall structure with an RMSD of 0.717. One exception 
is loop 2 which is shifted by approximately 1 Å in the caspase-8/DARPin_8.4 structure (Figure 5.5 A). 
A closer look at the residues that are involved in the interface indicates that only side chains of four 
amino acids (Lys250, Glu290, Glu294 and Lys297) have different rotamer positions. However, both 
crystal structures differ with an rmsd of 3.2 from the solution structure of monomeric procaspase-8, 
which was determined by nuclear magnetic resonance (NMR) spectroscopy [23] (Figure 5.5 A). While 
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the core of the monomeric procaspase-8 has the typical caspase fold with low flexibility, the active site 
forming loops display high flexibility [23]. Loop1 is rotated by approximately 90° compared to the 
position found in the crystal structure and occupies part of the substrate binding site together with the 
linker (Figure 5.5 B and C). Cleavage of the linker results in the formation of two new active site 
forming loops, loop2 and loop2’ which stabilizes active site in the second monomer [76] (Figure 5.5 
A). Furthermore it allows the formation of the dimer interface and loop1 is now able to rotate into the 
substrate-bound conformation. DARPin_8.4 recognizes caspase-8 in an inhibitor (or substrate)-bound 
conformation by interacting with loop1 (Figure 5.5 B). Three hydrogen bonds are formed between 
DARPin_8.4 residues Ile154, Glu156, Glu158 and capase-8 residues Lys246 and Lys250 (Figure 5.5 
C). 
 
Figure 5-5: Comparison of different caspase-8 structures 
(A) Superposition of the caspase-8/DARPin_8.4 crystal structure (blue) with the previously solved caspase-8/inhibitor crystal 
structure (grey, 1QTN) and the NMR structure of the monomeric procaspase-8 (cyan, 2K7Z). The position of DARPin_8.4 is 
indicated by the red ribbon representation. The position of the active site bound inhibitor z-IETD.fmk in sticks (yellow) is 
indicated. The linker connecting the large and small subunit of procaspase-8 is presented as a red loop. (B) Close up view of 
the active site of all three structures superimposed. Loop1 (red) of procaspase-8 is rotated by ~90° into the active site. (C) 
The C-Cap of caspase-8 (red) forms three hydrogen bonds with loop1 of caspase-8 and locks the helix in a substrate bound 
position as it is shown by the caspase-8/z-IETD.fmk structure (grey). The rotation of loop1 in the solution structure (cyan) is 
indicated leading to a steric clash with the inhibitor. 
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DARPin_8.4 induces dimerization of caspase-8 
As previously observed, binding of a DARPin can alter the activity of an enzyme [95]. We tested 
whether the presence of DARPin_8.4 has an influence on the activity of caspase-8 and observed that a 
10-fold excess of DARPin_8.4 leads to a 4-fold increase in activity compared to caspase-8 alone 
(Figure 5.6).  
 
Figure 5-6: Caspase-8 activity is influenced by DARPin_8.4 
Relative activity of caspase-8 in presence of different DARPin constructs. Bovine serum albumin (BSA) or DARPin_8.4 have 
been added to the caspase-8 activity reaction.  
 
The activity of caspase-8 is highly dependent on the monomer-dimer equilibrium with the dimer 
representing the catalytically active form. The ratio of monomer to dimer of caspase-8 in solution 
depends on the concentration and presence of an inhibitor [161]. The dissociation constant of the 
dimer interface of caspase-8 is 50 M and decreases to 5 M when bound to an inhibitor [161]. All 
caspase-8 crystal structures that have been solved, show caspase- 8 in an active conformation in 
complex with an inhibitor, including the structure (1QTN) [175] shown in Figure 5.5. Since we see no 
conformational difference in the caspase-8/IETD and caspase-8/DARPin_8.4 structures we assume, 
that the DARPin_8.4 binds to the active conformation of caspase-8. Interactions with Lys246 and 
Lys250 of the active site loop locks this loop in an active conformation. The NMR structure of the 
uncleaved caspase-8 monomer shows loop1 in an inactive conformation [23] (Figure 5.5 B) and 
several other intermediate conformations might exist. Since binding of an inhibitor induced 
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dimerization of the caspase monomer, we wanted to test, whether binding of DARPin_8.4 shows the 
same effect by binding to loop1. In order to test this hypothesis we performed an ultracentrifugation 
(UZ) experiment which allows us to resolve and quantify the monomer-dimer equilibrium. At a 
concentration of ~15 M, 4% of caspase-8 is present as dimer and 96% is monomeric. In the presence 
of DARPin_8.4 however, we observe that the equilibrium is shifted to the dimer, with approximately 
20% dimer and 80% monomer (Table 5.4). This finding supports the hypothesis that DARPin_8.4 
recognizes and locks the active substrate bound conformation of loop1, leading to dimerization of 
caspase-8. 
 
Sample  Monomer Dimer 
DARPin_8.4 measured size [kDa] 20 ± 4 - 
[78mM] proportion [%] 99 - 
 theoretical size [kDa] 18.5 36 
Caspase-8 measured size [kDa] 29 ± 3.4 63 ± 7 
[15,5 mM] proportion [%] 96 3.7 
 measured size [kDa] 29 58 
Caspase-8 measured size [kDa] 42.7 ± 5 83.2 ± 9 
[15,34 mM] proportion [%] 79.8 19.6 
 measured size [kDa] 47.5 94 
 
Table 5-4: Analytical Ultracentrifugation 
Analytical ultracentrifugation experiments to determine the oligomeric state of caspase-8, DARPin_8.4 and the complex of 
both proteins. 
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Discussion 
Caspase-8 is a very attractive drug target due to its central role in the apoptotic cascade. Not only the 
inhibition of caspase-8 is a viable strategy to combat diseases, but also activation of caspase-8 is 
highly interesting since evading of the apoptotic cascade is regarded as one hallmark of cancer [41]. 
Caspase-8 is present as an inactive zymogen (procaspase-8) in the cytoplasm and requires activation 
through an oligomerization platform (DISC) to obtain full catalytic activity. The main event at the 
DISC is the formation of a caspase-8 dimer followed by linker cleavage, loop rearrangement and 
formation of the active site.  
In order to activate caspase-8 specifically in in vitro experiments we have developed a novel approach 
which aims to dimerize caspase-8 based on specific interaction with DARPins. For this we have 
selected DARPins against caspase-8 using ribosome display and have identified DARPin_8.4 as a very 
potent binder. Interestingly we have obtained the same DARPin multiple times in two independent 
selections with only few mutations in the DARPin framework which are most likely due to reverse 
transcription of RNA to DNA or PCR amplification. The fact that this DARPin has been favored 
during selection probably due to the high affinity of 5.2 nM and particularly the slow koff rate of 9.31 
10
-4
 x s
-1
. In the ITC experiment we observed a KD of 47 nM which is significantly different from the 
KD determined by SPR. A possible explanation is the experimental setup since ITC measures the 
affinity in solution whereas SPR measures the affinity on a surface of a dextran coated chip. 
Furthermore protein interactions are very sensitive to pH, temperature and buffer conditions and small 
differences can result in different affinities. SPR measurements have been performed at 20 °C whereas 
ITC was performed at 25 °C which might be the reason for the two different KD-values. Furthermore 
ITC is not the method of choice for low nM affinities; since the resolution limit with 10 to 50 nM is 
above the affinity we measured by SPR.  
The caspase-8/DARPin_8.4 complex is significantly more stable than other DARPin protein 
interactions we have seen so far. We were still able to observe an interaction at pH 5.5. Therefore we 
were able to crystallize the complex in a broad range of conditions. The best crystals were obtained at 
191 A DARPin activator of caspase-8 
 
 
 
191 
pH 4.8 and diffracted to 1.8 Å resolution. The 1.8 Å structure illustrates the composition and interface 
of the complex and explains why this interaction has a low KD and is relatively insensitive against pH 
changes. The interface is one of the largest interfaces observed for DARPins so far (934 Å
2
), with both 
hydrogen bonds and hydrophobic interactions contributing to the interaction strength. The curvature of 
the convex caspase-8 surface perfectly fits with the concave DARPins interface with a surface 
complementary index of 0.7. The epitope of caspase-8 involves -helix2, the active site forming loop 
1 and three residues of the -strand 2. We assume that the hydrophobic core is essential in the 
interaction next to the 16 hydrogen bonds. The residues Ile298, Ile295 and Tyr293 of caspase-8 form a 
hydrophobic core with a hydrophobic patch on the DARPin surface.  
The superposition of our structure with a previously determined high resolution crystal structure 
reveals that no conformational differences can be observed. Merely loop2 shows moderate structural 
rearrangements and four amino acid side chains have different rotamer positions. An interesting 
finding is that the residues involved in the interaction are generally not conserved, except for Thr288. 
This is a strong indication that the interaction of DARPin_8.4 is specific for caspase-8 and that 
DARPin_8.4 does not bind any of the other caspases. This has also been supported by SPR 
measurements (data not shown) where no signal was observed for any of the caspases tested except for 
caspase-8. A residue which is not directly involved in the interaction (Tyr293) has recently been 
discovered to be essential for the regulation of caspase-8 activity [85]. Tyr293 is constitutively 
phosphorylated in neutrophils and dephosphorylation by the tyrosine kinase SHP-1 allows the 
activation of caspase-8. Tyr293 sits at the upper end of helix-2 and points towards loop1 and the active 
site residues (Figure 5.4). It is involved in hydrophobic interactions with the DARPin_8.4. The 
DARPin could be used for intracellular visualization of phosphorylation events if DARPin_8.4 is able 
to bind the dephosphorylated caspase-8 only. This hypothesis however, needs further experimental 
evidence. 
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Figure 5-7: Schematic representation of caspase-8 monomer-dimer equilibrium  
Caspase-8 (grey) in monomer-dimer equilibrium in different states is shown. Loop1 (red), the linker (blue), the peptide 
inhibitor z-IETD.fmk (yellow) and DARPin_8.4 (green) green are highlighted in color. (A) The procaspase-8 is present as a 
monomer only; the linker prevents dimerization and blocks the active site. (B) No crystal structure of the apo form of 
cleaved caspase-8 is available, but ultracentrifugation experiments revealed that it is almost exclusively present as 
monomer with only residual activity. Due to the absence of inhibitor, the active site forming loops including loop1 might be 
flexible and can adapt several conformations. (C) The KD for caspase-8 dimerization decreases when bound to an inhibitor 
and the equilibrium is balanced at ~5M [175]. (D) A similar effect is observed for DARPin_8.4, which locks loop1 in a 
ligand bound conformation. The equilibrium shifts towards the dimer. 
 
The DARPin selection against caspase-8 by ribosome display was performed in the absence of 
inhibitor. In contrast, the caspase-8/DARPin_8.4 complex crystallized only in the presence of the 
inhibitor z-IETD.fmk which is known to stabilize the active site forming loops. The crystal structure 
of the complex revealed that DARPin_8.4 binds to an inhibitor/substrate bound conformation of 
caspase-8. Our kinetic analysis of the interaction using ITC and SPR was performed in the absence of 
inhibitor. This indicates that DARPin_8.4 interacts with caspase-8 in the presence and absence of 
inhibitor. The crystal structure showed the interaction of DARPin_8.4 with the active site forming 
loop1, which represents the inhibitor/substrate bound form. The NMR structure of procaspase-8 [23] 
shows loop1 in an inactive conformation, with the linker which prevents formation of the active site 
(Figure 5.5 A). Based on the crystal structure and the solution structure we can conclude that loop1 
can be present in both conformations if no inhibitor or substrate is bound. Binding of DARPin_8.4 
locks loop1 in the active conformation.  
193 A DARPin activator of caspase-8 
 
 
 
193 
Procaspase-8 is monomeric in solution and exists in a monomer-dimer equilibrium after linker 
processing. The KD of the interface is ~50 M and binding of an inhibitor decreases the affinity to ~5 
M [161]. Binding of a substrate or inhibitor thus induces dimerization of caspase-8. This is in line 
with our finding, that caspase-8 has a higher activity when DARPin_8.4 is bound. The DARPin_8.4 
locks loop1 in a substrate bound conformation and thus facilitates dimerization and substrate binding. 
The activity increases by a factor of 4 upon DARPin_8.4 binding which agrees well with the finding 
that the amount of dimer increases by a factor of 5, as it was found by ultracentrifugation experiments. 
The different conformation of the active site loops and the effect on the monomer-dimer equilibrium is 
illustrated in Figure 5.7. 
In summary we have successfully selected and characterized a DARPin which specifically interacts 
with caspase-8. Binding of DARPin_8.4 increases the activity of caspase-8 significantly. Based on a 
high resolution structure we were able to uncover the molecular basis of this finding. The interaction 
increases the activity of caspase-8 by locking loop1 in a substrate bound conformation promoting the 
formation of a caspase-8 dimer. This study provides new evidence on the dynamic nature of caspase-8 
active site loops and dimer formation. 
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Material and Methods 
Ribosome Display and DARPin selection 
We performed 4 rounds of Ribosome Display to enrich caspase-8 specific binders based on a N3C and 
N2C library as described previously [120, 124]. To exclude cross specific DARPins that would also 
bind the most homologous caspases, -2 and -9 we included them as a prepanning step in each round, 
prior to incubation with the according caspase (Figure 1A). Biotinylated caspase-8 was immobilized 
on magnetic particles (Dynabeads, Invitrogen) for solution panning or on streptavidin coated plates 
(Maxisorb, Nunc) for surface panning (no inhibitor was added). The DARPin-ribosome-mRNA 
complex was incubated with 20 l of beads for 30 minutes at 4 °C in a tube that was previously 
blocked with TBST-BSA (50 mM TrisHCl pH 7.4, 150 mM NaCl, 0.05 % Tween-20, 0.1 % BSA). 
The incubation was followed by 4 washing cycles in WBT (50 mM Tris acetate pH 7.4, 150 mM 
NaCl, 50 mM Magnesium acetate, 0.05 % Tween-20). The RNA was eluted in EB (50 mM Tris 
acetate pH 7.4, 150 mM NaCl, 25 mM EDTA) and purified and reverse transcribed for amplification 
for the next selection round. In round three and four we added a 1000 fold excess of unbiotinylated 
caspase-3 for 10 minutes during the selection to favor the enrichment of DARPins with slow Koff rates. 
After four rounds of selection, we cloned the library in a pQE30 vector (Qiagen), transformed 
competent XL1 blue cells (Stratagene) and continued with crude cell extract ELISA.  
Crude cell extract ELISA 
Single colonies each containing one DARPin clone of the selected library were picked and inoculated 
in 0.9 ml auto-inducing media ZYM-5052 [172] containing deep 96-well plates (Abgene, UK). The 
cells were grown over night at 37 °C while shaking at 300 rpm in a shaker (TH15, Edmund Bühler 
GmbH). Then 200 l of each well were transferred into a sterile 96 well plate (Nunc) as a backup for 
further protein expression and plasmid preparation. The remaining 700 l of cell-suspension was 
harvested by centrifugation and the cell pellet was lysed with 50 l B-PER II (78260, Pierce) per well 
for 30 minutes shaking at room temperature. The lysed cells were resuspended by adding 950 l PBS, 
pH 7.3 and cell debris was removed by centrifugation (20 min, 4500 rpm at 4°C) in a table top 
centrifuge 5804 (Eppendorf). We took 20 l of the supernatant an added it to 384 ELISA plate (Nunc). 
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This plate has been previously coated with 20 l of a 22 nM Neutravidin solution (Pierce, 31000) and 
biotinylated caspase-8, followed by extensive washing. After 1h of incubation at room temperature 
and 3 washing cycles the plate was incubated with mouse anti-RGS-H4 antibody (34650, Qiagen) at a 
dilution of 1:2000 in PBS 1% BSA. We then added the secondary antibody (goat--mouse IgG 
alkaline phosphatase conjugate (Sigma, A3562)) followed by four washing cycles and added the 
substrate di-sodium 4-nitrophenyl phosphate (pNPP; 3 mM di-sodium 4-nitrophenyl phosphate, 50 
mM NaHCO3, 50 mM MgCl2.6H2O). The OD was measured at 405 nm using a multi-well plate 
reader (Infinite M1000, Tecan). 
Protein expression, purification and biotinylation 
DARPin_8.4 were expressed in auto-inducing media [172] or lysogeny broth media (LB) [110]. The 
expressed DARPin was purified with common His-tag purification methods using a self-made gravity 
column consisting of a plastic column (57024, Supelco) and 0.5 ml bead volume of Ni
2+
-NTA agarose 
(30210, Qiagen). DARPin_8.4 was eluted in PBS, 200 mM Imidazole pH 7.4 and the Imidazole was 
removed with a PD-10 desalting column (17-0435-01, GE Helthcare). We added sodium azide to 
(NaN3) a final concentration of 0.03% to prevent growth of bacteria and fungi. For crystallization we 
mixed both caspase-8 and DARPin_8.4 in a ratio of 1:2 and removed the excess of DARPin by size 
exclusion chromatography on a Superdex 200 10/300 GL (GE Healthcare) in 20 mM Tris pH7.5, 20 
mM Nacl. The fractions containing the complex of caspase-8 and DARPin_8.4 were pooled and 
concentrated to 15 to 21 mg/ml and used for crystallization.  
For chemical biotinylation of the caspase we used the linker EZ-Link Sulfo-NHS-LC-LC-Biotin 
(21338, Pierce), containing a reactive group, a 3.05 nm long linker and a biotin moiety. After 
purification, 1ml of caspase-8 (10 M) in PBS pH 7.3 was incubated with a seven fold molar excess (1 
ml of a 70 M solution) of biotin on ice for 30 minutes. The reaction was quenched by adding 10 l of 
5 M Tris-HCl, pH 7.5. The biotinylated protein was then purified by size exclusion chromatography, 
using a Superdex 200 10/300 GL (GE Healthcare) in PBS at 4 °C. The fractions containing the 
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biotinylated caspase were pooled and frozen in liquid nitrogen after adding sucrose to a final 
concentration of 10 %. 
Isothermal Titration Calorimetry 
Purified caspase-8 were dialyzed against the assay buffer PBS, pH7.3 and 0.005% Tween 20. The 
protein concentration was determined using absorption spectroscopy at 280 nm combined with amino 
acid analysis at the Functional Genomics Center Zurich (FGCZ), Switzerland. A MicroCal VP-ITC 
device (Microcal, GE Healthcare, USA) was used to record isothermal titration calorimetry profiles 
and integrated with the software Origin. The sample cell contained 1.4 ml of either 5 or 10 M 
monomeric caspase-8 at a temperature of 25 °C. 10 l of DARPin_8.4 was titrated at a concentration 
of 115.1 M with an injection interval of 300 seconds until saturation was reached. 
Surface Plasmon Resonance 
For SPR experiments we used the Proteon XPR36
TM
 (Bio-Rad Laboratories, Inc.) and a NLC sensor 
chip (Bio-Rad Laboratories, Inc.). We used sterile filtered PBS pH 7.3, 0.005% Tween-20 as a 
standard buffer for coating and all kinetic measurements. The biotinylated caspase-8 was coated on the 
sensor chip at a concentration of 5 nM and a flow rate of 30 l per minute. The coating procedure was 
interrupted once a total of 1600 relative units (RU) was reached on the monitoring system. A dilution 
series of the analyte (DARPin) was pipetted in 96 deep well microplate (176-6023, Biorad), which 
were sealed to prevent evaporation or contamination with dust particles. For Kinetic analysis we 
measured the analyte at eight different concentrations (0, 1, 1.8, 3.2, 5.8, 10.6, 19.08, 34.3, 61.8, 111.1 
and 200 nM) starting with the lowest concentration.  All experiments were performed at 20 °C. We 
used a flow rate of 100 l per minute, an association phase of 5 minutes and a dissociation phase of 20 
minutes. The data were recorded and further processed with the ProteOn Manager 2.1.1
TM
 (BioRad). 
The KD, kon and koff values were determined using the data analysis tool provided by the ProteON 
Manager
TM
 2.1.1 using the langumir model and equilibrium constants [166].  
Crystallography 
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The caspase-8/DARPin_8.4 complex was formed by incubating caspase-8 with DARPin_8.4 in a ratio 
of 1:2 for 10 minutes on ice. The complex was purified on a Superdex 200 HR 10/30 (Amersham 
Pharmacia, Sweden) size exclusion chromatography column in 20 mM Tris pH 7.5 (4°C), 20 mM 
NaCl. The samples were concentrated to 15 to 21 mg/ml using an Amicon Ultra (Millipore, 10 kDa 
MWCO). 
Prior to crystallization of the complex, we incubated the protein solution with the tetra peptide 
aldehyde inhibitor Ac-DEVD-CHO in a 1:2 ration (Two inhibitor molecules per active site). Crystals 
were grown at room temperature using the vapor-diffusion method. The protein solution (21 mg/ml) 
was mixed with an equal volume of reservoir solution containing 100 mM citric acid, pH 4.9, 200 mM 
Li2SO4 and 22.4 % PEG 4000. For cryoprotection, the crystals were equilibrated in the reservoir buffer 
and 10 – 15 % ethylene glycerol and subsequently flash frozen in a nitrogen stream at -170 °C. 
X-Ray Diffraction, Data Collection, Structure Determination and Refinement 
Data were collected at the Swiss Light Source (SLS) at the X06SA beamline equipped with a Pilatus 
6M fast readout pixel detector. XDS [177] was used for data processing and structure factors were 
calculated with IDXREF [178]. The complex crystallized in the orthorhombic space group P212121 
with unit cell dimensions a= 61 Å b= 81.6 Å, c=163.2 Å and ===90.0°. 
The crystal structure was solved by molecular replacement (MR) using PHASER [179]. We used a 
previously published high resolution structure of caspase-8 1QDU [148] and N3C DARPin 2QYJ 
[115] as templates for MR. For refinement of the structures we used REFMAC 5.5.01.09 [180]. Data 
reduction parameters are presented in Table 5.2. 
Caspase Activity measurements 
Specific activity of caspase-8 was measured using the peptide substrates AC-DEVD-AMC from 
PEPTIDE INSTITUTE Inc. (www.peptide.co.jp/en/). Enzyme concentration was 10 nM and Substrate 
concentration was 150 M and the assay was performed in standard caspase activity buffer containing 
20 mM PIPES, pH 6.5, 10% Sucrose (w/v), 0.1% CHAPS (w/v), 10 mM DTT, 150 mM NaCl, 1mM 
EDTA. AMC release was monitored by measuring the fluorescent at ex = 360 nm and em = 465 nm 
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using a spectrofluorometer (Infinite M-1000, Tecan). For activation measurements DARPin was added 
in the according molar ratio and the initial velocity was recorded.  
 
Ultracentrifugation 
Protein samples were dialyzed against PBS pH 7.3 at 4°C over night and equilibrated to 20°C prior to 
analysis by ultracentrifugation. We used an Optima XL-1 (Beckman Coulter, Fullerton, CA, USA) and 
a TI50 rotor using epoxy centerpieces (12mm) with sapphire windows. Absorption was measured at 
280 nM and results were analyzed using Sedfit [181]. 
Coordinates  
The atomic coordinates for the caspase-8 DARPin_8.4 complex have been deposited at the Protein 
Data Bank with the accession code 2Y1L. 
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DARPin Sequences 
 
DARPins selected against Caspase-1: 
>p1.1_GSDLGKKLLEAARAGQDDEVRILMANGTDVNATDKHGHTPLHLAAYRGHLEIVEVLLKYGADVNALDDYGMTPLHVA
AWAGHLEIVEVLLKHGADVNAWDADGTTPLHLAAHTGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.4_GSDLGRKLLEAARAGQDDEVRILMANGADVNATDKHGHTPLHLAAYRGHLEIVEVLLKYGADVNALDDYGMTPLHVA
AWAGHLEIVEVLLKHGADVNAWDADGTTPLHLAAHTGHLEIVEVLLKHGADVNAQDRFGKTAFDISIDNGNEDLAEILQKLN 
>p1.7_GSDLGKKLLEAARAGQDDEVRILMANGADVNATDKHGHTPLHLAAYRGHLEIVEVLLKYGADVNALDDYGMTPLHVA
AWAGHLEIVEVLLKHGADVNAWDADGTTPLHLAAHTGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.9_GSDLGRKLLEAARAGQDDEVRILMANGADVNATDKHGHTPLHLAAYRGHLEIVEVLLKYGADVNALDDYGMTPLHVA
AWSGHLEIVEVLLKHGADVNAWDADGTTPLHLAAHTGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.10_GSDLGKKLLEATRAGQDDEVRILMANGADVNATDKHGHTPLHLAAYRGHLEIVEVLLKYGADVNALDDYGMTPLHV
AAWAGHLEIVEVLLKHGADVNAWDADGTTPLHLAAHTGHLEIVEVLLKHSADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.15_GSDLGRKLLEAARAGQDDEVRILMANGADVNATDKHGHTPLHLAAYRGHLEIVEVLLKYGADVNALDDYGMTPLHV
AAWAGHLEIVEVLLKHGADVNAWDADGTTPLHLAAHTGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.16_GSDLGKKLLEAARAGQDDEVRILMANGADVNATDKHGHTPLHLAAYRGHLEIVEVLLKYGADVNALDDYGMTPLHV
AAWAGHLEIVEVLLKHGADVNAWDADGTTPLHLAAHTGHLEIVEVLLKYGTDVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.17_GSDLGKKLLEAARAGQDDEVRILMADGADVNAIDKHGHTPLHLAAYRGHLEIVEVLLKYGADVNALDDYGMTPLHV
AAWAGHLEIVEVLLKHGADVNAWDADGTTPLHLAAHTGHLEIVEVLLKYSADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.19_GSDLGRKLLEAARAGQDDEVRILMVNGADVNATDKHGHTPLHLAAYRGHLEIVEVLLKYGADVNALDDYGMTPLHV
AAWAGHLEIVEVLLKHGADVNAWDTDGTTPLHLAAHTGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.21_GSDLGRKLLEAARAGQDDEVRILMANGADVNATDKHGHTPLHLAAYRGHLEIVEVLLKYGADVNALDDYGMTPLHV
AAWAGHLEIVEVLLKHGADVNAWDADGTTPLHLAAHTGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDYGNEDLAEILQKLN 
>p1.39_GSDLGKKLLEAARAGQDDEVRILMANGADVNATDKHGHTPLHLAAYRGHLEIVEVLLKYGADVNALDDYGMTPLHV
AAWAGHLEIVEVLLKHGADVNAWDADGTTPLHLAAHTGHLEIVEVLLKYGADVNAQDKFGKTTFDISIDNGNEDLAEILQKLN 
>p1.53_GSDLGRKLLEAARAGQDDEVRILMANGADVNAIDKHGHTPLHLAAYRGHLEIVEVLLKYGADVNALDDYGMTPLHV
AAWAGHLEIVEVLLKHGADVNAWDADGTTPLHLAAHTGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.70_GSDLGKKLLEAARAGQDDEVRILMANGADVNATDVHGHTPLHLAAHVGHLEIVEVLLKHGADVNAADKIGWTPLHV
AGHSGHLEIVEVLLKHGADVNAWDDDGDTPLHLAAFDGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.73_GSDLGKKLLEAARAGQDDEVRILMANGADVNAFDQHGHTPLHLAAYDGHLEIVEVLLKYGADVNAFDSEGWTPLHV
AAFSGHLEIVEVLLKHGADVNAFDYSGFTPLHLAAHSGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.74_GSDLGKKLLEAARAGQDDEVRILMANGADVNATDVHGHTPMHLAAHVGHLEIVEVLLKHGADVNAADKIGWTPLHV
AGHSGHLEIVEVLLKHGADVNAWDDDGDTPLHLAAFDGHLEIVEVLLKYSADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.75_GSDLGKKLLEAARAGQDDEVRILMANGADVNAFDHHGHTPLHLAAYDGHLEIVEVLLKYGADVNAFDSEGWTPLHV
AAFSGHLEIVEVLLKHGADVNAFDYSGFTPLHLAAHSGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.76_GSDLGKKLLEAARAGQDDEVRILMANGTDVNATDTEGHTPLHLAAFGGHLEIVEVLLKHGADVNANDAFGWTPLHV
VAMAGHLEIVEVLLKYGADVNAVDIFGYTPLHLAADHGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.77_GSDLGKKLLEAARAGQDDEVRILMANGADVNALDDYGDTPLHLAAAWGHLEIVEVLLKHGTDVNAQDVVGHTPLHL
AAMAGHLEIVEVLLKLGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.81_GSDLGKKLLEAARAGQDDEVRILMANGADVNATNWNGNTPLHLAASFGRLEIVEVLLKNGADVNAKDLWGDTPLHL
AAAWGHLEIVEVLLKYGADVNATDDLGDTPLHLAAHWGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.85_GSDLGKKLLEAARAGQDDEVRILMANGADVNADDHNGVTPLHLAASWGHLEIVEVLLKHGADVNANDHYGFTPLHL
AAWSGHLEIVEVLLKNGADVNAQDHLCQTPLHLAAFFGHLEIVEVLLKHGADVNAQDKFGKTTFDISIDNGNEDLAEILQKLN 
>p1.93_GSDLGKKLLEAARAGQDDEVRILMANGADVNAQDRHGHTPLHLATFDGHLEIVEVLLKHGADVNASDWIGWTPLHV
ATFSGHLEIVEVLLKYGADVNAIDDRGDTPLYLAAVTGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.97_GFDLGKKLLEAARAGQDDEVRILMANGADVNADDTRGHTPLHLTAWYGHLEIVEVLLKHGADVNASDWIGWTPLHV
AAFSGHLEIVEVLLKYGADVNAYDDVGTAPLHLAASHGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p1.100_GSDLGKKLLEAARAGQDDEVRILMANGADVNAQDTLGDTPLHLAAAFGHLEIVEVLLKHGADVNAYDEFGYTPLH
LATLGHLEIVEVLLKHGADVNAEDLQGDTPLHLAAFAGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
 
DARPins selected against Caspase-2: 
>2.1_GSDLGKKLLEAARAGQDDEVRILMANGADVNATDWLGHTPLHLAAKTGHLEIVEVLLKYGADVNAWDNYGATPLHLAA
DNGHLEIVEVLLKHGADVNAKDYEGFTPLHLAAYDGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>2.2_GSDLGKKLLEAARAGQDDEVRILMANGADVNAVDMFGQTALHLAASDGHLEIVEVLLKNGSDVNASDHWGFTPLHLAA
LLGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDMAEILQKLN 
 
DARPins selected against Caspase-3: 
>p3.1_GSDLGKKLLEAAHAGQDDEVRILMANGADVNANDDIGLTPLHLAAAIGHLEIVEVLLKNGADVNAEDRRGWTPCTLA
ANAGHLEIVEVLLKHGADVNATDRRGITPLHLAAWTGHLEIXEVLLKYGADVNTQXKFXXTAFXISIXNXXEDLAEILXKLN 
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>p3.2_GSDLGKKLLEAARAGQDDEVRILMANGADVNARDETGFTPLAADAGHLEIVEVLLKHGADVNAADRRGQTPLHLAAK
LGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p3.3_GSDLGKKLLEAAHAGQDDEVRILMANGADVNAFDETGHTPQHLTADTGHLEIVEVLLKHGADVNAMDHLGWTPLHLA
ADAGHLEIVEVLLKNGADVNASDDFGSAPLHLAAIHGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p3.4_GSDLGKKLLEATRAGQDDEVRILMANGADVNAMDDAGVTPLHLAAKRGHLEIVEVLLKHGADVNASDIWGRTPLHLA
ATVGHLEIVEVLLEYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p3.6_GSDLGKKLLEAARAGQDDEVRILMANGADVNAVDDAGITPLHLAAKVGHLEIVEVLLKYGADVNALDIWGRTPLHLA
ARSGHLEIVEVLLKHGADVNARDVRGLTPLHLAAKRGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p3.8_GSDLGKKLLEAARAGQDDEVRILMANGADVNANDFVGKTLHLAASVGHLEIVEVLLKHGADVNAADDAGVTSLHLAA
SYGHLEIVEVLLKNGADVNARDIWGRTPLHLAAVSGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p3.13_GSDLGKKLLEAALAGQDDEVRILMANGADVNADDDTGITPLYLAAWKGHLEIVEVLLKYDADVNANDILGRTPLHL
AARLGHLEIVEVLLRYGADVNASDIEGTTPLHLAANAGHLEIVEVLLKNGADVNAQDKFGKTTFDISIDNGNEDLAEILQKLN 
 
DARPins selected against Caspase-4: 
>p4.1_GSDLGKKLLEAARAGQDDEVRILMANGADVNAADDFGSTPLHLATDGHLEIVEVLLKYGADVNAFDHEGDTPLHLAA
WVGHLEIVEVLLKYGADVNAQDYGDTPLHLAALRGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p4.2_GSDLGKKLLEATRAGQDDEVRILMANGADVNTADDFGSTPLHRATDGHLEIVEVLLKYGADVNAFDHEGDTPLHLAA
WVGHLEIVEVLLKYGADVNAIDHDGYTPLHLAAKWGYLEIVEVMLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p4.3_GSDLGKKLLEATRAGQDDEVRILMTNGADVNAADDFGSTPLHLATDGHLEIVEVLLKYGADVNAADTWGDTPLHLAA
MEGHLEIVEVLLKNGADVNAKDHEGETPRHLAAVNGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p4.4_GSDLGRKLLEAARAGQDDEVRILMANGADVNAADDFGSTPLHLATDGHLEIVEVLLKYGADVNAIDHDGYTPLHLAA
FRAHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p4.5_GSDLGKKLLEAARAGQDDEVRILMANGADVNARDTFGLTPLHLAAFRGHLEIVEVLLKYGADVNAADYFGETPLHLA
ADVGHLEIVEVLLKYGADVNTDDIEGATPLHLAANTGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p4.6_GSDLGKKLLEADRADQDDEVRILMANVADVNADDDMGSTPLHLAAVHGHLEIVEVLLKHGADVNALDLAGHTPLHLS
ANLGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p4.7_GSDLGKKLPEAARAGQDDEVRILMANGADVNANDISGKTPLHLAALTGHLEIVEVLLKNSADVNADDVHGYTPLHLA
AQTGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
 
DARPins selected against Caspase-5: 
>p5.1_GSDLGKKLLEAARAGQDDEVRILMANGADVNTIDHHGKTPLHLAAYRGHLEIVEVLLKYGADVNAKDKWDSTPLHLA
AWNGHLEIVEVLLKYGADVNAMDSDGMTPLHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p5.2_GSDLGKKLLEAARAGQDDEVRILMANGADVNTIDHHGKTPLHLAAYRGHLEIVEVLLKYGADVNAKDKWDSTPLHLA
AWNGHLEIVEVLLKYGADVNAMDSDGMTPLHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p5.3_GSDLGKKLLEAARAGQDDEVRILMANGADVNATDNFGDTPLHLAAWRGHLEIVEVLLKNGADVNANDFYGNTPLHLV
AYKGHLEVVEVLLKYGADVNAEDYSGRTPLHLTAHHGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p5.4_GSDLGKKLLEAARAGQDDEVRILMANGADVNAKDRLGETPLHLAAFDGHLEIVEVLLKHGADVNANDQMGKTPLHLA
ADAGHLEIVEVLLKYGADVNAIDIWGDTPLHLAAVHGHLEIVEVLLKYGADVNAQNKFGKTAFDISIDNGNEDLAEILQKLN 
>p5.5_GSDLGKKLLEAARAGQDDEVRILMANGADVNAWDTLGETPLHLAALTGHLEIVEVLLKHGADVNAYDHFGATPLHLA
AWEGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p5.6_GSDLGKKLLEAARAGQDDEVRILMANGADVNAWDTLGETPLHLAALTGHLEIVEVLLKHGADVNAYDHFGATPLHLA
AWEGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p5.7_GSDLGKKLLDAARTGQDDEVRILMANGADVNALDWFGSTPLHLAAYDGHLEIVEVLLMNGTDVNADDHYGKTPLHLA
AIEGHLEIVEVLLKHGADVNADDLWGDTPLHLAADLGHLDIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p5.8_GSDLGKKLLEAARAGQDDEVRILMANGADVNALDWFGITPLHLAAWMGHLEIVEVLLKNGADVNADDHYGKTPLHLA
AIEGHLEIVEVLLKHGADVNADDLWGDTPLHLVAILGHLEIVEVLLKNGADDNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p5.11_GSDLGKKLLEAARAGQDDEVRILMANGADVNATDWFGDTPLHLAAQYGHLEIVEVLLKHGADVNAYDEFGTTPLHL
AAYDGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p5.13_GSDLGKKLLEAARAGQDDEVRILMANGADVNAKDRLGETPLHLAAFDGHLEIVEVLLKHGADVNANDQMGKTPLHL
AADAGHLEIVEVLLKYGADVNAIDIWGDTPLHLAAVHGHLEXVEVLLKYGADVNAQNKFGKTAFDISIDNGNEDLAEILQKLN 
>p5.15_GSDLGRKLLEAARAGQDDEVRILMANGADVNADDWLGSTPLHLAAVAGHLEIVEVLLMNGADVNADDHYGKTPLHL
AAIEGHLEIVEVLLKHGADVNADDLWGDTPLHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p5.16_GSDLGRKLLEAARAGQDDEVRILMANGADVNADDWLGSTPLHLAAVAGHLEIVEVLLMNGADVNADDHYGKTPLHL
AAIEGHLEIVEVLLKHGADVNADDLWGDTPLHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p5.18_GSDLGKKLLEAARAGQDDEVRILMANGADVNADDWLGSTPLHLAAVAGHLEIVEVLLMNGADVNADDHYGKTPLHL
AAIEGHLEIVEVLLKHGADVNADDLWGDTPLHLAALIGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNVDLAEILQKLN 
>p5.25_GSDLGRKLLEAARAGQDDEVRILMANGADVNADDWLGSTPLHLAAVAGHLEIVEVLLMNGADVNADDHYGKTPLHL
AAIEGHLEIVEVLLKHGADVNADDLWGDTPLHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p5.27_GSDLGRKLLEAARAGQDDEVRILMANGADVNADDWLGSTPLHLAAVAGHLEIVEVLLMNGADVNADDHYGKTPLHL
AAIEGHLEIVEVLLKHGADVNADDLWGDTPLHLAAVDGHLEIVEVLLKYGAEVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
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>p5.29_GSDLGKKLLEAARAGQDDEVRILMANGADVNADDWLGSTPLHLAAVAGHLEIVEVLLMNGADVNADDHYGKTPLHL
VAIEGHLEIVEVLLKHGADVNADDLWGDTPLHLAAVDGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p5.31_GSDLGRKLLEAARAGQDDEVRILMANGADVNADDWLGSTPLHLAAVAGHLEIVEVLLMNGADVNADDHYGKTPLHL
AAIEGHLEIVEVLLKHGADVNADDLWGDTPLHLAAKWGYLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
 
DARPins selected against Caspase-6: 
>p6.1_GSDLGKKLLEAARAGQDDEVRILMANGADVNANDYQGNTPLHLAAQHDHLEIVEVLLKNGADVNTADHFGYTPLHLA
AGYGHLEIVEVLLKHGADVNAEDSHGRTPVHLAAYIGHLEIVEVLLKYGANVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p6.2_GSDLGKKLLEAARAGQDDEVRILMANGADVNASDNTGWTPLHLAALAGHLEIVEVLLKHGADVNAIDSDGVPPLHLA
AHVGHLEIVEVLLKNGADVNAQDVILGYTPLHLAASVGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p6.3_GSDLGKKLLEAARAGQDDEVRILMANGADVNAVDQYGNTPLHLVATMGHLEIVEVLLKNGADVNATDWEGMTPLHLA
AYDGHLEIVEVLLKYGADVNARDMYGYTPLHLAAYSCHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p6.4_GSDLGKKLLEAARAGQDDEVRILMANGADVNAVDQYGNTPLHLVATMGHLEIVEVLLKNGADVNAYDLDGSTPLHLA
AIIGHLEIVEVLLKYGADVDAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p6.5_GSDLGKKLLEAARAGQDDEVRILMANGADVNAVDQYGNTPLHLVATMGHLEIVEVLLKNGADVNATDWEGMTPLHLA
AYDGHLEIVEVLLKYGADVNARDMYGYTPLHLAAYSCHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p6.6_GSDLGKKLLEAARAGQDDEVRILMANGADVNAKDYMGWTPLHLAAHFGHLEIVEVLLKYGADVNASDFLGYTPLHLA
AGYGHLEIVEVLLKNGADVNASDILGRTPLHLAASMGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p6.7_GSDLGKKLLEAARAGQDDEVRILMANGADVNANDDNGDTPLHLTAFFGHLEIVEVLLKYGADVNAKDKHGYTPLHLT
AWAGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p6.8_GSALGKKLLEAARAGQDDEVRILMANGADVNAKDMTGDTSLHLAATNGHLEIVEVLLKYGADVNAYDSRGFTPLHLA
ALMGHLEIVEVLLKYGADVNAWDVSGSTPLHLAAFTGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p6.9_GSDLGKKLLEAARAGQDDEVRILMANGADVNAKDVAGLTPLHLAAQNGHLEIVEVLLKHGADVNASDFLGYTPLHLA
AGYGHLEIVEVLLKNGADVNASDILGRTPLHLAASMGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p6.10_GSDLGKKLLEAARAGQDDEVRIPMANGADVNANDDTGRTPLHLAAMMGHLEIVEVLLKYGADVNATDIWGATPLHR
AALNGHLEIVEVLLKNGTDVNAQDKFGKTAFDISIDNGSEDLAEILQKLN 
>p6.11_GSDLGKKLLEAARAGQDDEVRILMANGADVNAHDIDGTTPLHLAAVHGHLEIVEVLLKHGADVNAYDSRGYTPQHL
AAMYGHLEVVEVLLKNGADVNARDDNGMTPLHLAAWSGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p6.12_GSDLGKKLLEAARAGQDDEVRILMANGADVNANDYQGNTPLHLAAQHDHLEIVEVLLKNGADVNAADHFGYTPLHL
AAGYGHLEIVEVLLKHGADVNAEDSHGRTPVHLAAYIGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p6.14_GSDLGKKLLEAARAGQDDEVRILMANGADVNANDYQGNTPLHLAAQHDHLEIVEVLLKNGADVNAADHFGYTPLHL
AAGYGHLEIVEVLLKHGADVNAEDSHGRTPVHLAAYIGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p6.15_GSDLGKKLLEAARAGQDDEVRILMANGADVNASDNTGWTPLHLAALAGHLEIVEVLLKHGADVNAIDSDGVPPLHL
AAHVGHLEIVEVLLKNGADVNAQDVILGYTPLHLAASVGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKL 
>p6.16_GSDLGRKLLEAARVGQDDEVRILMANGADVNAADYAGMTPLHLSANSGHLEIVEVLLKYGADVNAGDTFGWTPLHL
TANRGHLEIIEVLVKYGADVNALEKGGNSPLHLAAMISHLEIVEVLLKYGADVNARDKFGKTAFDISIDNGNEDLAEILQKLN 
>p6.21_GSDLGKKLLEAARAGQDDEVRILMANGADVNARDIDGTTPLHLAAVWGHLEIVEVLLRNGADVNAYDSRGYTPLHL
AAMYGHLEVVEVLLKHGADVNARDDNGMTPLHLAAWSGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
 
DARPins selected against Caspase-7: 
>p7.1_GSDLGKKLLEAARAGQDDEVRILMANGADVNANDATGNTPLHLAAEEGHLEIVEVLLKYGADVNAVDADGSTPLHLA
ALFGHPEIVEVLLKNGADVNAADFYGHTPLHLAALFGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p7.2_GSDLGKKLLEAARAGQDDEVRILMANGTDVNARDWHGWTPLHLAAWHGHLEIVEVLLKYGADVNAHDTTGNTPLHLA
AHVGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p7.3_GSDLGKKLLEAARAGQDDEVRILMANGADVNAKDTHGWTPLHLAAWYGHLEIVEVLLKNGADVNADDHLGTTPLHLA
AVWGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p7.4_GSDLGKKLLEAARAGQDDEVRILMANGTDVNAADYAGMTPLHLSANSGHLEIVEVLLKYGADVNAGDTFGWTPLHLA
AWHGHLEIVEVLLKNGADVNATDLHGTTPLHLAAHMGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p7.5_GSDLGKKLLEAARAGQDDEVRILMANGADVNASDTFGWTPLHLAAFHGHLEIVEVLLKHGADVNASDTFGNTPLHLA
ARLGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p7.7_GSDLGKKLLEAARAGQDDEVRILMANGADVNAYDFYGWTPLHLAAWYGHLEIVEVLLKHGADVNANDKHGSTPLHLA
AHTGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p7.10_GSDLGKKLLEAARAGQDDEVRILMANGADVNATDKWGWTPLHLAAFHGHLEIVEVLLKNGADVNALDXXGSTPLHL
AAXXGXLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p7.14_GSDLGKKLLEAARAGQDDEVRILMANGADVNAHDRYGWTPLHLAAFHGHLEIVEVLLKYGADVNANDYLGTTPLHL
AAHWGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p7.17_GSDLGKKLLEAARAGQDDEVRILMANGTDVNARDWHGWTPLHLATWHGHLEIVEVLLKYGADVNAHDTTGNTPLHL
AAHMGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p7.18_GSDLGKKLLEAARAGQDDEVRILMANGADVNADDAWGQTPLHLAAQNGHLEIVEVLLKHDADVNATDWVGMTPLHL
AADDGHLEIVEALLKYGADVNAYDQLGNTPLNLAATDGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
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>p7.20_GSDLGKKLLEAARAGQDDEVRILMANGADVNARDDDGWTPLHLAAWYGHLEIVEVLLKHGADVNALDSLGTTPLHL
AAINGHLEIVEVLLKHGADVNAKDKFGKTAFDISIDNGNEDLAEILQKLN 
>p7.31_GSDLGKKLLEAARAGQDDEVRILMANGADVNAIDHQGLTPLHLAAQNGHLEIVEVLLKHGADVNAEDWYGWTPLHL
AAFHGHLEIVEVLLKHGADVNANDYLGTTPLHLAAVTGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p7.33_GSDLGKKLLEAARAGQDDEVRILMANGTDVNARDWHGWTPLHLAAWHGHLEIVEVLLKYGADVNAHDTTGNTPLHL
AAHMGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p7.43_GSDLGKKLLEAARAGQDDEVRILMANGADVNANDKHGWTPLHLAAFFGHLEIVEVLLKNGADVNAVDNMGTTPLHL
AAHMGRLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
 
DARPins selected against Caspase-8: 
>p8.1_GSDLGKKLLEAARAGQDDEVRILMANGADVNAEDASGWTPLHLAAFNGHLEIVEVLLKNGADVNAVDHAGMTPLRLA
ALFGHLEIVEVLLKNGADVNANDMEGHTPLHLAAMFGHLEIVEVLLKHGADANAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p8.2_GSDLGKKLLEAARAGQDDEVRILMANGADVNANDLAGWTPLHLAAFLGHLEIVEVLLKNGADVNASDLNGKTPLHLA
AVFGHLEIVEVLLKHGADVNAVDDAGHTPLHLAALFGHLEIVEVLLKYGAEVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p8.3_GSDLGKKLLEAARAGQDDEVRILMANGADVNAVDDRGMTPLHLAALNGHLEIVEVLLKNGADVNAADNTGWTPLHLA
ALRGHLEIVEVLLKHGADVNAQDHAGTTPLHLATYLGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p8.4_GSDLGKKLLEAARAGRDDEVRILMANGADVNAEDASGWTPLHLAAFNGHLEIVEVLLKNGADVNAVDHAGMTPLRLA
ALFGHLEIVEVLLKNGADVNANDMEGHTPLHLAAMFGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p8.5_GSDLGKKLLEAARAGQDDEVRILMANGADVNAEDASGWTPLHLAAFNGHLEIVEVLLKNGADVNAVDHAGMTPLRLA
ALFGHLEIVEVLLKNGADVNANDMEGHTPLHLAAMFGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p8.6_GSDLGKKLLEAARAGQDDEVRILMANGADVNAEDASGWTPLHLAAFNGHLEIVEVLLKNGADVNAVDHAGMTPLRLA
ALFGHLEIVEVLLKNGADVNANDMEGHTPLHLAAMFGHLEIVEVLLKHGADANAQDKFGKTAFDISIDNGNKDLAEILQKLN 
>p8.7_GSDLGKKLLEAARAGQDDEVRILMANGADVNAEDASGWTPLHLAAFNGHLEIVEVLLKNGADVNAVDHAGMTPLRLA
ALFGHLEIVEVLLKNGADVNANDMEGHTPLHLAAMFGHLEIVEVLLKHGADANAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p8.8_GSDLGKKLLEAARAGQDDEVRILMANGADVNAEDASGWTPLHLAAFNGHLEIVEVLLKNGADVNAVDHAGMTPLRLA
ALFGHLEIVEVLLKNDADVNANDMEGHTPLHLAAMFGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p8.9_GSDLGKKLLEAARAGQDDEVRILMANGADVNAEDASGWTPLHLAAFNGHLEIVEVLLKNGADVNAVDHAGMTPLRLA
ALFGHLEIVEVLLKNGADVNANDMEGHTPLHLAAMFGHLEIVEVLLKHGADANAQDKFGKTAFDISIDNGNEDLAEILQKLN 
>p8.10_GSDLGKKLLEAARAGQDDEVRILMANGADVNAEDASGWTPLHLAAFNGHLEIVEVLLKNGADVNAVDHAGMTPLRL
AALFGHLEIVEVLLKNGADVNANDMEGHTPLHLAAMFGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN 
 
DARPins selected against Caspase-9: 
>p9.3_GSDLGKKLLEAACAGQDXEVRILMANGADVNAWDNVGSTPLHLAGSNGHLEIVEVLLKYGADVNADDHFGDTPLHLA
AKQGHLEIVEVLLKNGADXNAFDXXGNXPLHLXXXYGHLEIVEXLLXNGADVNAQDKFXKTAFXISIXXGXEDLXEILXKLN 
>p9.4_GSDLGKKLLEAARAGQDDEVHILMANGADVNALDIFGGTPLHLAADDGHLEIVEVLLKYGADVNATDVSGLTPLHLA
ANWGHLEIVEVLLKYGADVGADDITGETPLHLAARDGHLEIVEVLLRHGADVNAQDKFGKTAFDISIDNGNEDLAEILXKLN 
 
 
* Each DARPin contains a purification tag and antibody recognition sequence (MRGSHHHHH) at the 
N-terminus of the sequence. 
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